CA3212877A1 - Methods and compounds for neoantigen vaccines - Google Patents
Methods and compounds for neoantigen vaccines Download PDFInfo
- Publication number
- CA3212877A1 CA3212877A1 CA3212877A CA3212877A CA3212877A1 CA 3212877 A1 CA3212877 A1 CA 3212877A1 CA 3212877 A CA3212877 A CA 3212877A CA 3212877 A CA3212877 A CA 3212877A CA 3212877 A1 CA3212877 A1 CA 3212877A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- peptide
- tumor
- mutations
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 146
- 150000001875 compounds Chemical class 0.000 title abstract description 9
- 229960005486 vaccine Drugs 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 282
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 170
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 134
- 230000035772 mutation Effects 0.000 claims abstract description 111
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 81
- 201000011510 cancer Diseases 0.000 claims abstract description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 249
- 102000004169 proteins and genes Human genes 0.000 claims description 207
- 108020004414 DNA Proteins 0.000 claims description 101
- 210000004027 cell Anatomy 0.000 claims description 89
- 238000009739 binding Methods 0.000 claims description 70
- 230000027455 binding Effects 0.000 claims description 69
- 102000039446 nucleic acids Human genes 0.000 claims description 64
- 108020004707 nucleic acids Proteins 0.000 claims description 64
- 239000012634 fragment Substances 0.000 claims description 63
- 230000009870 specific binding Effects 0.000 claims description 48
- 229920001184 polypeptide Polymers 0.000 claims description 47
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 44
- 108091054438 MHC class II family Proteins 0.000 claims description 41
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 38
- 102000043131 MHC class II family Human genes 0.000 claims description 37
- 238000012163 sequencing technique Methods 0.000 claims description 33
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 31
- 238000004458 analytical method Methods 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 238000003556 assay Methods 0.000 claims description 27
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 26
- 210000003705 ribosome Anatomy 0.000 claims description 25
- 238000002823 phage display Methods 0.000 claims description 21
- 238000007482 whole exome sequencing Methods 0.000 claims description 20
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 13
- 238000002824 mRNA display Methods 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 238000011331 genomic analysis Methods 0.000 claims description 11
- 238000007481 next generation sequencing Methods 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 238000003559 RNA-seq method Methods 0.000 claims description 10
- 238000007385 chemical modification Methods 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 210000000265 leukocyte Anatomy 0.000 claims description 10
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 9
- 108091054437 MHC class I family Proteins 0.000 claims description 9
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 9
- 230000037433 frameshift Effects 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 230000037432 silent mutation Effects 0.000 claims description 9
- 230000037439 somatic mutation Effects 0.000 claims description 9
- 102000043129 MHC class I family Human genes 0.000 claims description 8
- 238000012405 in silico analysis Methods 0.000 claims description 8
- 108700026244 Open Reading Frames Proteins 0.000 claims description 7
- 238000004422 calculation algorithm Methods 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 238000002818 protein evolution Methods 0.000 claims description 7
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 238000002819 bacterial display Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 108091035707 Consensus sequence Proteins 0.000 claims description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 4
- 230000037436 splice-site mutation Effects 0.000 claims description 4
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000009851 immunogenic response Effects 0.000 claims description 3
- KYEKLQMDNZPEFU-KVTDHHQDSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)N=C1 KYEKLQMDNZPEFU-KVTDHHQDSA-N 0.000 claims description 2
- MUSPKJVFRAYWAR-XVFCMESISA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)S[C@H]1N1C(=O)NC(=O)C=C1 MUSPKJVFRAYWAR-XVFCMESISA-N 0.000 claims description 2
- CWXIOHYALLRNSZ-JWMKEVCDSA-N 2-Thiodihydropseudouridine Chemical compound C1C(C(=O)NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O CWXIOHYALLRNSZ-JWMKEVCDSA-N 0.000 claims description 2
- JUMHLCXWYQVTLL-KVTDHHQDSA-N 2-thio-5-aza-uridine Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C(=S)NC(=O)N=C1 JUMHLCXWYQVTLL-KVTDHHQDSA-N 0.000 claims description 2
- VRVXMIJPUBNPGH-XVFCMESISA-N 2-thio-dihydrouridine Chemical compound OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)NC1=S VRVXMIJPUBNPGH-XVFCMESISA-N 0.000 claims description 2
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 claims description 2
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 claims description 2
- YKWUPFSEFXSGRT-JWMKEVCDSA-N Dihydropseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1C(=O)NC(=O)NC1 YKWUPFSEFXSGRT-JWMKEVCDSA-N 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 229940035893 uracil Drugs 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims 7
- BVLGKOVALHRKNM-XUTVFYLZSA-N 2-Thio-1-methylpseudouridine Chemical compound CN1C=C(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O BVLGKOVALHRKNM-XUTVFYLZSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 26
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 12
- 235000018102 proteins Nutrition 0.000 description 162
- 229940024606 amino acid Drugs 0.000 description 55
- 150000001413 amino acids Chemical group 0.000 description 55
- 235000001014 amino acid Nutrition 0.000 description 54
- 230000014616 translation Effects 0.000 description 43
- 239000000284 extract Substances 0.000 description 37
- 238000001514 detection method Methods 0.000 description 29
- 238000000338 in vitro Methods 0.000 description 28
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 23
- -1 mRNA Substances 0.000 description 23
- 238000001243 protein synthesis Methods 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- 238000013519 translation Methods 0.000 description 22
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 21
- 230000000875 corresponding effect Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 19
- 108091026890 Coding region Proteins 0.000 description 18
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 229950010131 puromycin Drugs 0.000 description 14
- 210000002220 organoid Anatomy 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 229940023041 peptide vaccine Drugs 0.000 description 12
- 238000000159 protein binding assay Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 101710090029 Replication-associated protein A Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 101710094648 Coat protein Proteins 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 8
- 101710125418 Major capsid protein Proteins 0.000 description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 8
- 108020004566 Transfer RNA Proteins 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000000126 in silico method Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 8
- 101710132601 Capsid protein Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 7
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 101710141454 Nucleoprotein Proteins 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 101710083689 Probable capsid protein Proteins 0.000 description 7
- 108010090804 Streptavidin Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 235000003969 glutathione Nutrition 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000000392 somatic effect Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108700024394 Exon Proteins 0.000 description 6
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 208000032818 Microsatellite Instability Diseases 0.000 description 6
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000002101 lytic effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000000869 mutational effect Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000013076 target substance Substances 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 241000724791 Filamentous phage Species 0.000 description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 5
- 108010006519 Molecular Chaperones Proteins 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- 239000005700 Putrescine Substances 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000003314 affinity selection Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 230000010627 oxidative phosphorylation Effects 0.000 description 4
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940063673 spermidine Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 description 3
- 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 3
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 3
- 102000013009 Pyruvate Kinase Human genes 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000012350 deep sequencing Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108010052621 fas Receptor Proteins 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 3
- 230000001320 lysogenic effect Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- AMMRPAYSYYGRKP-BGZDPUMWSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-ethylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AMMRPAYSYYGRKP-BGZDPUMWSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 108010092060 Acetate kinase Proteins 0.000 description 2
- 102100038740 Activator of RNA decay Human genes 0.000 description 2
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 2
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101710192393 Attachment protein G3P Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 101710185679 CD276 antigen Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- UGTJLJZQQFGTJD-UHFFFAOYSA-N Carbonylcyanide-3-chlorophenylhydrazone Chemical compound ClC1=CC=CC(NN=C(C#N)C#N)=C1 UGTJLJZQQFGTJD-UHFFFAOYSA-N 0.000 description 2
- 102100021397 Cell surface glycoprotein CD200 receptor 2 Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100021309 Elongation factor Ts, mitochondrial Human genes 0.000 description 2
- 102100033238 Elongation factor Tu, mitochondrial Human genes 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000969556 Homo sapiens Cell surface glycoprotein CD200 receptor 2 Proteins 0.000 description 2
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 2
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 2
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 2
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 2
- 101001129851 Homo sapiens Paired immunoglobulin-like type 2 receptor alpha Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 102100031651 Paired immunoglobulin-like type 2 receptor alpha Human genes 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 102000010562 Peptide Elongation Factor G Human genes 0.000 description 2
- 108010077742 Peptide Elongation Factor G Proteins 0.000 description 2
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 2
- 108090000279 Peptidyltransferases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100025803 Progesterone receptor Human genes 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 244000250129 Trigonella foenum graecum Species 0.000 description 2
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108010063460 elongation factor T Proteins 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 238000012268 genome sequencing Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 101150073223 hisat gene Proteins 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010028930 invariant chain Proteins 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 238000002898 library design Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 230000009149 molecular binding Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 229940039748 oxalate Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108020003519 protein disulfide isomerase Proteins 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 108090000589 ribonuclease E Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000010464 virion assembly Effects 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 1
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MNHVIVWFCMBFCV-AVGNSLFASA-N (2S)-2-[[(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-6-diazo-5-oxohexanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O MNHVIVWFCMBFCV-AVGNSLFASA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2r,3r,3as,9ar)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- AXEOMQHKTSGLGS-VIFPVBQESA-N (2s)-2-amino-3-(4-hydroxy-2-methylphenyl)propanoic acid Chemical compound CC1=CC(O)=CC=C1C[C@H](N)C(O)=O AXEOMQHKTSGLGS-VIFPVBQESA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7s,9s)-7-[(2s,4r,6s)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- AUFGTPPARQZWDO-YUZLPWPTSA-N 10-formyltetrahydrofolate Chemical compound C1NC=2NC(N)=NC(=O)C=2NC1CN(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YUZLPWPTSA-N 0.000 description 1
- OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- RYSMHWILUNYBFW-GRIPGOBMSA-N 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](N)[C@H]1O RYSMHWILUNYBFW-GRIPGOBMSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- RHRPPNDIWVFSRX-UHFFFAOYSA-N 3,4-dimethyl-1,3-thiazol-3-ium Chemical compound CC1=CSC=[N+]1C RHRPPNDIWVFSRX-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- FGFVODMBKZRMMW-XUTVFYLZSA-N 4-Methoxy-2-thiopseudouridine Chemical compound COC1=C(C=NC(=S)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O FGFVODMBKZRMMW-XUTVFYLZSA-N 0.000 description 1
- HOCJTJWYMOSXMU-XUTVFYLZSA-N 4-Methoxypseudouridine Chemical compound COC1=C(C=NC(=O)N1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O HOCJTJWYMOSXMU-XUTVFYLZSA-N 0.000 description 1
- VTGBLFNEDHVUQA-XUTVFYLZSA-N 4-Thio-1-methyl-pseudouridine Chemical compound S=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 VTGBLFNEDHVUQA-XUTVFYLZSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- DDHOXEOVAJVODV-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=S)NC1=O DDHOXEOVAJVODV-GBNDHIKLSA-N 0.000 description 1
- BNAWMJKJLNJZFU-GBNDHIKLSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidene-1h-pyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=S BNAWMJKJLNJZFU-GBNDHIKLSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- DQOGWKZQQBYYMW-LQGIGNHCSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 DQOGWKZQQBYYMW-LQGIGNHCSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1h-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78nz2pmp25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108700032558 Aspergillus restrictus MITF Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JNRZNAGCSGWZMY-UHFFFAOYSA-N C(C(=O)C)(=O)OP(=O)=O Chemical compound C(C(=O)C)(=O)OP(=O)=O JNRZNAGCSGWZMY-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000001353 Chip-sequencing Methods 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102210048110 DRB1*01:02 Human genes 0.000 description 1
- 102210047356 DRB1*03:01 Human genes 0.000 description 1
- 102210047482 DRB1*07:01 Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100015982 Dictyostelium discoideum gcsA gene Proteins 0.000 description 1
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 1
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700005092 MHC Class II Genes Proteins 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 101710159527 Maturation protein A Proteins 0.000 description 1
- 101710091157 Maturation protein A2 Proteins 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100172084 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) egtA gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001596784 Pegasus Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000532838 Platypus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001077668 Rattus norvegicus Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101710195674 Replication initiator protein Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 241001415395 Spea Species 0.000 description 1
- 206010041662 Splinter Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000913727 Streptomyces alboniger Species 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 101710100179 UMP-CMP kinase Proteins 0.000 description 1
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- VUPBDWQPEOWRQP-RTUCOMKBSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1S,2S)-3-[[(2R,3S)-5-[[(2S,3R)-1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate Chemical compound C[C@@H](O)[C@H](NC(=O)C[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NC(O[C@@H]1O[C@@H](C)[C@@H](N)[C@@H](O)[C@H]1O)C(O)c1nc(cs1)-c1nc(cs1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN VUPBDWQPEOWRQP-RTUCOMKBSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- IVCRCPJOLWECJU-XQVQQVTHSA-N [(7r,8r,9s,10r,13s,14s,17s)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 IVCRCPJOLWECJU-XQVQQVTHSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
- IGCAUIJHGNYDKE-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC([O-])=O.CC([O-])=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCC[NH2+]CCO)=CC=C2NCC[NH2+]CCO IGCAUIJHGNYDKE-UHFFFAOYSA-N 0.000 description 1
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 acivicin Drugs 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 229950004821 ambomycin Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 201000007696 anal canal cancer Diseases 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- PHKGGXPMPXXISP-DFWYDOINSA-N azanium;(4s)-4-amino-5-hydroxy-5-oxopentanoate Chemical compound [NH4+].[O-]C(=O)[C@@H]([NH3+])CCC([O-])=O PHKGGXPMPXXISP-DFWYDOINSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229950004295 azotomycin Drugs 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- LVKZSFMYNWRPJX-UHFFFAOYSA-N benzenearsonic acid Natural products O[As](O)(=O)C1=CC=CC=C1 LVKZSFMYNWRPJX-UHFFFAOYSA-N 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 229950009338 caracemide Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 1
- 229950005155 carbetimer Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229950010667 cedefingol Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229950011359 cirolemycin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- YCWXIQRLONXJLF-PFFGJIDWSA-N d06307 Chemical compound OS(O)(=O)=O.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC YCWXIQRLONXJLF-PFFGJIDWSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- 229950010621 dezaguanine Drugs 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- CZLKTMHQYXYHOO-QTNFYWBSSA-L disodium;(2s)-2-[(2-phosphonatoacetyl)amino]butanedioic acid Chemical compound [Na+].[Na+].OC(=O)C[C@@H](C(O)=O)NC(=O)CP([O-])([O-])=O CZLKTMHQYXYHOO-QTNFYWBSSA-L 0.000 description 1
- SVJSWELRJWVPQD-KJWOGLQMSA-L disodium;(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-KJWOGLQMSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 229950005133 duazomycin Drugs 0.000 description 1
- 229930192837 duazomycin Natural products 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950010625 enloplatin Drugs 0.000 description 1
- 229950001022 enpromate Drugs 0.000 description 1
- 229950004926 epipropidine Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229950001426 erbulozole Drugs 0.000 description 1
- KLEPCGBEXOCIGS-QPPBQGQZSA-N erbulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-QPPBQGQZSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- 229940011957 ethiodized oil Drugs 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl n-[4-[[(2r,4r)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
- 229950005096 fazarabine Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229950005682 flurocitabine Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 fosquidone Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-OUBTZVSYSA-N gold-198 Chemical compound [198Au] PCHJSUWPFVWCPO-OUBTZVSYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 101150019860 gshA gene Proteins 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;n-methyl-n-[4-[(7-methyl-3h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229950006905 ilmofosine Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000013918 magnesium diglutamate Nutrition 0.000 description 1
- 229940063886 magnesium glutamate Drugs 0.000 description 1
- MYUGVHJLXONYNC-QHTZZOMLSA-J magnesium;(2s)-2-aminopentanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O MYUGVHJLXONYNC-QHTZZOMLSA-J 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
- 229950002676 menogaril Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 108010057757 methionyl-tRNA formyltransferase Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N metoprine, methodichlorophen Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 201000003956 middle ear cancer Diseases 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229950002137 mitocarcin Drugs 0.000 description 1
- 229950000911 mitogillin Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950007612 mitomalcin Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000013917 monoammonium glutamate Nutrition 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N n-[(2s,3s)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N n-[(e)-1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N n-methyl-n-[(e)-(n-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- 239000011807 nanoball Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000007425 nasal cavity carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229950008017 ormaplatin Drugs 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229950000370 oxisuran Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229950006960 peliomycin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
- 229950009351 perfosfamide Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 plomestane Drugs 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- MKSVFGKWZLUTTO-FZFAUISWSA-N puromycin dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO MKSVFGKWZLUTTO-FZFAUISWSA-N 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 229960004356 riboprine Drugs 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
- 229950005230 rogletimide Drugs 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 101150100082 sdaA gene Proteins 0.000 description 1
- 229920006012 semi-aromatic polyamide Polymers 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 229950009089 simtrazene Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229950009641 sparsomycin Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 229950006050 spiromustine Drugs 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- AHBGXTDRMVNFER-FCHARDOESA-L strontium-89(2+);dichloride Chemical compound [Cl-].[Cl-].[89Sr+2] AHBGXTDRMVNFER-FCHARDOESA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229950007841 sulofenur Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229950002687 talisomycin Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 101150099895 tnaA gene Proteins 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960002190 topotecan hydrochloride Drugs 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000005924 vaccine-induced immune response Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DVPVGSLIUJPOCJ-XXRQFBABSA-N x1j761618a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 DVPVGSLIUJPOCJ-XXRQFBABSA-N 0.000 description 1
- 229950003017 zeniplatin Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
Abstract
The present disclosure includes compounds and methods for treating a subject having a disease such as cancer. A treatment method includes administering to the patient a therapeutically effective amount of one or more peptides corresponding to a tumor neoantigen or administering to the patient a therapeutically effective amount of one or more oligonucleotides each having a nucleic acid sequence that encodes a peptide corresponding to a tumor neoantigen. The tumor neoantigens may be identified from patient-specific tumor mutations in the patient's tumor cells.
Description
METHODS AND COMPOUNDS FOR NEOANTIGEN VACCINES
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Patent Application No.
63/166,697, filed on March 26, 2021, the contents of which are incorporated herein by reference in its entirety.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII-formatted sequence listing with a file named "91482-255W0-PCT Sequence_Listing.txr created on March 25, 2022, and having a size of 7,379 bytes, is filed concurrently with the specification. The sequence listing contained in this ASCII-formatted document is part of the specification and is herein incorporated by reference in its entirety.
TECHNICAL FIELD
The present invention relates to novel proteins and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer.
BACKGROUND
Cancer is a group of diseases involving abnormal cell growth with a potential to spread to various parts of the body. Hundreds of types of cancers affect humans, and millions of people have been diagnosed and millions more are being diagnosed every year. The most common types of cancers include lung cancer, breast cancers, prostate cancers, colorectal cancers, among others. Treatment for cancers includes surgery, radiation therapy, chemotherapy, immunotherapy, hormone therapy, and stem cell replacement. Treatment options can be invasive and have a variety of undesirable side effects.
Accordingly, while the scientific community has made progress in this field, there remains a need in the art for improved compounds and methods for prevention and treatment of cancer.
SUMMARY
A need exists for a therapeutic strategy for treatment of disease, including cancer. In order to actively drive an antitumor immune response, therapeutic cancer vaccines have been developed. Unlike prophylactic vaccines that are used preventatively to treat infectious diseases, therapeutic vaccines are designed to treat established cancer by stimulating an immune response against a specific tumor-associated antigen. The advantage of active immunotherapies is that they have the potential to provide long-lasting anticancer activity by engaging both the innate and adaptive arms of the immune response. Neoantigens are Major Histocompatibility Complex (MHC)-presented peptides of novel sequence that are formed by somatic mutation and represent an especially promising immunotherapeutic target, since they appear exclusively on the tumor and so cause minimal off-target effects.
The present invention provides a method for treating cancer in a patient. A
treatment method may include administering to the patient a therapeutically effective amount of one or more peptides corresponding to tumor neoantigens or administering to the patient a therapeutically effective amount of one or more oligonucleotide each having a nucleic acid sequence that encodes a peptide corresponding to a tumor neoantigen. The neoantigens may be identified from patient-specific tumor mutations in the patient's tumor cells.
According to various embodiments, the method may comprise: (a) obtaining tumor cells from a tumor resected from the patient; (b) detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA
and normal DNA and/or RNA from the patient; (c) identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient; and (d) administering to the patient a therapeutically effective amount of the peptides corresponding to the tumor neoantigens ("neoantigen peptides"). An adjuvant may be administered to the patient concurrently with the neoantigens peptides.
According to other embodiments, the method may comprise: (a) obtaining tumor cells from a tumor resected from the patient; (b) detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA
and normal DNA and/or RNA from the patient; (c) identifying a neoantigen resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient; (d) designing a peptide based on the neoantigen; (e) generating a nucleic acid sequence that encodes the peptide; and
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Patent Application No.
63/166,697, filed on March 26, 2021, the contents of which are incorporated herein by reference in its entirety.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII-formatted sequence listing with a file named "91482-255W0-PCT Sequence_Listing.txr created on March 25, 2022, and having a size of 7,379 bytes, is filed concurrently with the specification. The sequence listing contained in this ASCII-formatted document is part of the specification and is herein incorporated by reference in its entirety.
TECHNICAL FIELD
The present invention relates to novel proteins and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer.
BACKGROUND
Cancer is a group of diseases involving abnormal cell growth with a potential to spread to various parts of the body. Hundreds of types of cancers affect humans, and millions of people have been diagnosed and millions more are being diagnosed every year. The most common types of cancers include lung cancer, breast cancers, prostate cancers, colorectal cancers, among others. Treatment for cancers includes surgery, radiation therapy, chemotherapy, immunotherapy, hormone therapy, and stem cell replacement. Treatment options can be invasive and have a variety of undesirable side effects.
Accordingly, while the scientific community has made progress in this field, there remains a need in the art for improved compounds and methods for prevention and treatment of cancer.
SUMMARY
A need exists for a therapeutic strategy for treatment of disease, including cancer. In order to actively drive an antitumor immune response, therapeutic cancer vaccines have been developed. Unlike prophylactic vaccines that are used preventatively to treat infectious diseases, therapeutic vaccines are designed to treat established cancer by stimulating an immune response against a specific tumor-associated antigen. The advantage of active immunotherapies is that they have the potential to provide long-lasting anticancer activity by engaging both the innate and adaptive arms of the immune response. Neoantigens are Major Histocompatibility Complex (MHC)-presented peptides of novel sequence that are formed by somatic mutation and represent an especially promising immunotherapeutic target, since they appear exclusively on the tumor and so cause minimal off-target effects.
The present invention provides a method for treating cancer in a patient. A
treatment method may include administering to the patient a therapeutically effective amount of one or more peptides corresponding to tumor neoantigens or administering to the patient a therapeutically effective amount of one or more oligonucleotide each having a nucleic acid sequence that encodes a peptide corresponding to a tumor neoantigen. The neoantigens may be identified from patient-specific tumor mutations in the patient's tumor cells.
According to various embodiments, the method may comprise: (a) obtaining tumor cells from a tumor resected from the patient; (b) detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA
and normal DNA and/or RNA from the patient; (c) identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient; and (d) administering to the patient a therapeutically effective amount of the peptides corresponding to the tumor neoantigens ("neoantigen peptides"). An adjuvant may be administered to the patient concurrently with the neoantigens peptides.
According to other embodiments, the method may comprise: (a) obtaining tumor cells from a tumor resected from the patient; (b) detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA
and normal DNA and/or RNA from the patient; (c) identifying a neoantigen resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient; (d) designing a peptide based on the neoantigen; (e) generating a nucleic acid sequence that encodes the peptide; and
2
3 (f) administering to the patient a therapeutically effective amount of an oligonucleotide having the nucleic acid sequence that encodes the peptide.
In certain aspects, detecting a plurality of patient-specific tumor mutations may comprise genomic profiling with next generation sequencing of a targeted gene panel. In one aspect, the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
In other aspects, the genomic analysis may comprise identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
In yet other aspects, the plurality of patient-specific tumor mutations may comprise a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof; and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which hinds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
In some aspects, the method may further comprise identifying the MHC class 1 and 2 genotypes of the patient. In one aspect, identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
In certain aspects, identifying the neoantigens may comprise: (i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA
proteins or fragments thereof; (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs; (iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA
proteins or fragments thereof; (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA proteins or fragments thereof In some aspects, the library of peptide constructs may comprise variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions. In one aspect, the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
In other aspects, identifying the neoantigens may comprise: (i) generating a genetically encoded combinatorial library of polypeptides with phage display, ribosomal display, mRNA display, biscistronic DNA display, P2A DNA display, CIS display, yeast display, or bacterial display, wherein the combinatorial library comprises polypeptides linked to corresponding nucleic acid molecules encoding the polypeptides; (ii) contacting the combinatorial library with the HLA proteins or fragments thereof; (iii) separating HLA proteins or fragments thereof demonstrating specific binding with the combinatorial library; and (iv) sequencing all or a portion of the nucleic acid molecules of the combinatorial library bound to the HLA proteins or fragments thereof to identify the neoantigens.
In one aspect, the combinatorial library of polypeptides may comprise variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
In certain aspects, specific binding between neoantigens and HLA proteins or fragments thereof may be determined by: (i) culturing a cell transformed with at least one nucleic molecule comprising a nucleotide sequence encoding: an MHC class II component comprising at least a portion of an MHC class II a chain and at least a portion of an MHC
class II (3 chain, such that the MHC class II a chain and MHC class II [3 chain form a peptide binding groove;
and a spaceholder molecule and a first processable linker, wherein the spaceholder molecule is linked to the MHC class II component by the processable linker and the spaceholder molecule binds within the peptide binding groove thereby hindering the binding of any other peptide within the peptide binding groove; the step of culturing being conducted to produce the MHC
class II component; (ii) recovering the MHC class II component; (iii) processing the processable linker, thereby releasing the spaceholder molecule from the peptide binding groove; (iv) incubating the MHC class II component in the presence of a neoantigen, wherein the incubation facilitates the binding of the neoantigen to the peptide binding groove; (v) recovering the MHC class II component that has bound the neoantigen.
In one aspect, the spaceholder molecule may have the consensus sequence AAXAAAAAAAXAA (SEQ ID NO: 30). In another aspect, the spaceholder molecule is selected from the group consisting of PVSKMRMATPLLMQA (SEQ ID NO: 25);
AAMAAAAAAAMAA (SEQ ID NO: 26); AAMAAAAAAAAAA (SEQ ID NO: 27);
AAFAAAAAAAAAA (SEQ ID NO: 28); and ASMSAASAASMAA (SEQ ID NO: 29).
In certain aspects, detecting a plurality of patient-specific tumor mutations may comprise genomic profiling with next generation sequencing of a targeted gene panel. In one aspect, the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
In other aspects, the genomic analysis may comprise identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
In yet other aspects, the plurality of patient-specific tumor mutations may comprise a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof; and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which hinds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
In some aspects, the method may further comprise identifying the MHC class 1 and 2 genotypes of the patient. In one aspect, identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
In certain aspects, identifying the neoantigens may comprise: (i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA
proteins or fragments thereof; (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs; (iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA
proteins or fragments thereof; (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA proteins or fragments thereof In some aspects, the library of peptide constructs may comprise variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions. In one aspect, the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
In other aspects, identifying the neoantigens may comprise: (i) generating a genetically encoded combinatorial library of polypeptides with phage display, ribosomal display, mRNA display, biscistronic DNA display, P2A DNA display, CIS display, yeast display, or bacterial display, wherein the combinatorial library comprises polypeptides linked to corresponding nucleic acid molecules encoding the polypeptides; (ii) contacting the combinatorial library with the HLA proteins or fragments thereof; (iii) separating HLA proteins or fragments thereof demonstrating specific binding with the combinatorial library; and (iv) sequencing all or a portion of the nucleic acid molecules of the combinatorial library bound to the HLA proteins or fragments thereof to identify the neoantigens.
In one aspect, the combinatorial library of polypeptides may comprise variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
In certain aspects, specific binding between neoantigens and HLA proteins or fragments thereof may be determined by: (i) culturing a cell transformed with at least one nucleic molecule comprising a nucleotide sequence encoding: an MHC class II component comprising at least a portion of an MHC class II a chain and at least a portion of an MHC
class II (3 chain, such that the MHC class II a chain and MHC class II [3 chain form a peptide binding groove;
and a spaceholder molecule and a first processable linker, wherein the spaceholder molecule is linked to the MHC class II component by the processable linker and the spaceholder molecule binds within the peptide binding groove thereby hindering the binding of any other peptide within the peptide binding groove; the step of culturing being conducted to produce the MHC
class II component; (ii) recovering the MHC class II component; (iii) processing the processable linker, thereby releasing the spaceholder molecule from the peptide binding groove; (iv) incubating the MHC class II component in the presence of a neoantigen, wherein the incubation facilitates the binding of the neoantigen to the peptide binding groove; (v) recovering the MHC class II component that has bound the neoantigen.
In one aspect, the spaceholder molecule may have the consensus sequence AAXAAAAAAAXAA (SEQ ID NO: 30). In another aspect, the spaceholder molecule is selected from the group consisting of PVSKMRMATPLLMQA (SEQ ID NO: 25);
AAMAAAAAAAMAA (SEQ ID NO: 26); AAMAAAAAAAAAA (SEQ ID NO: 27);
AAFAAAAAAAAAA (SEQ ID NO: 28); and ASMSAASAASMAA (SEQ ID NO: 29).
4 In some aspects, the processable linker is linked to the MHC class II a chain of the MHC class II component. In other aspects, recovering the MHC class II
component with bound neoantigen comprises affinity chromatography with an antibody recognizing the MHC class II
component.
In certain aspects, specific binding between neoantigens and HLA proteins or fragments thereof is determined by phage display, the HLA proteins or fragments thereof are expressed on the surface of a phage, and the neoantigens are incubated with the phage to assay specific binding.
In one aspect, the method further comprises an in silico analysis to determine specific binding between neoantigens and MHC class I proteins or fragments thereof, wherein the in silico analysis comprises applying a computational algorithm to predict relative binding to MHC I proteins based on the peptide sequences of the neoantigens.
In other aspects, the present invention relates to a method of treating cancer in a patient, the method comprising: obtaining tumor cells from a tumor resected from the patient; detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient; identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient; generating a messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding one or more peptides based on the neoantigens; and administering to the patient a therapeutically effective amount of the mRNA polynucleotide.
In some aspects, the mRNA polynucleotide comprises at least one chemical modification. In one aspect, the chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine,
component with bound neoantigen comprises affinity chromatography with an antibody recognizing the MHC class II
component.
In certain aspects, specific binding between neoantigens and HLA proteins or fragments thereof is determined by phage display, the HLA proteins or fragments thereof are expressed on the surface of a phage, and the neoantigens are incubated with the phage to assay specific binding.
In one aspect, the method further comprises an in silico analysis to determine specific binding between neoantigens and MHC class I proteins or fragments thereof, wherein the in silico analysis comprises applying a computational algorithm to predict relative binding to MHC I proteins based on the peptide sequences of the neoantigens.
In other aspects, the present invention relates to a method of treating cancer in a patient, the method comprising: obtaining tumor cells from a tumor resected from the patient; detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient; identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient; generating a messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding one or more peptides based on the neoantigens; and administering to the patient a therapeutically effective amount of the mRNA polynucleotide.
In some aspects, the mRNA polynucleotide comprises at least one chemical modification. In one aspect, the chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine,
5 -methyluri dine, 2-thi o-1-methyl-1 -deaza-p s eudouri dine, 2-thi o-1-methyl-p s eudouri din e, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-10-methyl uridine. In another aspect, the chemical modification is in the carbon 5-position of the uracil. In another aspect, the chemical modification is a N1-methylpseudouridine or N1-ethylpseudouridine.
In certain aspects, at least 80% of the uracils in the open reading frame have a chemical modification. In other aspects, the mRNA polynucleotide further encodes a 5' terminal cap. In one aspect, the 5' terminal cap is 7mG(5')ppp(5')NlmpNp.
In other aspects, the disclosed methods further comprise administering an effective amount of a therapeutic population of tumor infiltrating lymphocytes (TILs).
In some aspects, the therapeutic population of TILs is administered simultaneously or sequentially with the peptides or mRNA polynucleotide. the therapeutic population of TILs has been activated and/or educated by at least one neoantigen presented by the peptides or encoded by the mRNA
polynucleotide.
In some aspects, administering the peptides or mRNA polynucleotide with the therapeutic population of TILs enhances the immunogenic response and/or anti-tumor activity in the patient. In one aspect, the increase in the immunogenic response and/or anti-tumor activity in the patient is synergistic.
The foregoing features and elements may be combined in various combinations without exclusivity, unless expressly indicated otherwise. These features and elements as well as the operation thereof will become more apparent in light of the following description. It should be understood, however, the following description is intended to be exemplary in nature and non-limiting.
BRIEF DESCRIPTION OF THE DRAWINGS
The subject matter of the present disclosure is particularly pointed out and distinctly claimed in the concluding portion of the specification. A more complete understanding of the present disclosure, however, may best be obtained by referring to the detailed description and claims when considered in connection with the figures, wherein like numerals may denote like elements.
FIG. 1 illustrates a method that uses genomic tools to produce a personalized neoantigen vaccine;
FIG. 2 illustrates an overview of an approach for development of a neoantigen peptide-based vaccine and a method of treating a patient using the neoantigen peptide-based vaccine;
FIG. 3 illustrates a step-wise work flow for efficient synthesis and analysis of large libraries of DNA-barcoded peptides; the peptide-DNA library depicted shows a puromycin ("Puro") adaptor that facilitates linking of the DNA to the encoded peptide;
FIG. 4 illustrates analysis of tumor exomes to identify candidate neoantigens, characterization of the candidate neoantigens with the MHC-peptide-DNA
conjugate assay, and evaluation of T cell response to the neoantigens that bound to HLA
proteins in the MHC-peptide-DNA conjugate assay;
In certain aspects, at least 80% of the uracils in the open reading frame have a chemical modification. In other aspects, the mRNA polynucleotide further encodes a 5' terminal cap. In one aspect, the 5' terminal cap is 7mG(5')ppp(5')NlmpNp.
In other aspects, the disclosed methods further comprise administering an effective amount of a therapeutic population of tumor infiltrating lymphocytes (TILs).
In some aspects, the therapeutic population of TILs is administered simultaneously or sequentially with the peptides or mRNA polynucleotide. the therapeutic population of TILs has been activated and/or educated by at least one neoantigen presented by the peptides or encoded by the mRNA
polynucleotide.
In some aspects, administering the peptides or mRNA polynucleotide with the therapeutic population of TILs enhances the immunogenic response and/or anti-tumor activity in the patient. In one aspect, the increase in the immunogenic response and/or anti-tumor activity in the patient is synergistic.
The foregoing features and elements may be combined in various combinations without exclusivity, unless expressly indicated otherwise. These features and elements as well as the operation thereof will become more apparent in light of the following description. It should be understood, however, the following description is intended to be exemplary in nature and non-limiting.
BRIEF DESCRIPTION OF THE DRAWINGS
The subject matter of the present disclosure is particularly pointed out and distinctly claimed in the concluding portion of the specification. A more complete understanding of the present disclosure, however, may best be obtained by referring to the detailed description and claims when considered in connection with the figures, wherein like numerals may denote like elements.
FIG. 1 illustrates a method that uses genomic tools to produce a personalized neoantigen vaccine;
FIG. 2 illustrates an overview of an approach for development of a neoantigen peptide-based vaccine and a method of treating a patient using the neoantigen peptide-based vaccine;
FIG. 3 illustrates a step-wise work flow for efficient synthesis and analysis of large libraries of DNA-barcoded peptides; the peptide-DNA library depicted shows a puromycin ("Puro") adaptor that facilitates linking of the DNA to the encoded peptide;
FIG. 4 illustrates analysis of tumor exomes to identify candidate neoantigens, characterization of the candidate neoantigens with the MHC-peptide-DNA
conjugate assay, and evaluation of T cell response to the neoantigens that bound to HLA
proteins in the MHC-peptide-DNA conjugate assay;
6 FIG. 5 illustrates a DNA conjugate assay library design for the analysis of mutations identified from an analysis of tumor exomes;
FIG. 6 illustrates an embodiment of the MHC-peptide-DNA conjugate assay used to identify neoantigens that bind to MHC Class II molecules; in the control group ("uncleaved"), the CLIP peptide is not removed from the HLA construct and candidate neoantigens bind non-specifically while in the test group ("cleaved") removal of the CLIP peptide opens the recognition site of the HLA construct allowing for specific binding of candidate neoantigens;
FIG. 7 illustrates the identification of enriched peptides (i.e., neoantigens) from 2 human patients (i.e., TG0006 and TG00013); the numbers of mutations identified in each patient with exome analysis are shown under each patient ID; the human leukocyte antigen serotypes of the HLA complexes used in the binding assays are identified in the upper left-hand corner of each graph. Enriched peptides are shown as larger data points FIGS. 8A and 8B illustrate additional data sets identifying enriched peptides (i.e., neoantigens) from human patient TG00013; enriched peptides appear as data points in the upper portion of each graph corresponding to those peptides with a log average % read with cleaved HLA complexes closer to 0 (i.e., closer to 100% binding with cleaved HLA
complexes);
FIG. 9 illustrates the amino acid sequences of the enriched peptides, the corresponding mutation for each peptide, and the human leukocyte antigen serotype of the HLA
complex with which the peptide specifically binds for human patient TG00013; and FIG. 10 illustrates a comparison of the MHC-peptide-DNA conjugate assay versus in silico prediction to identify neoantigens; the IEDB consensus sequences used for the in silico analysis are obtained from the Immune Epitope Database and Analysis Resource (IEDB), a public resource maintained by the National Institute of Allergy and Infectious Diseases (NIAID).
FIG. 11 illustrates information on several human patients who were evaluated by collecting tumor infiltrating lymphocytes (TILs) and generating peptides to activate and educate these TILs to enhance recognition of neoantigens and anti-tumor activity.
FIG. 12 illustrates a non-limiting example of peptide vaccine manufacturing with the disclosed methods.
FIG. 13 illustrates infiltration of tumor cell organoids by peripheral blood mononuclear cells (PBMC) derived from the patient with the tumor. The PBMCs were administered alone or with DMSO (negative controls), in combination with IL-2, or in combination with IL-2 and a peptide identified as a neoantigen. The images were captured 24 hours after the organoids
FIG. 6 illustrates an embodiment of the MHC-peptide-DNA conjugate assay used to identify neoantigens that bind to MHC Class II molecules; in the control group ("uncleaved"), the CLIP peptide is not removed from the HLA construct and candidate neoantigens bind non-specifically while in the test group ("cleaved") removal of the CLIP peptide opens the recognition site of the HLA construct allowing for specific binding of candidate neoantigens;
FIG. 7 illustrates the identification of enriched peptides (i.e., neoantigens) from 2 human patients (i.e., TG0006 and TG00013); the numbers of mutations identified in each patient with exome analysis are shown under each patient ID; the human leukocyte antigen serotypes of the HLA complexes used in the binding assays are identified in the upper left-hand corner of each graph. Enriched peptides are shown as larger data points FIGS. 8A and 8B illustrate additional data sets identifying enriched peptides (i.e., neoantigens) from human patient TG00013; enriched peptides appear as data points in the upper portion of each graph corresponding to those peptides with a log average % read with cleaved HLA complexes closer to 0 (i.e., closer to 100% binding with cleaved HLA
complexes);
FIG. 9 illustrates the amino acid sequences of the enriched peptides, the corresponding mutation for each peptide, and the human leukocyte antigen serotype of the HLA
complex with which the peptide specifically binds for human patient TG00013; and FIG. 10 illustrates a comparison of the MHC-peptide-DNA conjugate assay versus in silico prediction to identify neoantigens; the IEDB consensus sequences used for the in silico analysis are obtained from the Immune Epitope Database and Analysis Resource (IEDB), a public resource maintained by the National Institute of Allergy and Infectious Diseases (NIAID).
FIG. 11 illustrates information on several human patients who were evaluated by collecting tumor infiltrating lymphocytes (TILs) and generating peptides to activate and educate these TILs to enhance recognition of neoantigens and anti-tumor activity.
FIG. 12 illustrates a non-limiting example of peptide vaccine manufacturing with the disclosed methods.
FIG. 13 illustrates infiltration of tumor cell organoids by peripheral blood mononuclear cells (PBMC) derived from the patient with the tumor. The PBMCs were administered alone or with DMSO (negative controls), in combination with IL-2, or in combination with IL-2 and a peptide identified as a neoantigen. The images were captured 24 hours after the organoids
7 were subjected to the various treatment. As shown in the bar graphs, after only 24 hours the PBMCs in combination the IL-2 and the peptide demonstrated significant infiltration of the organoid.
FIG. 14 illustrates a study to test the safety and efficacy of the disclosed peptide vaccines. ORR: objective response rate; DOR: duration of any observed response; PFS:
progression-free survival; OS: overall survival.
DETAILED DESCRIPTION
It is to be understood that unless specifically stated otherwise, references to -a," -an,"
and/or -the" may include one or more than one and that reference to an item in the singular may also include the item in the plural. Reference to an element by the indefinite article "a,"
"an" and/or "the" does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. As used herein, the term -comprise," and conjugations or any other variation thereof, are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
A "neoepitope" is understood in the art to refer to an epitope that emerges or develops in a subject after exposure to or occurrence of a particular event (e.g., development or progression of a particular disease, disorder or condition, e.g., infection, cancer, stage of cancer, etc.). As used herein, a neoepitope is one whose presence and/or level is correlated with exposure to or occurrence of the event. In some embodiments, a neoepitope is one that triggers an immune response against cells that express it (e.g., at a relevant level).
In some embodiments, a neoepitope is one that triggers an immune response that kills or otherwise destroys cells that express it (e.g., at a relevant level). In some embodiments, a relevant event that triggers a neoepitope is or comprises somatic mutation in a cell. In some embodiments, a neoepitope is not expressed in non-cancer cells to a level and/or in a manner that triggers and/or supports an immune response (e.g., an immune response sufficient to target cancer cells expressing the neoepitope). In some embodiments, a neoepitope is a neoantigen.
The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to a polymeric form of amino acids of any length, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.
The term "peptide construct- as used herein, refers to a peptide of any length attached to an identifying oligonucleotide. The attachment may be via an intervening linker and the attachment may be covalent or non-covalent. The identifying oligonucleotide may be the message that was translated to form the peptide portion of the construct, or it may be any other sequence that is known and can be used to identify the attached peptide by sequencing. 'Peptide construct sets' refer to a pool of peptide constructs generated from a custom-designed set of oligonucleotides. The sets may contain as few as one copy per species of peptide construct but typically contain many copies of each peptide construct.
The term "amino acid- refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified. Unnatural amino acids are not encoded by the genetic code and can, but do not necessarily have the same basic structure as a naturally occurring amino acid. -Amino acid analogs" refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methi nine sulfoxi de, methi nine methyl sul foni um Such analogs may have modified R
groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. "Amino acid mimetics" refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
Amino acids may be referred to by either the three letter symbols or by the one-letter symbols recommended by the IUPAC, the IUAPC letter code are as follows: G =
Glycine; A
= Alanine; L = Leucine; M = Methionine; F = Phenylalanine; W = Tryptophan; K =
Lysine; Q
= Glutamine; E = Glutamic Acid; S = Serine; P = Proline; V = Valine; I =
Isoleucine; C =
Cysteine; Y = Tyrosine; H = Histidine; R = Arginine; N = Asparagine; D =
Aspartic Acid; T =
Threonine.
The terms "homologous" and "similar" refer to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species.
Such proteins (and their encoding genes) have sequence homology, as reflected by their sequence similarity, whether in terms of percent similarity or the presence of specific residues or motifs as conserved positions. In a specific embodiment, two peptide sequences are -substantially homologous or similar" when at least about 80%, or at least about 90%, or at least about 95) of the amino acids match over the defined lengths of the amino acid sequences.
The term "variants" applies to both amino acid and nucleic acid sequences.
Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Variants may include individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence.
"Function-conservative variants- are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids with similar properties are well known in the art. For example, arginine, histidine and lysine are hydrophilic-basic amino acids and may be interchangeable. Similarly, isoleucine, a hydrophobic amino acid, may be replaced with leucine, methionine or valine. Such changes are expected to have little or no effect on the apparent molecular weight or i soel ectri c point of the protein or polypeptide.
Amino acids other than those indicated as conserved may differ in a protein so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme. A "variant" also includes a polypeptide which has at least 60% amino acid identity as determined by BLAST or FASTA algorithms, preferably at least 75% most preferably at least 85%, and even more preferably at least 90%, and still more preferably at least 95%, and which has the same or substantially similar properties or functions as the native or parent protein to which it is compared. A particular variant is a "gain-of-function" variant, meaning a polypeptide variant in which the change of at least one given amino acid residue in a protein or enzyme improves a specific function of the polypeptide, including, but not limited to protein activity. The change in amino acid residue can be replacement of an amino acid with one having similar properties.
As used herein, the term "binding" refers to an attractive interaction between two molecules which results in a stable association in which the molecules are in close proximity to each other. Molecular binding can be classified into the following types:
non-covalent, reversible covalent and irreversible covalent. Molecules that can participate in molecular binding include proteins, nucleic acids, carbohydrates, lipids, and small organic molecules such as pharmaceutical compounds. For example, proteins that form stable complexes with other molecules are often referred to as receptors while their binding partners are called ligands.
Nucleic acids can also form stable complex with themselves or others, for example, DNA-protein complex, DNA-DNA complex, DNA-RNA complex, protein-protein complex.
As used herein, the term "specific binding" refers to the specificity of a binder, e.g., a protein or an antibody, such that it preferentially binds to a target, such as a polypeptide antigen, a receptor, or an antibody. When referring to a binding partner, e.g., protein, nucleic acid, antibody or other affinity capture agent, etc., "specific binding" can include a binding reaction of two or more binding partners with high affinity and/or complementarity to ensure selective hybridization under designated assay conditions. Typically, specific binding will be at least three times the standard deviation of the background signal. Thus, under designated conditions the binding partner binds to its particular target molecule and does not bind in a significant amount to other molecules present in the sample. Recognition by a binder or an antibody of a particular target in the presence of other potential interfering substances is one characteristic of such binding. Preferably, binders, antibodies or antibody fragments, peptides, or fusion peptides that are specific for or bind specifically to a target bind to the target with higher affinity than binding to other non-target substances. Al so preferably, binders, antibodies or anti body fragments, peptides, or fusion peptides that are specific for or bind specifically to a target avoid binding to a significant percentage of non- target substances, e.g., non-target substances present in a testing sample. The binding affinity of an antibody to a target antigen, antigenic fragment, peptide, or fusion peptide, comprising the cognate epitope can be readily determined using any of a number of methods available in the art including, but not limited to, enzyme linked immunosorbent assay (ELISA). In some embodiments, binders, antibodies or antibody fragments, peptides, or fusion peptides of the present disclosure avoid binding greater than about 90% of non-target substances, although higher percentages are clearly contemplated and preferred. For example, binders, antibodies or antibody fragments, or peptides, of the present disclosure avoid binding about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, and about 99% or more of non-target substances. In other embodiments, binders, antibodies or antibody fragments, or peptides of the present disclosure avoid binding greater than about 10%, 20%, 30%, 40%, 50 '/0 , 60%, or 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%
of non- target substances.
The terms -target," -target molecule," and "target agent- are used interchangeably herein and refer to a protein, toxin, enzyme, pathogen, cell or biomarker that is incubated with a library to identify peptides demonstrating specific binding to the target. A
target or a marker may be any molecular structure produced by a cell, expressed inside the cell, accessible on the cell surface, or secreted by the cell. A marker may be any protein, carbohydrate, fat, nucleic acid, catalytic site, or any target of these such as an enzyme, glycoprotein, cell membrane, virus, cell, organ, organelle, or any uni- or multimolecular structure or any other such structure now known or yet to be disclosed whether alone or in combination. A target may also be called a marker and the terms are used interchangeably. A target may be represented by the sequence of amino acids, or sequence of one or more strands of a nucleic acid from which it may be derived. For example, a target may be represented by a protein sequence.
Alternatively, a target may be represented by a nucleic acid sequence, the protein or peptide or the fragments thereof encoded by the nucleic acid sequence.
Examples of such nucleic acids include both single stranded and double stranded nucleic acid sequences including miRNA, tRNA, siRNA, mRNA, cDNA, or genomic DNA
sequences including complimentary sequences. The concept of a marker is not limited to the products of the exact nucleic acid sequence or protein sequence by which it may be represented.
Rather, a marker encompasses all molecules that may be detected by a method of assessing the expression of the marker. Examples of molecules encompassed by a marker include point mutations, silent mutations, deletions, frameshift mutations, translocations, alternative splicing derivatives, differentially methylated sequences, differentially modified protein sequences, truncations, soluble forms of cell membrane associated markers, and any other variation that results in a product that may be identified as the marker. The term "target"
further encompasses the products (i.e., proteins) of the gene or a gene allele thereof, whose expression or activity is directly or indirectly associated with a particular phenotype or cellular condition, or physiological characteristic.
The terms "capture agent" and "capture group" as used herein refer to any moiety that allows capture of a target molecule or a peptide construct via binding to or linkage with an affinity group or domain on the target molecule or an affinity tag of the peptide construct. The binding between the capture agent and its affinity tag may be a covalent bond and/or a non-covalent bond. A capture agent includes, e.g., a member of a binding pair that selectively binds to an affinity tag on a fusion peptide, a chemical linkage that is added by recombinant technology or other mechanisms, co-factors for enzymes and the like. Capture agents can be associated with a peptide construct using conventional techniques including hybridization, cross-linking (e.g., covalent immobilization using a furocoumarin such as psoralen), ligation, attachment via chemically-reactive groups, introduction through post-translational modification and the like.
"Sequence determination," "sequencing," and the like include determination of information relating to the nucleotide base sequence of a nucleic acid. Such information may include the identification or determination of partial as well as full sequence information of the nucleic acid. Sequence information may be determined with varying degrees of statistical reliability or confidence. In one aspect, the term includes the determination of the identity and ordering of a plurality of contiguous nucleotides in a nucleic acid. "High throughput sequencing- or -next generation sequencing- includes sequence determination using methods that determine many (typically thousands to billions) of nucleic acid sequences in an intrinsically parallel manner, i.e., where DNA templates are prepared for sequencing not one at a time, but in a bulk process, and where many sequences are read out preferably in parallel, or alternatively using an ultra-high throughput serial process that itself may be parallelized.
Such methods include but are not limited to pyrosequencing (for example, as commercialized by 454 Life Sciences, Inc., Branford, CT); sequencing by ligation (for example, as commercialized in the SOLiDTm technology, Life Technologies, Inc., Carlsbad, CA);
sequencing by synthesis using modified nucleotides (such as commercialized in TruSeqTm and HiSeem technology by Illumina, Inc., San Diego, CA; HeliScopem by Helicos Biosciences Corporation, Cambridge, MA; and PacBio RS by Pacific Biosciences of California, Inc., Menlo Park, CA), sequencing by ion detection technologies (such as Ion TorrentTm technology, Life Technologies, Carlsbad, CA); sequencing of DNA nanoballs (Complete Genomics, Inc., Mountain View, CA); nanopore -based sequencing technologies (for example, as developed by Oxford Nanopore Technologies, LTD, Oxford, UK), and like highly parallelized sequencing methods.
The term "exome" is used in accordance with its art-understood meaning referring to the set of exon sequences that are found in a particular genome.
As used herein, the term -mutation" refers to permanent change in the DNA
sequence that makes up a gene. In some embodiments, mutations range in size from a single DNA
building block (DNA base) to a large segment of a chromosome. In some embodiments, mutations can include missense mutations, frameshift mutations, duplications, insertions, nonsense mutation, deletions and repeat expansions. In some embodiments, a missense mutation is a change in one DNA base pair that results in the substitution of one amino acid for another in the protein made by a gene. In some embodiments, a nonsense mutation is also a change in one DNA base pair. Instead of substituting one amino acid for another, however, the altered DNA sequence prematurely signals the cell to stop building a protein. In some embodiments, an insertion changes the number of DNA bases in a gene by adding a piece of DNA. In some embodiments, a deletion changes the number of DNA
bases by removing a piece of DNA. In some embodiments, small deletions may remove one or a few base pairs within a gene, while larger deletions can remove an entire gene or several neighboring genes. In some embodiments, a duplication consists of a piece of DNA that is abnormally copied one or more times. In some embodiments, frameshift mutations occur when the addition or loss of DNA bases changes a gene's reading frame. A reading frame consists of groups of 3 bases that each code for one amino acid. In some embodiments, a frameshift mutation shifts the grouping of these bases and changes the code for amino acids.
In some embodiments, insertions, deletions, and duplications can all be frameshift mutations.
In some embodiments, a repeat expansion is another type of mutation. In some embodiments, nucleotide repeats are short DNA sequences that are repeated a number of times in a row. For example, a trinucleotide repeat is made up of 3-base-pair sequences, and a tetranucleotide repeat is made up of 4-base-pair sequences. In some embodiments, a repeat expansion is a mutation that increases the number of times that the short DNA sequence is repeated.
"Small molecule," as used herein, means a molecule less than 5 kilodaltons, more typically, less than 1 kilodalton. As used herein, -small molecule" includes peptides.
"Affinity tag" is given its ordinary meaning in the art. An affinity tag is any biological or chemical material that can readily be attached to a target biological or chemical material. Affinity tags may be attached to a target biological or chemical molecule by any suitable method. For example, in some embodiments, the affinity tag may be attached to the target molecule using genetic methods. For example, the nucleic acid sequence coding the affinity tag may be inserted near a sequence that encodes a biological molecule; the sequence may be positioned anywhere within the nucleic acid that enables the affinity tag to be expressed with the biological molecule, for example, within, adjacent to, or nearby. In other embodiments, the affinity tag may also be attached to the target biological or chemical molecule after the molecule has been produced (e.g., expressed or synthesized). As one example, an affinity tag such as biotin may be chemically coupled, for instance covalently, to a target protein or peptide to facilitate the binding of the target to streptavidin.
Affinity tags include, for example, metal binding tags such as histidine tags, GST (in glutathione/GST binding), streptavidin (in biotin/streptavidin binding).
Other affinity tags include Myc or Max in a Myc/Max pair, or polyamino acids, such as polyhistidines. At various locations herein, specific affinity tags are described in connection with binding interactions. The molecule that the affinity tag interacts with (i.e., binds to), which may be a known biological or chemical binding partner, is the "recognition entity." It is to be understood that the invention involves, in any embodiment employing an affinity tag, a series of individual embodiments each involving selection of any of the affinity tags described herein.
A "recognition entity" may be any chemical or biological material that is able to bind to an affinity tag. A recognition entity may be, for example, a small molecule such as maltose (which binds to MBP, or maltose binding protein), glutathione, NTA/Ni2+, biotin (which may bind to streptavidin), or an antibody. An affinity tag/recognition entity interaction may facilitate attachment of the target molecule, for example, to another biological or chemical material, or to a substrate (e.g., a nitrocellulose membrane or other immobilized substrate).
Examples of affinity tag/recognition entity interactions include polyhistidine/NTA/Ni2+, glutathione S -transferas e/glutathi one, maltose binding protein/maltose, streptavidin/biotin, biotin/streptavidin, antigen (or antigen fragment)/antibody (or antibody fragment), and the like.
The term -ribosomal display- refers to a reaction system able to yield a ternary complex of an mRNA, ribosome and corresponding protein of interest. Ribosomal display can be used for screening cell surface receptors, antibodies, and fragments thereof for target antigen or ligand binding. The steps of producing the reaction system can include: 1) generating a DNA
library and transcribing the library into an RNA library, 2) purifying the RNA
and in vitro translation in a cell-free protein synthesis system, 3) allowing the ribosome complexes of the translation reaction to bind to a target antigen or ligand, 4) selecting bound ribosome complexes; and 5) isolating RNA from the complexes and reverse transcribing the transcripts to cDNA, wherein the cDNA can be amplified, sequenced and/or further modified.
In some embodiments, the pharmaceutical composition includes one or more peptides or oligonucleotides, as described herein, together with a pharmaceutically acceptable carrier, diluent or excipient. In the preparation of the pharmaceutical compositions comprising the peptides or oligonucleotides described in the teachings herein, a variety of vehicles, vectors, excipients, and routes of administration may be used. The pharmaceutical compositions will generally comprise a pharmaceutically acceptable carrier and a pharmacologically (or therapeutically) effective amount of the peptides or oligonucleotides. In various embodiments, the pharmaceutical compositions comprising the one or more peptides may include an adjuvant or other agent for inducing or enhancing a patient's immune response. In other embodiments, the pharmaceutical compositions comprising the one or more oligonucleotides may be delivered without an adjuvant.
The pharmaceutical compositions described herein may be administered by any means that enables the active agent to reach the agent's site of action in the body of the subject. The dosage administered varies depending upon factors, such as: pharmacodynamic characteristics;
mode and route of administration; age, health, and weight of the recipient subject; nature and extent of symptoms; concurrent treatments; and frequency of treatment.
As used herein, the terms "administration" and "administering" of an agent to a subject include any route of introducing or delivering the agent to a subject to perform its intended function. Administration can be carried out by any suitable route, including intravenously, intramuscularly, intraperitoneally, inhalationally, intranasally, or subcutaneously.
Administration includes self-administration and the administration by another.
The term "effective amount" or "therapeutically effective amount" refers to that amount of an agent or combination of agents as described herein that is sufficient to effect the intended application including, but not limited to, disease treatment. A
therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated (e.g., the weight, age and gender of the subject), the severity of the disease condition, or the manner of administration. The term also applies to a dose that will induce a particular response in target cells. The specific dose will vary depending on the particular agents chosen, the dosing regimen to be followed, whether the agent is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which the compound is carried.
The terms "treatment," "treating," "treat," and the like, refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
-Treatment", as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development or progression; and (c) relieving the disease, i.e., causing regression of the disease and/or relieving one or more disease symptoms. -Treatment" is also meant to encompass delivery of an agent in order to provide for a pharmacologic effect, even in the absence of a disease or condition. For example, -treatment" encompasses delivery of a composition that can elicit an immune response or confer immunity in the absence of a disease condition, e.g., in the case of a vaccine.
As used herein, the term "patient- or "subject" refers to any organism to which a provided composition is or may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. For example, subject may refer to a human or a non-human animal. In some aspects, subject refers to any vertebrate including, without limitation, humans and other primates (e.g., chimpanzees and other apes and monkey species), farm animals (e.g., cattle, sheep, pigs, goats and horses), domestic mammals (e.g., dogs and cats), laboratory animals (e.g., rodents such as mice, rats, and guinea pigs), and birds (e.g., domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like). In some embodiments, the subject is a mammal. In further embodiments, the subject is a human.
In some embodiments, a patient is suffering from or susceptible to one or more disorders or conditions. In some embodiments, a patient displays one or more symptoms of a disease, disorder or condition. In some embodiments, a patient has been diagnosed with one or more diseases, disorders or conditions. In some embodiments, the disorder or condition is or includes cancer, or the presence of one or more tumors.
Detection of Tumor Mutations and/or Neoepitopes Cancers may be screened to detect mutations and/or neoepitopes (e.g., to detect neoantigen identity, and/or neoepitope nature, level, and/or frequency) as described herein using any of a variety of known technologies. In some embodiments, particular mutations or neoepitopes, or expression thereof, is/are detected at the nucleic acid level (e.g., in DNA or RNA). One of skill in the art would recognize that mutations or neoepitopes, or expression thereof, can be detected in a sample comprising DNA
or RNA from cancer cells. Further, one of skill in the art would understand that a sample comprising DNA
or RNA from cancer cells can include but is not limited to circulating tumor DNA (cIDNA), cell free DNA (cfDNA), cells, tissues, or organs. In some embodiments, mutations or neoepitopes, or expression thereof, is detected at the protein level (e.g., in a sample comprising polypeptides from cancer cells, which sample may be or comprise polypeptide complexes or other higher order structures including but not limited to cells, tissues, or organs).
In some particular embodiments, detection involves nucleic acid sequencing. In some embodiments, detection involves whole exome sequencing. In some embodiments, detection involves an immunoassay. In some embodiments, detection involves use of a microarray. In some embodiments, detection involves massively parallel exome sequencing. In some embodiments, detection involves genome sequencing. In some embodiments, detection involves RNA sequencing. In some embodiments, detection involves standard DNA
or RNA
sequencing. In some embodiments, detection involves mass spectrometry.
In some embodiments, detection involves next generation sequencing (DNA and/or RNA). In some embodiments, detection involves genome sequencing, genome resequencing, targeted sequencing panels, transcriptome profiling (RNA-Seq), DNA-protein interactions (ChIP-sequencing), and/or epigenome characterization. In some embodiments, re-sequencing of a patient's genome may be utilized, for example to detect genomic variations.
In some embodiments, detection involves using a technique such as ELISA, western blotting, immunoassay, mass spectrometry, microarray analysis, etc.
In some embodiments, detection involves next generation sequencing (DNA and/or RNA). In some embodiments, detection involves next generation sequencing of targeted gene panels (e.g. the ASHTON" tumor/normal exome-RNA test (GEMEXTRA"), MSK-IMPACT, or FOUNDATIONONE"). In some embodiments, detection involves genomic profiling.
In some embodiments, detection involves genomic profiling using the GEMEXTRA
test. The GEMEXTRA test is a comprehensive exome and transcriptome profiling assay that both informs the care of cancer patients and enables future research into the disease. Greater than 19,000 genes are assayed via hybridization capture and clinical-depth sequencing for the identification of somatic point mutations, small and large insertions and deletions and structural rearrangements. Measures of microsatellite instability (MSI) and tumor mutational burden (TMB) are also taken to inform the application of immunoncology therapies. To ensure somatic origin of identified variants, both the germline and tumor exomes are sequenced and compared.
The entire transcriptome is also sequenced, enabling the detection of gene fusion and alternative splicing events from the patient's RNA. GEMEXTRA" is applicable to both solid and hematological cancers.
In some embodiments, detection involves genomic profiling using Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) (see Cheng D T, Mitchell T N, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17(3):251-264; and Ross D S, Zehir A, Cheng D T, et al. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status:
Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. .111461 Diagn. 2017; 19(2):244-254). MSK-IMPACT is a comprehensive molecular profiling assay that involves hybridization capture and deep sequencing of all exons and selected introns of multiple oncogenes and tumor-suppressor genes, allowing for detection of point mutations, small and large insertions or deletions, and rearrangements. MSK-IMPACT also captures intergenic and intronic single-nucleotide polymorphisms (e.g., tiling probes), interspersed across a genome, aiding in accurate assessment of genome-wide copy number. In some embodiments, probes may target a megab as e.
In some embodiments, detection involves genomic profiling using the FOUNDATIONONE CDX1m (-F1CDx") assay. The F1CDx assay is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutation burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. F1CDx is approved by the United States Food and Drug Administration (FDA) for several tumor indications, including NSCLC, melanoma, breast cancer, colorectal cancer, and ovarian cancer.
The F1CDx assay employs a single DNA extraction method from routine FFPE
biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and selected intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons.
In total, the assay detects alterations in a total of 324 genes. Using the ILLUMINA HiSeq 4000 platform, hybrid capture- selected libraries are sequenced to high uniform depth (targeting >500X
median coverage with >99% of exons at coverage >100X). Sequence data is then processed using a customized analysis pipeline designed to detect all classes of genomic alterations, including base substitutions, indels, copy number alterations (amplifications and homozygous gene deletions), and selected genomic rearrangements (e.g., gene fusions).
Additionally, genomic signatures including microsatellite instability (MSI) and tumor mutation burden (TMB) are reported.
In some embodiments, detection may involve sequencing of exon and/or intron sequences from at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 or more genes (e.g., oncogenes and/or tumor-suppressor genes). For example, literature reports indicate that MSK-IMPACT has been used to achieve deep sequencing of all exons and selected introns of 468 oncogenes and tumor-suppressor genes.
Alternatively or additionally, in some embodiments, detection may involve sequencing of intergenic and/or intronic single-nucleotide polymorphisms. For example, literature reports indicate that MSK-IMPACT has been used to achieve deep sequencing of >1000 intergenic and intronic single-nucleotide polymorphisms.
In some embodiments, detection involves sequencing of splice variants. Cancer cells are able to adapt and evolve by developing mechanisms to escape control by their microenvironment. The diversity and plasticity offered by alternative splicing, therefore, provide an opportunity for cancer cells to produce protein isoforms suitable for tumor growth and/or spreading (David C J and Manley J L. Genes Dev. 2010; 24(20:2343-2364).
Genome-wide approaches has revealed that large-scale alternative splicing occurs during tumorigenesis (Venables J P et al. Nat Struct Mol Biol. 2009; 16(6):670-676.), and the genomic portraits of alternative splicing patterns have proven useful in the classification of tumors (Venables J
P. Bioessays. 2006; 28(4):378-386; Skotheim RI et al., Int .1- Biochem Cell Biol. 2007; 39(7-
FIG. 14 illustrates a study to test the safety and efficacy of the disclosed peptide vaccines. ORR: objective response rate; DOR: duration of any observed response; PFS:
progression-free survival; OS: overall survival.
DETAILED DESCRIPTION
It is to be understood that unless specifically stated otherwise, references to -a," -an,"
and/or -the" may include one or more than one and that reference to an item in the singular may also include the item in the plural. Reference to an element by the indefinite article "a,"
"an" and/or "the" does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. As used herein, the term -comprise," and conjugations or any other variation thereof, are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
A "neoepitope" is understood in the art to refer to an epitope that emerges or develops in a subject after exposure to or occurrence of a particular event (e.g., development or progression of a particular disease, disorder or condition, e.g., infection, cancer, stage of cancer, etc.). As used herein, a neoepitope is one whose presence and/or level is correlated with exposure to or occurrence of the event. In some embodiments, a neoepitope is one that triggers an immune response against cells that express it (e.g., at a relevant level).
In some embodiments, a neoepitope is one that triggers an immune response that kills or otherwise destroys cells that express it (e.g., at a relevant level). In some embodiments, a relevant event that triggers a neoepitope is or comprises somatic mutation in a cell. In some embodiments, a neoepitope is not expressed in non-cancer cells to a level and/or in a manner that triggers and/or supports an immune response (e.g., an immune response sufficient to target cancer cells expressing the neoepitope). In some embodiments, a neoepitope is a neoantigen.
The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to a polymeric form of amino acids of any length, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.
The term "peptide construct- as used herein, refers to a peptide of any length attached to an identifying oligonucleotide. The attachment may be via an intervening linker and the attachment may be covalent or non-covalent. The identifying oligonucleotide may be the message that was translated to form the peptide portion of the construct, or it may be any other sequence that is known and can be used to identify the attached peptide by sequencing. 'Peptide construct sets' refer to a pool of peptide constructs generated from a custom-designed set of oligonucleotides. The sets may contain as few as one copy per species of peptide construct but typically contain many copies of each peptide construct.
The term "amino acid- refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified. Unnatural amino acids are not encoded by the genetic code and can, but do not necessarily have the same basic structure as a naturally occurring amino acid. -Amino acid analogs" refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methi nine sulfoxi de, methi nine methyl sul foni um Such analogs may have modified R
groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. "Amino acid mimetics" refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
Amino acids may be referred to by either the three letter symbols or by the one-letter symbols recommended by the IUPAC, the IUAPC letter code are as follows: G =
Glycine; A
= Alanine; L = Leucine; M = Methionine; F = Phenylalanine; W = Tryptophan; K =
Lysine; Q
= Glutamine; E = Glutamic Acid; S = Serine; P = Proline; V = Valine; I =
Isoleucine; C =
Cysteine; Y = Tyrosine; H = Histidine; R = Arginine; N = Asparagine; D =
Aspartic Acid; T =
Threonine.
The terms "homologous" and "similar" refer to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species.
Such proteins (and their encoding genes) have sequence homology, as reflected by their sequence similarity, whether in terms of percent similarity or the presence of specific residues or motifs as conserved positions. In a specific embodiment, two peptide sequences are -substantially homologous or similar" when at least about 80%, or at least about 90%, or at least about 95) of the amino acids match over the defined lengths of the amino acid sequences.
The term "variants" applies to both amino acid and nucleic acid sequences.
Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Variants may include individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence.
"Function-conservative variants- are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids with similar properties are well known in the art. For example, arginine, histidine and lysine are hydrophilic-basic amino acids and may be interchangeable. Similarly, isoleucine, a hydrophobic amino acid, may be replaced with leucine, methionine or valine. Such changes are expected to have little or no effect on the apparent molecular weight or i soel ectri c point of the protein or polypeptide.
Amino acids other than those indicated as conserved may differ in a protein so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme. A "variant" also includes a polypeptide which has at least 60% amino acid identity as determined by BLAST or FASTA algorithms, preferably at least 75% most preferably at least 85%, and even more preferably at least 90%, and still more preferably at least 95%, and which has the same or substantially similar properties or functions as the native or parent protein to which it is compared. A particular variant is a "gain-of-function" variant, meaning a polypeptide variant in which the change of at least one given amino acid residue in a protein or enzyme improves a specific function of the polypeptide, including, but not limited to protein activity. The change in amino acid residue can be replacement of an amino acid with one having similar properties.
As used herein, the term "binding" refers to an attractive interaction between two molecules which results in a stable association in which the molecules are in close proximity to each other. Molecular binding can be classified into the following types:
non-covalent, reversible covalent and irreversible covalent. Molecules that can participate in molecular binding include proteins, nucleic acids, carbohydrates, lipids, and small organic molecules such as pharmaceutical compounds. For example, proteins that form stable complexes with other molecules are often referred to as receptors while their binding partners are called ligands.
Nucleic acids can also form stable complex with themselves or others, for example, DNA-protein complex, DNA-DNA complex, DNA-RNA complex, protein-protein complex.
As used herein, the term "specific binding" refers to the specificity of a binder, e.g., a protein or an antibody, such that it preferentially binds to a target, such as a polypeptide antigen, a receptor, or an antibody. When referring to a binding partner, e.g., protein, nucleic acid, antibody or other affinity capture agent, etc., "specific binding" can include a binding reaction of two or more binding partners with high affinity and/or complementarity to ensure selective hybridization under designated assay conditions. Typically, specific binding will be at least three times the standard deviation of the background signal. Thus, under designated conditions the binding partner binds to its particular target molecule and does not bind in a significant amount to other molecules present in the sample. Recognition by a binder or an antibody of a particular target in the presence of other potential interfering substances is one characteristic of such binding. Preferably, binders, antibodies or antibody fragments, peptides, or fusion peptides that are specific for or bind specifically to a target bind to the target with higher affinity than binding to other non-target substances. Al so preferably, binders, antibodies or anti body fragments, peptides, or fusion peptides that are specific for or bind specifically to a target avoid binding to a significant percentage of non- target substances, e.g., non-target substances present in a testing sample. The binding affinity of an antibody to a target antigen, antigenic fragment, peptide, or fusion peptide, comprising the cognate epitope can be readily determined using any of a number of methods available in the art including, but not limited to, enzyme linked immunosorbent assay (ELISA). In some embodiments, binders, antibodies or antibody fragments, peptides, or fusion peptides of the present disclosure avoid binding greater than about 90% of non-target substances, although higher percentages are clearly contemplated and preferred. For example, binders, antibodies or antibody fragments, or peptides, of the present disclosure avoid binding about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, and about 99% or more of non-target substances. In other embodiments, binders, antibodies or antibody fragments, or peptides of the present disclosure avoid binding greater than about 10%, 20%, 30%, 40%, 50 '/0 , 60%, or 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%
of non- target substances.
The terms -target," -target molecule," and "target agent- are used interchangeably herein and refer to a protein, toxin, enzyme, pathogen, cell or biomarker that is incubated with a library to identify peptides demonstrating specific binding to the target. A
target or a marker may be any molecular structure produced by a cell, expressed inside the cell, accessible on the cell surface, or secreted by the cell. A marker may be any protein, carbohydrate, fat, nucleic acid, catalytic site, or any target of these such as an enzyme, glycoprotein, cell membrane, virus, cell, organ, organelle, or any uni- or multimolecular structure or any other such structure now known or yet to be disclosed whether alone or in combination. A target may also be called a marker and the terms are used interchangeably. A target may be represented by the sequence of amino acids, or sequence of one or more strands of a nucleic acid from which it may be derived. For example, a target may be represented by a protein sequence.
Alternatively, a target may be represented by a nucleic acid sequence, the protein or peptide or the fragments thereof encoded by the nucleic acid sequence.
Examples of such nucleic acids include both single stranded and double stranded nucleic acid sequences including miRNA, tRNA, siRNA, mRNA, cDNA, or genomic DNA
sequences including complimentary sequences. The concept of a marker is not limited to the products of the exact nucleic acid sequence or protein sequence by which it may be represented.
Rather, a marker encompasses all molecules that may be detected by a method of assessing the expression of the marker. Examples of molecules encompassed by a marker include point mutations, silent mutations, deletions, frameshift mutations, translocations, alternative splicing derivatives, differentially methylated sequences, differentially modified protein sequences, truncations, soluble forms of cell membrane associated markers, and any other variation that results in a product that may be identified as the marker. The term "target"
further encompasses the products (i.e., proteins) of the gene or a gene allele thereof, whose expression or activity is directly or indirectly associated with a particular phenotype or cellular condition, or physiological characteristic.
The terms "capture agent" and "capture group" as used herein refer to any moiety that allows capture of a target molecule or a peptide construct via binding to or linkage with an affinity group or domain on the target molecule or an affinity tag of the peptide construct. The binding between the capture agent and its affinity tag may be a covalent bond and/or a non-covalent bond. A capture agent includes, e.g., a member of a binding pair that selectively binds to an affinity tag on a fusion peptide, a chemical linkage that is added by recombinant technology or other mechanisms, co-factors for enzymes and the like. Capture agents can be associated with a peptide construct using conventional techniques including hybridization, cross-linking (e.g., covalent immobilization using a furocoumarin such as psoralen), ligation, attachment via chemically-reactive groups, introduction through post-translational modification and the like.
"Sequence determination," "sequencing," and the like include determination of information relating to the nucleotide base sequence of a nucleic acid. Such information may include the identification or determination of partial as well as full sequence information of the nucleic acid. Sequence information may be determined with varying degrees of statistical reliability or confidence. In one aspect, the term includes the determination of the identity and ordering of a plurality of contiguous nucleotides in a nucleic acid. "High throughput sequencing- or -next generation sequencing- includes sequence determination using methods that determine many (typically thousands to billions) of nucleic acid sequences in an intrinsically parallel manner, i.e., where DNA templates are prepared for sequencing not one at a time, but in a bulk process, and where many sequences are read out preferably in parallel, or alternatively using an ultra-high throughput serial process that itself may be parallelized.
Such methods include but are not limited to pyrosequencing (for example, as commercialized by 454 Life Sciences, Inc., Branford, CT); sequencing by ligation (for example, as commercialized in the SOLiDTm technology, Life Technologies, Inc., Carlsbad, CA);
sequencing by synthesis using modified nucleotides (such as commercialized in TruSeqTm and HiSeem technology by Illumina, Inc., San Diego, CA; HeliScopem by Helicos Biosciences Corporation, Cambridge, MA; and PacBio RS by Pacific Biosciences of California, Inc., Menlo Park, CA), sequencing by ion detection technologies (such as Ion TorrentTm technology, Life Technologies, Carlsbad, CA); sequencing of DNA nanoballs (Complete Genomics, Inc., Mountain View, CA); nanopore -based sequencing technologies (for example, as developed by Oxford Nanopore Technologies, LTD, Oxford, UK), and like highly parallelized sequencing methods.
The term "exome" is used in accordance with its art-understood meaning referring to the set of exon sequences that are found in a particular genome.
As used herein, the term -mutation" refers to permanent change in the DNA
sequence that makes up a gene. In some embodiments, mutations range in size from a single DNA
building block (DNA base) to a large segment of a chromosome. In some embodiments, mutations can include missense mutations, frameshift mutations, duplications, insertions, nonsense mutation, deletions and repeat expansions. In some embodiments, a missense mutation is a change in one DNA base pair that results in the substitution of one amino acid for another in the protein made by a gene. In some embodiments, a nonsense mutation is also a change in one DNA base pair. Instead of substituting one amino acid for another, however, the altered DNA sequence prematurely signals the cell to stop building a protein. In some embodiments, an insertion changes the number of DNA bases in a gene by adding a piece of DNA. In some embodiments, a deletion changes the number of DNA
bases by removing a piece of DNA. In some embodiments, small deletions may remove one or a few base pairs within a gene, while larger deletions can remove an entire gene or several neighboring genes. In some embodiments, a duplication consists of a piece of DNA that is abnormally copied one or more times. In some embodiments, frameshift mutations occur when the addition or loss of DNA bases changes a gene's reading frame. A reading frame consists of groups of 3 bases that each code for one amino acid. In some embodiments, a frameshift mutation shifts the grouping of these bases and changes the code for amino acids.
In some embodiments, insertions, deletions, and duplications can all be frameshift mutations.
In some embodiments, a repeat expansion is another type of mutation. In some embodiments, nucleotide repeats are short DNA sequences that are repeated a number of times in a row. For example, a trinucleotide repeat is made up of 3-base-pair sequences, and a tetranucleotide repeat is made up of 4-base-pair sequences. In some embodiments, a repeat expansion is a mutation that increases the number of times that the short DNA sequence is repeated.
"Small molecule," as used herein, means a molecule less than 5 kilodaltons, more typically, less than 1 kilodalton. As used herein, -small molecule" includes peptides.
"Affinity tag" is given its ordinary meaning in the art. An affinity tag is any biological or chemical material that can readily be attached to a target biological or chemical material. Affinity tags may be attached to a target biological or chemical molecule by any suitable method. For example, in some embodiments, the affinity tag may be attached to the target molecule using genetic methods. For example, the nucleic acid sequence coding the affinity tag may be inserted near a sequence that encodes a biological molecule; the sequence may be positioned anywhere within the nucleic acid that enables the affinity tag to be expressed with the biological molecule, for example, within, adjacent to, or nearby. In other embodiments, the affinity tag may also be attached to the target biological or chemical molecule after the molecule has been produced (e.g., expressed or synthesized). As one example, an affinity tag such as biotin may be chemically coupled, for instance covalently, to a target protein or peptide to facilitate the binding of the target to streptavidin.
Affinity tags include, for example, metal binding tags such as histidine tags, GST (in glutathione/GST binding), streptavidin (in biotin/streptavidin binding).
Other affinity tags include Myc or Max in a Myc/Max pair, or polyamino acids, such as polyhistidines. At various locations herein, specific affinity tags are described in connection with binding interactions. The molecule that the affinity tag interacts with (i.e., binds to), which may be a known biological or chemical binding partner, is the "recognition entity." It is to be understood that the invention involves, in any embodiment employing an affinity tag, a series of individual embodiments each involving selection of any of the affinity tags described herein.
A "recognition entity" may be any chemical or biological material that is able to bind to an affinity tag. A recognition entity may be, for example, a small molecule such as maltose (which binds to MBP, or maltose binding protein), glutathione, NTA/Ni2+, biotin (which may bind to streptavidin), or an antibody. An affinity tag/recognition entity interaction may facilitate attachment of the target molecule, for example, to another biological or chemical material, or to a substrate (e.g., a nitrocellulose membrane or other immobilized substrate).
Examples of affinity tag/recognition entity interactions include polyhistidine/NTA/Ni2+, glutathione S -transferas e/glutathi one, maltose binding protein/maltose, streptavidin/biotin, biotin/streptavidin, antigen (or antigen fragment)/antibody (or antibody fragment), and the like.
The term -ribosomal display- refers to a reaction system able to yield a ternary complex of an mRNA, ribosome and corresponding protein of interest. Ribosomal display can be used for screening cell surface receptors, antibodies, and fragments thereof for target antigen or ligand binding. The steps of producing the reaction system can include: 1) generating a DNA
library and transcribing the library into an RNA library, 2) purifying the RNA
and in vitro translation in a cell-free protein synthesis system, 3) allowing the ribosome complexes of the translation reaction to bind to a target antigen or ligand, 4) selecting bound ribosome complexes; and 5) isolating RNA from the complexes and reverse transcribing the transcripts to cDNA, wherein the cDNA can be amplified, sequenced and/or further modified.
In some embodiments, the pharmaceutical composition includes one or more peptides or oligonucleotides, as described herein, together with a pharmaceutically acceptable carrier, diluent or excipient. In the preparation of the pharmaceutical compositions comprising the peptides or oligonucleotides described in the teachings herein, a variety of vehicles, vectors, excipients, and routes of administration may be used. The pharmaceutical compositions will generally comprise a pharmaceutically acceptable carrier and a pharmacologically (or therapeutically) effective amount of the peptides or oligonucleotides. In various embodiments, the pharmaceutical compositions comprising the one or more peptides may include an adjuvant or other agent for inducing or enhancing a patient's immune response. In other embodiments, the pharmaceutical compositions comprising the one or more oligonucleotides may be delivered without an adjuvant.
The pharmaceutical compositions described herein may be administered by any means that enables the active agent to reach the agent's site of action in the body of the subject. The dosage administered varies depending upon factors, such as: pharmacodynamic characteristics;
mode and route of administration; age, health, and weight of the recipient subject; nature and extent of symptoms; concurrent treatments; and frequency of treatment.
As used herein, the terms "administration" and "administering" of an agent to a subject include any route of introducing or delivering the agent to a subject to perform its intended function. Administration can be carried out by any suitable route, including intravenously, intramuscularly, intraperitoneally, inhalationally, intranasally, or subcutaneously.
Administration includes self-administration and the administration by another.
The term "effective amount" or "therapeutically effective amount" refers to that amount of an agent or combination of agents as described herein that is sufficient to effect the intended application including, but not limited to, disease treatment. A
therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated (e.g., the weight, age and gender of the subject), the severity of the disease condition, or the manner of administration. The term also applies to a dose that will induce a particular response in target cells. The specific dose will vary depending on the particular agents chosen, the dosing regimen to be followed, whether the agent is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which the compound is carried.
The terms "treatment," "treating," "treat," and the like, refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
-Treatment", as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development or progression; and (c) relieving the disease, i.e., causing regression of the disease and/or relieving one or more disease symptoms. -Treatment" is also meant to encompass delivery of an agent in order to provide for a pharmacologic effect, even in the absence of a disease or condition. For example, -treatment" encompasses delivery of a composition that can elicit an immune response or confer immunity in the absence of a disease condition, e.g., in the case of a vaccine.
As used herein, the term "patient- or "subject" refers to any organism to which a provided composition is or may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. For example, subject may refer to a human or a non-human animal. In some aspects, subject refers to any vertebrate including, without limitation, humans and other primates (e.g., chimpanzees and other apes and monkey species), farm animals (e.g., cattle, sheep, pigs, goats and horses), domestic mammals (e.g., dogs and cats), laboratory animals (e.g., rodents such as mice, rats, and guinea pigs), and birds (e.g., domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like). In some embodiments, the subject is a mammal. In further embodiments, the subject is a human.
In some embodiments, a patient is suffering from or susceptible to one or more disorders or conditions. In some embodiments, a patient displays one or more symptoms of a disease, disorder or condition. In some embodiments, a patient has been diagnosed with one or more diseases, disorders or conditions. In some embodiments, the disorder or condition is or includes cancer, or the presence of one or more tumors.
Detection of Tumor Mutations and/or Neoepitopes Cancers may be screened to detect mutations and/or neoepitopes (e.g., to detect neoantigen identity, and/or neoepitope nature, level, and/or frequency) as described herein using any of a variety of known technologies. In some embodiments, particular mutations or neoepitopes, or expression thereof, is/are detected at the nucleic acid level (e.g., in DNA or RNA). One of skill in the art would recognize that mutations or neoepitopes, or expression thereof, can be detected in a sample comprising DNA
or RNA from cancer cells. Further, one of skill in the art would understand that a sample comprising DNA
or RNA from cancer cells can include but is not limited to circulating tumor DNA (cIDNA), cell free DNA (cfDNA), cells, tissues, or organs. In some embodiments, mutations or neoepitopes, or expression thereof, is detected at the protein level (e.g., in a sample comprising polypeptides from cancer cells, which sample may be or comprise polypeptide complexes or other higher order structures including but not limited to cells, tissues, or organs).
In some particular embodiments, detection involves nucleic acid sequencing. In some embodiments, detection involves whole exome sequencing. In some embodiments, detection involves an immunoassay. In some embodiments, detection involves use of a microarray. In some embodiments, detection involves massively parallel exome sequencing. In some embodiments, detection involves genome sequencing. In some embodiments, detection involves RNA sequencing. In some embodiments, detection involves standard DNA
or RNA
sequencing. In some embodiments, detection involves mass spectrometry.
In some embodiments, detection involves next generation sequencing (DNA and/or RNA). In some embodiments, detection involves genome sequencing, genome resequencing, targeted sequencing panels, transcriptome profiling (RNA-Seq), DNA-protein interactions (ChIP-sequencing), and/or epigenome characterization. In some embodiments, re-sequencing of a patient's genome may be utilized, for example to detect genomic variations.
In some embodiments, detection involves using a technique such as ELISA, western blotting, immunoassay, mass spectrometry, microarray analysis, etc.
In some embodiments, detection involves next generation sequencing (DNA and/or RNA). In some embodiments, detection involves next generation sequencing of targeted gene panels (e.g. the ASHTON" tumor/normal exome-RNA test (GEMEXTRA"), MSK-IMPACT, or FOUNDATIONONE"). In some embodiments, detection involves genomic profiling.
In some embodiments, detection involves genomic profiling using the GEMEXTRA
test. The GEMEXTRA test is a comprehensive exome and transcriptome profiling assay that both informs the care of cancer patients and enables future research into the disease. Greater than 19,000 genes are assayed via hybridization capture and clinical-depth sequencing for the identification of somatic point mutations, small and large insertions and deletions and structural rearrangements. Measures of microsatellite instability (MSI) and tumor mutational burden (TMB) are also taken to inform the application of immunoncology therapies. To ensure somatic origin of identified variants, both the germline and tumor exomes are sequenced and compared.
The entire transcriptome is also sequenced, enabling the detection of gene fusion and alternative splicing events from the patient's RNA. GEMEXTRA" is applicable to both solid and hematological cancers.
In some embodiments, detection involves genomic profiling using Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) (see Cheng D T, Mitchell T N, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17(3):251-264; and Ross D S, Zehir A, Cheng D T, et al. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status:
Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. .111461 Diagn. 2017; 19(2):244-254). MSK-IMPACT is a comprehensive molecular profiling assay that involves hybridization capture and deep sequencing of all exons and selected introns of multiple oncogenes and tumor-suppressor genes, allowing for detection of point mutations, small and large insertions or deletions, and rearrangements. MSK-IMPACT also captures intergenic and intronic single-nucleotide polymorphisms (e.g., tiling probes), interspersed across a genome, aiding in accurate assessment of genome-wide copy number. In some embodiments, probes may target a megab as e.
In some embodiments, detection involves genomic profiling using the FOUNDATIONONE CDX1m (-F1CDx") assay. The F1CDx assay is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutation burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. F1CDx is approved by the United States Food and Drug Administration (FDA) for several tumor indications, including NSCLC, melanoma, breast cancer, colorectal cancer, and ovarian cancer.
The F1CDx assay employs a single DNA extraction method from routine FFPE
biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and selected intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons.
In total, the assay detects alterations in a total of 324 genes. Using the ILLUMINA HiSeq 4000 platform, hybrid capture- selected libraries are sequenced to high uniform depth (targeting >500X
median coverage with >99% of exons at coverage >100X). Sequence data is then processed using a customized analysis pipeline designed to detect all classes of genomic alterations, including base substitutions, indels, copy number alterations (amplifications and homozygous gene deletions), and selected genomic rearrangements (e.g., gene fusions).
Additionally, genomic signatures including microsatellite instability (MSI) and tumor mutation burden (TMB) are reported.
In some embodiments, detection may involve sequencing of exon and/or intron sequences from at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 or more genes (e.g., oncogenes and/or tumor-suppressor genes). For example, literature reports indicate that MSK-IMPACT has been used to achieve deep sequencing of all exons and selected introns of 468 oncogenes and tumor-suppressor genes.
Alternatively or additionally, in some embodiments, detection may involve sequencing of intergenic and/or intronic single-nucleotide polymorphisms. For example, literature reports indicate that MSK-IMPACT has been used to achieve deep sequencing of >1000 intergenic and intronic single-nucleotide polymorphisms.
In some embodiments, detection involves sequencing of splice variants. Cancer cells are able to adapt and evolve by developing mechanisms to escape control by their microenvironment. The diversity and plasticity offered by alternative splicing, therefore, provide an opportunity for cancer cells to produce protein isoforms suitable for tumor growth and/or spreading (David C J and Manley J L. Genes Dev. 2010; 24(20:2343-2364).
Genome-wide approaches has revealed that large-scale alternative splicing occurs during tumorigenesis (Venables J P et al. Nat Struct Mol Biol. 2009; 16(6):670-676.), and the genomic portraits of alternative splicing patterns have proven useful in the classification of tumors (Venables J
P. Bioessays. 2006; 28(4):378-386; Skotheim RI et al., Int .1- Biochem Cell Biol. 2007; 39(7-
8):1432-1449; Omenn G S et al., Di.s Markers. 2010; 28(4):241-251).
Reports of aberrant splicing events and alterations in ratios of alternatively spliced transcripts in different cancers have been noted (Rajan P et al., Nat Rev Urol. 2009; 6(8):454-460). These events result in novel transcripts not observed in normal cell counterparts. It has been reported that nearly all areas of tumor biology are affected by alternative splicing, including metabolism, apoptosis, cell cycle control, invasion, metastasis and angiogenesis (Venables J P., Bioessays. 2006; 28(4):378-386; Ghigna C et al., Curr Genomics. 2008;
Reports of aberrant splicing events and alterations in ratios of alternatively spliced transcripts in different cancers have been noted (Rajan P et al., Nat Rev Urol. 2009; 6(8):454-460). These events result in novel transcripts not observed in normal cell counterparts. It has been reported that nearly all areas of tumor biology are affected by alternative splicing, including metabolism, apoptosis, cell cycle control, invasion, metastasis and angiogenesis (Venables J P., Bioessays. 2006; 28(4):378-386; Ghigna C et al., Curr Genomics. 2008;
9(8):556-570).
One of the earliest examples of alternative splice variants with opposing apoptotic effects is Bcl-x. The Bcl-x pre-mRNA can be alternatively spliced to produce two splice variants, anti-apoptotic Bc1-xL (long form) and pro-apoptotic Bc1-xS (short form) (Boise L H et al. Cell. 1993; 74(4):597-608). High Bc1-xL/Bc1-xS ratios, promoting tumor cell survival, can be found in a number of cancer types, including human lymphoma, breast cancer, and human hepatocellular carcinoma (Minn A J et al., J Rio!
Chem. 1996;
271(10:6306-6312.44-46; Olopade 01 et al., Cancer J Sci Am. 1997; 3(4):230-237; Takehara T et al., Hepatologv. 2001; 34(1):55-61). Another example of an apoptosis-related gene that undergoes alternative splicing in cancer cells is the Fas receptor gene.
Expressed on the cell surface of many cell types, the Fas receptor is activated by the Fas ligand produced by cytotoxic T cells, which initiates a death-signaling cascade leading to apoptosis of cells expressing the Fas receptor (Bouillet P et al, Nat Rev Immunol. 2009;
9(7):514-519). There are at least 3 short mRNA variants of Fas missing the encoded transmembrane domain and the resulting translated protein variants are presumably secreted by cancer cells and act as decoy receptors for the Fas ligand, thus allowing cancer cells to escape from apoptosis (Cheng J et al., Science. 1994; 263(5154):1759-1762;
Cascino I et al., Journal of immunology. 1995; 154(6):2706-2713).
Alternative splicing of the H-Ras oncogene occurs on a previously unknown spliced exon (named as IDX) caused by an intronic mutation in the H-Ras gene (Cohen J B et al., Cell. 1989; 58(3):461-472). This mutation of the IDX splice site results in an H-Ras mRNA variant, which is more resistant to the nonsense-mediated mRNA
decay (NMD) process, and consequently overexpressed in cancers (Barbier J et al., Mol Cell Biol. 2007;
27(20):7315-7333). Alternative splicing also plays a role in promoting invasive and metastatic behavior in cancers. CD44 was among the first genes with splice variants specifically associated with metastasis, where variants containing exons 4-7 (v4-7) and 6-7 (v6-7) were shown to be expressed in a metastasizing pancreatic carcinoma cell line, but not in the corresponding parental tumor (Gunthert U et al., Cell. 1991; 65(1):13-24).
Mutational Calling Software Tools In certain aspects, a Pegasus human research pipeline at TGen.
https://github.comftgen/pegasusPipe is used. The sequences are aligned to the HG19 human genome or the HG38 human genome. In one aspect, somatic mutations are called using three separate mutational callers: Seurat, Mutect, and Strelka. All mutations that were seen in more than one of the callers were selected and used to generate peptides. The rationale behind this is that each caller has its own strengths and weaknesses. By pulling mutations that are called by multiple callers the risk of identifying false positives is reduced. The callers are available at: Mutect:https://software.broadinstitute.org/cancer/cga/mutect (Broad Institute Software);
Seurat: https://github.com/tgen/seurat (TGen Caller);
and Strelka:
https://github.com/Illumina/strelka (GNU general public license). Best practices are followed for DNA and RNA workflows. Alternatively, CLIA certified somatic calls are used with no changes to generate peptides as candidate neoantigens for further analysis.
In some embodiments, single or multiple mutation callers may be utilized to call genomic variants. For samples consisting of sequencing tumor and normal tissue the callers that may be used are: Strelka, Strelka2, VarDict, VarScan2, qSNP, Shimmer, RADIA, SOAPsnv, SomaticSniper, FaSD-somatic, Samtools, JointSNVMix, Virmid, SNVSniffer, Seurat, CaVEMan, MuTect, MuTect2, LoFreq, EBCall, deepSNV, LoLoPicker, MuSE, MutationSeq, SomaticSeq, SnooPer, FreeBayes, HapMuC, SPLINTER, Pisces, DeepSNVMiner, smCounter, DeepVariant, Cake, Tnscope, DNAscope, NeoMutate, Maftools, scABA, Sanivar, Sarek, BATCAVE, SomaticNet, CoVaCS, RegTools, xAtlas, R2D2, SiNPle, Bambino, and exactSNP. For samples consisting of tumor only sequencing callers that may be utilized are: Platypus, LumosVar, LumosVar2, SNVMix2, SNVer, OutLyzer, ISOWN, SomVarIUS, SiNVICT, FreeBayes, SNPiR, eSNV-dectect, RNAIndel, VaDir, and Cl airvoy ante.
In certain embodiments, single or multiple mutation callers recognizing splice variants may be utilized to call genomic variants. For samples consisting of sequencing tumor and normal tissue the callers that may be used are: RegTools, ASGAL, MATS (rMATS), SUPPA
(SUPPA2), Leafcutter, MAJIQ, JunctionSeq, findAS, Cufflinks/Cuffdiff, IsoformSwitchAnalyzeR, ALEXA-seq, MISO, SplicingCompass, Flux Capacitor, JuncBASE, SpliceR, FineSplice, ARH-seq, Spladder, DEXSeq, edgeR, Limma, DiffSplice, dSpliceType, SpliceDetector, HISAT2, STAR, Subread, Subjunct, PennDiff, DSGseq, AltAnalyze, Splicing Express, SpliceTrap, PSGInfer, FDM, IsoEM2, MADS+, Spanki, SpliceMap, CASPER, AV1SPA, PASA, SpliceSeq, MATT, Aspli, 1PSA, SANJUAN, VAST-Tools, SpliceV, Asprofile, DESeq2, Yanagi, ABLas, IRIS, and AS-Quant HLA Typing In some embodiments, whole exome sequencing (WES) and/or RNA sequencing from tumor and/or normal tissue may be used to identify the MHC class 1 and 2 genotypes for individual patients.
Single or multiple HLA callers may be utilized to identify the HLA types. For DNA
sequencing the HLA callers that may be utilized are: BWAkit, PHLAT, OptiType, HLAMiner, HISAT, HISAT2, xHLA, HLA-Vbseq, GATK HLA Caller, PolySolver, HLAReporter, Athlates, HLAseq, HLAssign, SOAP-HLA, STC-SEq, HapLogic, Gyper, HLATyphon, HLA-LA, HLA-PRG, MHC-PRG, Prohlatype, GraphTyper, ALPHLARD, Omixon, SNP2HLA, HLAscan, NeoEpitopePred, and Assign. For RNA sequencing the HLA callers that may be utilized are: BWAkit, seq2HLA, PHLAT, HLAProfiler, OptiType, HLAMiner, HLAForest, arcasHLA, HISAT, HISAT2, HLAseq, HLAssign, STC-Seq, HLATyphon, ALPHLARD, Omixon, and HLAscan.
In some embodiments, whole exome sequencing data may be analyzed for HLA
typing using Polysolver (polymorphic loci resolver) (Shukla et al., 2015). Polysolver is an algorithm for inferring alleles of the three major MHC class I (HLA-A, HLA-B, HLA-C) genes. For example, a patient's HLA class I alleles may be inferred from whole exome sequencing data using Polysolver. In other variations, in the absence of whole exome sequencing data, a patient's HLA class I alleles may be inferred from transcriptome sequencing data by an alternative HLA typing algorithm.
In one embodiment, HLA typing is conducted in sit/co using one or more techniques such as OptiType, run on a computing device. See Szolek, et al., OptiType:
precision HLA
typing from next-generation sequencing data, Bioinformatics. 2014 Dec 1;30(23), incorporated herein in its entirety for all purposes. A variety of other in silico techniques may also be used.
See Major, et al., HLA typing from 1000 genomes whole genome and whole exome Ilumina data, PLoS One. 2013 Nov 68(1 0:e78410; Wittig, et al., Development of a high-resolution NGS-based HLA-typing and analysis pipeline, Nucl. Acids Res. (2015).
Generation of Peptides from Tumor Mutations In some embodiments mutational data is acquired as described above in the section entitled -Detection of Tumor Mutations and/or Neoepitopes". The mutational calls may be converted to mutant protein sequences using single or multiple tools including but not limited to: Varcode, customProDB, and pyGeno. The tools will generate the peptides sequences for downstream in-vitro and in-silico HLA binding assays. Additionally, in some embodiments, the peptides will undergo testing to validate that each peptide is unique to the human proteome.
The peptides may be aligned to several different protein databases from NCBI
including: Non-redundant protein sequences, Reference proteins, model organisms, UniProtKB/Swiss-Prot, Patented protein sequences, Protein Data Bank proteins, Metagenomic proteins, and Transcriptome Shotgun Assembly proteins. Using the databases listed above rBlast may be utilized to run protein BLAST to identify proteins with 100% identity to the human proteome.
In certain aspects, Varcode software is utilized in python to predict the impact of the genome variant data. Varcode generates the wild type and mutant protein sequences from the mutation and/or neoepitopes at the desired peptide size. In certain aspects, the desired peptide size is 3,4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20 or more amino acids. In one aspect, the desired peptide size is 15 amino acids.
Varcode dependency is Pyensembl, which is a python access point to Ensembl reference genome data to generate peptides. In some embodiments, Varcode predicts the impact of each mutation on the protein. Silent mutations and mutations that are in noncoding regions on the genome are excluded. Varcode is then used to generate mutations across the peptide sequence. These variant peptides (i.e., candidate neoantigens) containing the mutations generated with Varcode are further analyzed with in silico methods and/or biochemical assays (e.g., a peptide-DNA conjugate assay) to identify which peptides bind patient-specific MHC
class I and II proteins and which are ultimately be recognized by the patient's tumor infiltrating lymphocytes (TILs).
Analysis of Neoantigens with a Peptide-DNA Conjugate Approach The peptide-DNA conjugate platform is well suited to rapidly screen large populations of diverse molecules for candidate neoantigens. In some embodiments, the present invention provides the following strategy for identification of neoantigens. According to various embodiments, a peptide-DNA conjugate method comprises a method for pooled, highly-parallel expression of proteins, each associated with a nucleic acid barcode.
In some embodiments, the peptide-DNA conjugate method comprises a method for pooled, highly-parallel in vitro expression of proteins, each covalently linked to a DNA
barcode through a puromycin-containing linkage. In other embodiments, the peptide-DNA conjugate method comprises phage display, mRNA display, or other method.
The peptide-DNA conjugate approach is a proprietary technology that can rapidly generate a large number of potential neoantigens as candidate binding agents for the patient-specific HLA proteins. The peptide-DNA conjugate approach is a method that generates peptide libraries (10-50 amino acids long) with each peptide conjugated to a unique DNA tag that can be used to monitor peptide abundance following binding experiments.
Importantly, the peptide sequences can be used in large multiplexed binding assays with upwards of 100,000 of unique programmable peptides.
Binding assays for any molecular target can be used to screen large diverse peptide-DNA conjugate libraries. A biological structure (e.g., a patient-specific HLA
proteins or fragments thereof corresponding to the patient's genotype) can be mixed with diverse peptides, separated from unbound peptides, and then queried for those that "stick." The particular libraries could be intelligently designed libraries based upon prior knowledge of the target (e.g., from exome sequencing and analysis).
The peptide-DNA conjugate platform is described in greater detail in U.S.
Patent No.
9,958,454; U.S. Patent No. 10,288,608; and U.S. Patent Application Publication No.
2016/0025726, the contents of which are hereby incorporated by reference.
In some embodiments, the peptide-DNA conjugate method is used to identifying neoantigens. In certain aspects, identification of neoantigen comprises (i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA
proteins or fragments thereof; (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs; (iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA
proteins or fragments thereof; (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA proteins or fragments thereof In some aspects, the identifying nucleic acid portion of each peptide construct comprises a polynucleotide sequence or complement thereof encoding the peptide portion of the peptide construct.
Identification of Neoantigens with Phage Display, Ribosomal display, mRNA
Display, Yeast Display, Bacterial Display, and Related Techniques In some embodiments, the polypeptides of interest are genetically encoded to facilitate identification of neoantigens. An example of a genetically encoded polypeptide library is a mRNA display library. Another example is a replicable genetic display package (rgdp) library such as a phage display library. In one embodiment, the polypeptides of interest are genetically encoded as a phage display library. In these embodiments, the nucleic acid may be comprised by the phage genome. In these embodiments, the polypeptide may be comprised by the phage coat.
In some embodiments, the invention may be used to produce a genetically encoded combinatorial library of polypeptides which are generated by translating a number of nucleic acids into corresponding polypeptides and linking molecules of said molecular scaffold to said polypeptides. The genetically encoded combinatorial library of polypeptides may be generated by phage display, yeast display, ribosomal display, bacterial display or mRNA
display.
Phage Display Techniques and methodology for performing phage display can be found in WO
2009/098450.
Different phage display systems have been developed throughout the years, making use of different phage vectors (M13 filamentous phage, lambda, T4 and T7 phage) and various phage coat proteins for covalent fusion. The M13 filamentous phage is employed most commonly. The strength of the filamentous phage display system lies within the lysogenic life cycle of this phage and the availability of M13 phagemid vectors (Webster, 1006; Hufton et al., 1999). Lysogenic phage integrate their DNA into the host cell genome, are replicated along with the bacterial cell and do not require the lysis of the bacterial cell for phage particle formation. Instead, phage particles are shed from the bacterial surface without inducing cell death (Webster, 1996). Moreover, the development of M13 phagemid vectors has allowed for excellent workability. Phagemids are plasmids containing the replication origin and packaging signal of the filamentous phage, together with the plasmid origin of replication and the gene encoding the phage coat protein coupled with the DNA insert (Webster, 1996;
Armstrong et al., 1996). For phage propagation, bacterial cells infected with phagemid need to be "superinfected" with a so-called helper phage that provides all the other essential phage components for the formation of viable phage virions. Besides excellent workability, the use of a phagemid vector system allows for monovalent display of the recombinant protein (maximally one recombinant protein per phage virion) as the helper phage contributes non-recombinant phage coat proteins (Armstrong et al., 1996).
Different M13 vector systems for phage display through various coat proteins are available (Smith and Petrenko, 1997; Barbas, 1993). Major coat protein pVIII and minor coat protein pill, are used most frequently for display purposes (Armstrong et al., 1996;
Rodi and Makowski, 1999). As the N-terminal end of both proteins is exposed at the phage surface, foreign DNA sequences are inserted upstream of the genes encoding the coat proteins. The development of phage vectors for C-terminal fusion to M13 minor coat protein pVI, of which the C-terminal end is exposed at the surface of the phage, has been an important step towards the development of cDNA phage display libraries (Hufton et al., 1999; Jespers et al., 1995).
More recently, display methods were also developed in the lytic phage systems, namely for lambda phage, T4 and T7 phage. For the formation and shedding of recombinant lytic phage virions containing recombinant coat proteins, bacterial cells need to be lysed on phage propagation (Russel, 1991). Moreover, as there are no plasmid vectors available for the lytic phage, DNA isolation and experimental approaches are more labor-intensive in comparison to working with plasmids (Sambrook et al., 1989). As both lytic and lysogenic phage life cycles employ different phage assembly strategies, both approaches allow the display of different proteins (Hufton et al., 1999). As the virion proteins of M13 filamentous phage (and thus, also the recombinant phage coat protein) are embedded into the bacterial cell membrane prior to phage virion assembly, this process puts constraints on the proteins that can be displayed at the surface of the phage; for efficient display, the cDNA
products must be able to traverse the bacterial cell membrane and need to allow for the formation of a viable and infectious virion (Webster, 1996; Russel, 1991; Rodi et al., 2002).
For lytic phage virion production on the other hand, the recombinant proteins are formed and retained within the cytosol of bacterial cells prior and during virion assembly so that the spectrum of recombinant proteins that can be displayed by lytic phage is less constrained (Hufton et al., 1999; Russel, 1991; Krumpe et al., 2006).
Phage display is described, for example, in Ladner et al., U.S. Pat. No.
5,223,409;
Smith (1985) Science 228:1315-1317; WO 92/18619; WO 91/17271; WO 92/20791; WO
92/15679; WO 93/01288; WO 92/01047; WO 92/09690; WO 90/02809; de Haard et al.
(1999) 1 Biol. Chem 274:18218-30; Hoogenboom et al. (1998) Immunotechnology 4:1-20;
Hoogenboom et al. (2000) Immunol Today 2:371-8;
Fuchs et al.
(1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum Anabod Hybridomas 3:81-85;
Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EV/B0 112:725-734;
Hawkins et al. (1992) J Mol Blot 226:889-896; Clackson et al. (1991) Nature 352:624-628;
Gram et al. (1992) Proc Nat! Acad Sci USA 89:3576-3580; Garrard et al.
(1991) Bio/Technology 9:1373-1377; Rebar et al. (1996)Methods Enzymol. 267:129-49;
Hoogenboom et al. (1991) Nue Acid Res 19:4133-4137; and Barbas et al.
(1991) PNAS 88:7978-7982.
Ribosomal Display In certain aspects, the methods described herein comprise the use of ribosomal display to identify neoantigens. Ribosomal display can be used to perform in vitro protein synthesis of a protein of interest (e.g., a candidate neoantigen). Ribosomal display can also be used to perform in vitro protein evolution to create proteins with desired properties, for example, Fab fragments that bind to a specific target molecule. Ribosomal display is a well-known technology useful for generating libraries. This entirely in vitro method allows for libraries with a diversity of 1016 members. The process results in translated proteins that are associated with their RNA progenitor which can be used, as a complex, to select for proteins with desired properties (e.g., bind to an immobilized target molecule). The RNA-protein complex that shows the desired property, e.g., high binding affinity, can then be reverse transcribed to cDNA
and the sequence amplified via PCR. The process also provides for repeated cycles of iteration or protein expression. In addition, nucleic acid mutations can be introduced efficiently into the selected nucleic acid library in subsequent cycles, leading to continuous DNA
diversification and thus, protein evolution. The end result is a nucleic acid sequence that can be used to produce a protein of interest (e.g., neoantigens that specifically bind to the patient-specific HLA
proteins, and ultimately the patent's TILs).
In the method provided herein, a protein of interest is displayed on the surface of a ribosome from which the protein of interest is being translated. Briefly, a library of RNA
molecules is translated in an in vitro translation system to the 3' end of the RNA molecule, such that the ribosome does not fall off This is accomplished by not incorporating a functional stop codon in the RNA template. Normally, the stop codon is recognized by release factors that trigger detachment of the nascent polypeptide from the ribosome. In ribosomal display, the peptide emerges from the ribosome, but does not fall free of the complex. This allows, for example, the nascent polypeptide to associate with another polypeptide to form a functional dimer. In some instances, there is an additional folding step in an oxidizing environment (important for forming disulfide bonds).
The whole complex of folded protein of interest, ribosome and RNA, which is stable for several days, can then be screened for desired properties, such as specific binding to a binding pair ligand by the translated protein of interest. The RNA encoding the selected protein of interest can be reverse transcribed into single stranded cDNA which can be converted to double-stranded DNA and amplified by PCR, providing the coding sequence of the selected protein (e.g., a neoantigen). The reverse transcription reaction can be performed on mRNA associated in the ribosomal display complex, or the mRNA can be isolated from the ribosomal display complex then used in the reverse transcription step.
Suitable methods for disruption/dissociation of ribosome complexes are known in the art and include EDTA
treatment and/or phenol extraction.
In general, nucleic acid (DNA) constructs for ribosomal display contain a promoter (T7, SP6 or T3), a translation initiation signal such as a Shine-Dalgarno (prokaryotic) or Kozak (eukaryotic) sequence, initiation codon, and coding sequence of the protein of interest (e.g., \in or Vi. chain domain). One or more nucleic acid sequences encoding one or more detection tags may be included to provide for production of a protein further comprising one or more detection tags (e.g., histidine tag). To enable the complete nascent protein to be displayed and fold into its active conformation, a spacer domain of at least 23-30 amino acids length can be added at the C terminus, to allow the protein to exit completely from the ribosome. The spacer can provide a known sequence for the design of primers for RT-PCR recovery of the DNA
sequences.
To remove the stop codon from DNA, a 3' primer lacking the stop codon can be used during PCR construction. Constructs designed for bacterial-based display systems can incorporate sequences containing stem-loop structures at the 5' and 3' ends of the DNA to stabilize mRNA against degradation by RNase activities in bacterial cell-free systems.
The mRNA translation system used in the methods described herein may be any suitable available system. A prokaryotic or eukaryotic translation system may be used, for example crude E. coli lysate (commercially available from e.g. Promega Corp., Madison, Wis.;
Agilent Technologies, Santa Clara, Calif; GE Healthcare Biosciences, Pittsburgh, Pa.; Life Technologies, Carlsbad, Calif), a reconstituted ribosome system such as PURE
(see, e.g., Shimizu et al., Nat. Biotechnol., 19:751-755 (2001)), or a cell free protein synthesis system as described below.
The PURE system can include about 32 individually purified components used for in vitro protein biosynthesis (e.g., initiation, elongation and termination). In some embodiments, the components include initiation factors (e.g., IF1, IF2, IF3), elongation factors (e.g., EF-G, EF-Tu, EF-Ts), release factors (e.g., RF1, RF3), a termination factor (e.g., RRF), 20 aminoacyl-tRNA synthetases, methionyl-tRNA transformylase, T7 RNA polymerase, ribosomes, tRNAs, NTPs, creatine phosphate, 10-formy1-5,6,7,8-tetrahydrofolic acid, 20 amino acids, creatine kinase, myokinase, nucleoside-diphosphate kinase and pyrophosphatase.
Ribosomal display has been used to successfully generate antibody fragments with high affinity for their target. Detailed description of ribosomal display is found in, e.g., Hanes, Proc. Natl. Acad. Sci. USA, 95: 14130-14135 (1998); Schaffitzel et al., I
Immunological Methods, 231:119-135 (1999); He et al.,i Immunological Methods, 231, 105-117 (1999);
Roberts R W, Current Opinion in Chemical Biology, 3: 268-273 (1999).
Other Display Methods for In Vitro Selection Other in vitro library display methods can be used in the methods described herein, such as, but not limited to, mRNA display, bicistronic display, P2A display, and CIS display (cis-activity display).
mRNA Display In mRNA display, each member of the RNA library is directly attached to the protein of interest it encodes by a stable covalent linkage to puromycin, an antibiotic that can mimic the aminoacyl end of tRNA (see, e.g., Robert R W and Szostak J W, Proc. Natl.
Acad. Sci.
(ISA, 94:12297-12302 (1997)). Puromycin is an aminonucleoside antibiotic, active in either prokaryotes or eukaryotes, derived from Streptomyces alboniger Protein synthesis is inhibited by premature chain termination during translation taking place in the ribosome. Part of the molecule acts as an analog of the 3' end of a tyrosyl-tRNA, where a part of its structure mimics a molecule of adenosine and another part mimics a molecule of tyrosine. It enters the A site and transfers to the growing chain, causing the formation of a puromycylated nascent chain and premature chain release. The 3' position contains an amide linkage instead of the normal ester linkage of tRNA, making the molecule much more resistant to hydrolysis and stopping procession along the ribosome.
Other puromycin analog inhibitors of protein synthesis include 0-demethylpuromycin, 0-prop argyl-puromy ci n, 9- {3 '-deoxy-3 '4(4-m ethy -L-ph enyl al anypamino] 43-D-ribofuranosy1}-6-(N,N'-dimethylamino)purine [L-(4-Me)-Phe-PANS] and 6-dimethylamino-943-(p-azido-L-beta-phenylalanylamino)-3-deoxy -beta-rib ofurano syl] purine.
Members of the RNA library can be ligated to puromycin via a linker such as, but not limited to, a polynucleotide or a chemical linker, e.g., polyethylene glycol (Fukuda et al., Nucleic Acid Research, 34(19):e127 (2006)). In some embodiments, the polynucleotide linker comprising RNA is linked at the 3' terminal end to puromycin. In other embodiments, the PEG liker is linked to puromycin.
As puromycin that is linked to the 3' terminal end of a RNA molecule enters a ribosome, it establishes a covalent bond to the nascent protein (encoded by the RNA
molecule) as a result of peptidyl transferase activity in the ribosome. In turn, a stable amide linkage forms between the protein and the 0-methyl tyrosine portion of puromycin.
The RNA library of RNA-puromycin fusions can undergo in vitro translation, as described herein, to generate RNA-puromycin-protein complexes (e.g., RNA-puromycin-neoantigen complexes). In some embodiments, the RNA-puromycin fusions comprise RNA
molecules encoding candidate neoantigens identified by exome analysis of tumor cells and wild-type cells from a patient.
Affinity selection can be performed on the mRNA-displayed protein library to screen for proteins having desired properties, such a specific binding to a binding pair ligand.
The mRNA display can be performed in solution or on a solid support. The selected mRNA-displayed protein of interest can be purified by standard methods known in the art such as affinity chromatography. The mRNA can be cloned, PCR amplified, and/or sequenced to determine the coding sequence of the selected protein of interest. In one embodiment, the selected mRNA-displayed library contains a population of neoantigens that bind to the patient-specific HLA proteins or fragments thereof, and ultimately the patient's TILs.
In some aspects, members of a library of nucleic acid members are linked to puromycin, where each member encodes a prospective protein of interest having a primary amino acid sequence different from the other proteins encoded by the other nucleic acid members.
The mRNA display system can contain a population or mixture of different complexes such that each complex has a different mRNA linked to puromycin, the ribosome, and a prospective protein of interest.
Biscistronic DNA Display Bicistronic DNA display can be employed for in vitro selection of proteins of interest (see, e.g., Sumida et al., Nucleic Acid Research, 37(22):e147 (2009)). The method is based on complexing in vitro translated proteins of interest to their encoding DNA, which used to determine the sequence of the protein of interest. Typically, a DNA template containing multiple ORFs that can be linked to the protein it encodes is generated. In addition, the coupled transcription/translation reaction is compartmentalized in a water-in-oil emulsion (e.g., micelle).
In some instances, when multiple ORFs are used, they can be separated by ribosomal binding sides. In some embodiments, the coding sequence of the protein of interest is fused to the coding sequence of streptavidin. In some embodiments, the DNA
template is biotinylated through a linker. The linker can be cleavable.
During in vitro transcription/translation, the protein can be expressed in a micelle. In one non-limiting illustrative embodiment, the DNA template contains the coding sequence of a candidate neoantigen, and the candidate neoantigen is expressed in a micelle. In embodiments, a candidate neoantigen forms and is associated with the DNA
encoding the candidate neoantigen through a linkage, such as a streptavidin-biotin link.
The DNA displayed protein of interest, such as a candidate neoantigen, can be recovered from the emulsion and screened by affinity selection. The DNA template of the selected DNA-displayed protein of interest can be cleaved from the complex by methods such as UV
irradiation and then PCR amplified, cloned, and/or sequenced.
In some embodiments, the methods provided herein include generating a library of nucleic acid members, each member encoding a prospective protein of interest (i.e., a candidate neoantigen) having a primary amino acid different from the other proteins encoded by the other nucleic acid members. In some embodiments, the library comprises DNA members, and the method includes transcribing the library into RNA and translating the RNA in a cell free protein synthesis system to generate a bicistronic DNA display system in a water-in-oil emulsion. In some embodiments, the bicistronic DNA display system contains a population of proteins of interest that are selected for specific binding to a binding pair ligand. In one embodiment, the bicistronic DNA display system contains a population of candidate neoantigens, wherein each candidate neoantigen is associated with a DNA molecule encoding the candidate neoantigen.
P2A DNA Display In P2A DNA display, which utilizes the cis-activity of the endonuclease P2A, a fusion protein of P2A and a protein of interest binds to the same DNA molecule from which it is expressed (see, e.g., Reiersen et al., Nucleic Acids Research, 33(1): el 0).
The DNA template can contain the coding sequence encoding the protein of interest genetically fused to the coding sequence of P2A, a promoter, and an origin of replication. The coding sequence of P2A can be obtained and a genetic fusion with the protein of interest can be constructed by standard methods known to those in the art.
In some embodiments, P2A DNA display is used to select a protein of interest.
The protein of interest can be selected by generating a library of fusion proteins, where each member of the library comprises a fusion protein between P2A and a protein of interest, and selecting proteins of interest based on a desired property, for example, specific binding to a binding pair ligand. The library can be constructed from a library of nucleic acid members, where each member comprises a DNA template encoding a different protein of interest (i.e., each protein of interest has a primary amino acid sequence that is different from other proteins encoded by other members of the nucleic acid library) that is genetically fused to the coding sequence of P2A.
In some embodiments, the P2A DNA-displayed library can be screened by affinity selection strategies, e.g., in solution or on a solid support. The selected protein of interest can be purified by, e.g., affinity chromatography, and the complexed DNA can be PCR amplified, cloned and/or sequenced.
CIS Display Similar to P2A DNA display, CIS display involves a DNA-based approach to directly link in vitro transcribed/translated proteins to the DNA molecules that encode them (see, e.g., Odegrip et al., Proc. Natl. Acad. Sc,. USA, 101(9):2806-2810). This method uses RepA, a DNA
replication initiator protein, to non-covalently bind to the DNA molecule from which it is expressed if the DNA molecule has a CIS element. The DNA molecule can be created to encode proteins of interest (e.g., candidate neoantigens) in addition to RepA.
In some embodiments, CIS display is used to select a protein of interest. The protein of interest can be selected by generating a DNA library of fusion proteins, where each member comprises a fusion protein between RepA and a protein of interest, and selecting proteins of interest based on a desired property, for example, specific binding to a binding pair ligand. The library can be constructed from a DNA library, where each member of the library comprises a DNA template encoding a different protein of interest (i.e., each protein of interest has a primary amino acid sequence that is different from other proteins encoded by other members of the nucleic acid library) that is genetically fused to the coding sequence of RepA.
In some embodiments, members of the DNA library contain a coding sequence of the protein of interest, a coding sequence of RepA, a CIS element, an origin of replication and a promoter, wherein the coding sequence of the protein of interest is genetically fused to the coding sequence of RepA. The CIS element can be genetically linked to the RepA
coding sequence.
In some embodiments, the library contains a fusion protein between RepA and a protein of interest, and a DNA molecule encoding the fusion protein.
The RepA DNA-displayed library can be screened by affinity selection strategies, e.g., in solution or on a solid support. The selected protein of interest can be purified by, e.g., affinity chromatography, and the complexed DNA can be PCR amplified, cloned and/or sequenced.
Cell-Free Protein Synthesis ((7FPS) In order to express the biologically active proteins of interest described herein (i.e., neoantigens), a cell free protein synthesis system can be used. Cell extracts have been developed that support the synthesis of proteins in vitro from purified mRNA
transcripts or from mRNA transcribed from DNA during the in vitro synthesis reaction.
CFPS of polypeptides in a reaction mix comprises bacterial extracts and/or defined reagents. The reaction mix comprises at least ATP or an energy source; a template for production of the macromolecule, e.g., DNA, mRNA, etc.; amino acids, and such co-factors, enzymes and other reagents that are necessary for polypeptide synthesis, e.g., ribosomes, tRNA, polymerases, transcriptional factors, aminoacyl synthetases, elongation factors, initiation factors, etc. In one embodiment of the invention, the energy source is a homeostatic energy source. Also included may be enzyme(s) that catalyze the regeneration of ATP from high-energy phosphate bonds, e.g., acetate kinase, creatine kinase, etc. Such enzymes may be present in the extracts used for translation, or may be added to the reaction mix. Such synthetic reaction systems are well-known in the art, and have been described in the literature.
The templates for cell-free protein synthesis can be either mRNA or DNA. The template can comprise sequences for any particular gene of interest, and may encode a full-length polypeptide or a fragment of any length thereof Nucleic acids that serve as protein synthesis templates are optionally derived from a natural source or they can be synthetic or recombinant. For example, DNAs can be recombinant DNAs, e.g., plasmids, viruses or the like.
The term -reaction mix" as used herein, refers to a reaction mixture capable of catalyzing the synthesis of polypeptides from a nucleic acid template. The reaction mixture comprises extracts from bacterial cells, e.g., E. coil S30 extracts. S30 extracts are well known in the art, and are described in, e.g., Lesley, S. A., et al. (1991), 1 Biol.
Chem. 266, 2632-8.
The synthesis can be performed under either aerobic or anaerobic conditions.
In some embodiments, the bacterial extract is dried. The dried bacterial extract can be reconstituted in milli-Q water (e.g., reverse osmosis water) at 110% of the original solids as determined by measuring the percent solids of the starting material. In one embodiment, an accurately weighed aliquot of dried extract, representing 110% of the original solids of 10 mL
of extract, is added to 10 mL of Milli-Q water in a glass beaker with a stir bar on a magnetic stirrer. The resulting mixture is stirred until the powder is dissolved. Once dissolved, the material is transferred to a 15 mL Falcon tube and stored at ¨80 C unless used immediately.
The volume percent of extract in the reaction mix will vary, where the extract is usually at least about 10% of the total volume; more usually at least about 20%; and in some instances, may provide for additional benefit when provided at least about 50%; or at least about 60%;
and usually not more than about 75% of the total volume.
The general system includes a nucleic acid template that encodes a protein of interest.
The nucleic acid template is an RNA molecule (e.g., mRNA) or a nucleic acid that encodes an mRNA (e.g., RNA, DNA) and be in any form (e.g., linear, circular, supercoiled, single stranded, double stranded, etc.). Nucleic acid templates guide production of the desired protein.
To maintain the template, cells that are used to produce the extract can be selected for reduction, substantial reduction or elimination of activities of detrimental enzymes or for enzymes with modified activity. Bacterial cells with modified nuclease or phosphatase activity (e.g., with at least one mutated phosphatase or nuclease gene or combinations thereof) can be used for synthesis of cell extracts to increase synthesis efficiency. For example, an E. coli strain used to make an S30 extract for CFPS can be RNase E or RNase A deficient (for example, by mutation).
In a generic CFPS reaction, a gene encoding a protein of interest is expressed in a transcription buffer, resulting in mRNA that is translated into the protein of interest in a CFPS
extract and a translation buffer. The transcription buffer, cell-free extract and translation buffer can be added separately, or two or more of these solutions can be combined before their addition, or added contemporaneously.
To synthesize a protein of interest in vitro, a CFPS extract at some point comprises a mRNA molecule that encodes the protein of interest. In some CFPS systems, mRNA is added exogenously after being purified from natural sources or prepared synthetically in vitro from cloned DNA using RNA polymerases such as RNA polymerase II, SP6 RNA
polymerase, T3 RNA polymerase, T7 RNA polymerase, RNA polymerase III and/or phage derived RNA
polymerases. In other systems, the mRNA is produced in vitro from a template DNA; both transcription and translation occur in this type of CFPS reaction. In some embodiments, the transcription and translation systems are coupled or comprise complementary transcription and translation systems, which carry out the synthesis of both RNA and protein in the same reaction. In such in vitro transcription and translation systems, the CFPS
extracts contain all the components (exogenous or endogenous) necessary both for transcription (to produce mRNA) and for translation (to synthesize protein) in a single system.
A cell free protein synthesis reaction mixture comprises the following components: a template nucleic acid, such as DNA, that comprises a gene of interest operably linked to at least one promoter and, optionally, one or more other regulatory sequences (e.g., a cloning or expression vector containing the gene of interest) or a PCR fragment; an RNA
polymerase that recognizes the promoter(s) to which the gene of interest is operably linked and, optionally, one or more transcription factors directed to an optional regulatory sequence to which the template nucleic acid is operably linked; ribonucleotide triphosphates (rNTPs);
optionally, other transcription factors and co-factors therefor; ribosomes; transfer RNA (tRNA);
other or optional translation factors (e.g., translation initiation, elongation and termination factors) and co-factors therefore; one or more energy sources, (e.g., ATP, GTP);
optionally, one or more energy regenerating components (e.g., PEP/pyruvate kinase, AP/acetate kinase or creatine phosphate/creatine kinase); optionally factors that enhance yield and/or efficiency (e.g., nucleases, nuclease inhibitors, protein stabilizers, chaperones) and co-factors therefore; and;
optionally, solubilizing agents. The reaction mix further comprises amino acids and other materials specifically required for protein synthesis, including salts (e.g., potassium, magnesium, ammonium, and manganese salts of acetic acid, glutamic acid, or sulfuric acids), polymeric compounds (e.g., polyethylene glycol, dextran, diethyl aminoethyl dextran, quaternary aminoethyl and aminoethyl dextran, etc.), cyclic AMP, inhibitors of protein or nucleic acid degrading enzymes, inhibitors or regulators of protein synthesis, oxidation/reduction adjuster (e.g., DTI, ascorbic acid, glutathione, and/or their oxides), non-denaturing surfactants (e.g., Triton X-100), buffer components, spermine, spermidine, putrescine, etc. Components of CFPS reactions are discussed in more detail in U.S. Pat. Nos.
7,338,789 and 7,351,563, and U.S. App. Pub. No. 2010/0184135, the disclosures of which are incorporated by reference in its entirety for all purposes.
Depending on the specific enzymes present in the extract, for example, one or more of the many known nuclease, polymerase or phosphatase inhibitors can be selected and advantageously used to improve synthesis efficiency.
Protein and nucleic acid synthesis typically requires an energy source. Energy is required for initiation of transcription to produce mRNA (e.g., when a DNA
template is used and for initiation of translation high energy phosphate for example in the form of GTP is used).
Each subsequent step of one codon by the ribosome (three nucleotides; one amino acid) requires hydrolysis of an additional GTP to GDP. ATP is also typically required. For an amino acid to be polymerized during protein synthesis, it must first be activated.
Significant quantities of energy from high energy phosphate bonds are thus required for protein and/or nucleic acid synthesis to proceed.
An energy source is a chemical substrate that can be enzymatically processed to provide energy to achieve desired chemical reactions. Energy sources that allow release of energy for synthesis by cleavage of high-energy phosphate bonds such as those found in nucleoside triphosphates, e.g., ATP, are commonly used. Any source convertible to high energy phosphate bonds is especially suitable. ATP, GTP, and other triphosphates can normally be considered as equivalent energy sources for supporting protein synthesis.
To provide energy for the synthesis reaction, the system can include added energy sources such as glucose, pyruvate, phosphoenolpyruvate (PEP), carbamoyl phosphate, acetyl phosphate, creatine phosphate, phosphopyruvate, glyceral dehyde-3-phosph ate, Phosphoglycerate and glucose-6-phosphate that can generate or regenerate high-energy triphosphate compounds such as ATP, GTP, other NTPs, etc.
When sufficient energy is not initially present in the synthesis system, an additional source of energy is preferably supplemented. Energy sources can also be added or supplemented during the in vitro synthesis reaction.
In some embodiments, the cell-free protein synthesis reaction is performed using the PAN0x-SP system comprising NTPs, E. coil tRNA, amino acids, Mg' acetate, Mg' glutamate, K+ acetate, IC glutamate, folinic acid, Tris pH 8.2, DTT, pyruvate kinase, T7 RNA polymerase, disulfide isomerase, phosphoenol pyruvate (PEP), NAD, CoA, Na + oxalate, putrescine, spermidine, and S30 extract.
In some instances, the cell-free synthesis reaction does not require the addition of commonly secondary energy sources, yet uses co-activation of oxidative phosphorylation and protein synthesis. In some instances, CFPS is performed in a reaction such as the Cytomim (cytoplasm mimic) system. The Cytomim system is defined as a reaction condition performed in the absence of polyethylene glycol with optimized magnesium concentration.
This system does not accumulate phosphate, which is known to inhibit protein synthesis.
The presence of an active oxidative phosphorylation pathway can be tested using inhibitors that specifically inhibit the steps in the pathway, such as electron transport chain inhibitors. Examples of inhibitors of the oxidative phosphorylation pathway include toxins such as cyanide, carbon monoxide, azide, carbonyl cyanide m-chlorophenyl hydrazone (CCCP), and 2,4-dinitrophenol, antibiotics such as oligomycin, pesticides such as rotenone, and competitive inhibitors of succinate dehydrogenase such as malonate and oxaloacetate.
In some embodiments, the cell-free protein synthesis reaction is performed using the Cytomim system comprising NTPs, E. coil tRNA, amino acids, Mg2+ acetate, Mg2+
glutamate, K+ acetate, K+ glutamate, folinic acid, Tris pH 8.2, DTT, pyruvate kinase, T7 RNA polymerase, disulfide isomerase, sodium pyruvate, NAD, CoA, Na + oxalate, putrescine, spermidine, and S30 extract. In some embodiments, the energy substrate for the Cytomim system is pyruvate, glutamic acid, and/or glucose. In some embodiments of the system, the nucleoside triphosphates (NTPs) are replaced with nucleoside monophosphates (NMPs).
The cell extract can be treated with iodoacetamide in order to inactivate enzymes that can reduce disulfide bonds and impair proper protein folding. In some embodiments, the cell extract comprises an exogenous protein chaperone. The protein chaperone can be expressed by the bacterial strain used to make the cell free extract, or the protein chaperone can be added to the cell extract Non-limiting examples of exogenous protein chaperones include disulfide bond isomerase (PDI), such as, but not limited to E. coil DsbC, and peptidyl prolyl cis-trans isomerase (PPIase), such as but not limited to FkpA. In some embodiments, the extract comprises both a PDI and a PPIase, e.g., both DsbC and FkpA. Glutathione disulfide (GSSG) and/or glutathione (GSH) can also be added to the extract at a ratio that promotes proper protein folding and prevents the formation of aberrant protein disulfides.
In some embodiments, the CFPS reaction includes inverted membrane vesicles to perform oxidative phosphorylation. These vesicles can be formed during the high pressure homogenization step of the preparation of cell extract process, as described herein, and remain in the extract used in the reaction mix.
Methods of preparing a cell extract are described in. e.g., Zawada, J.
"Preparation and Testing of E. coil S30 In Vitro Transcription Translation Extracts", Douthwaite, J. A. and Jackson, R. H. (eds.), Ribosomal display and Related Technologies: Methods and Protocols, Methods in Molecular Biology, vol. 805, pp. 31-41 (Humana Press, 2012); Jewett et al., Molecular Systems Biology: 4, 1-10 (2008); Shin J. and Norieaux V., I
Biol. Eng., 4:8 (2010). Briefly, a bacterial culture is grown and harvested; suspended in an appropriate buffer (e.g., S30 buffer), and homogenized to lyse the cells.
The cell-free extract can be thawed to room temperature before use in the CFPS
reaction. The extract can be incubated with 50 p.M iodoacetamide for 30 minutes when synthesizing protein with disulfide bonds. In some embodiments, the CFPS
reaction includes about 30% (v/v) iodoacetamide-treated extract with about 8 mM magnesium glutamate, about mM ammonium glutamate, about 130 mM potassium glutamate, about 35 mM sodium pyruvate, about 1.2 mM AMP, about 0.86 mM each of GMP, UMP, and CMP, about 2 mM
amino acids (about 1 mIVI for tyrosine), about 4 mM sodium oxalate, about 0.5 mIVI putrescine, 5 about 1.5 mM spermidine, about 16.7 mM potassium phosphate, about 100 mM T7 RNA
polymerase, about 2-10 ng/mL plasmid DNA template, about 1-10 plVI E. coli DsbC, and a total concentration of about 2 mM oxidized (GSSG) glutathione. Optionally, the cell free extract can include 1 mM of reduced (GSH).
Generating a Lys ate
One of the earliest examples of alternative splice variants with opposing apoptotic effects is Bcl-x. The Bcl-x pre-mRNA can be alternatively spliced to produce two splice variants, anti-apoptotic Bc1-xL (long form) and pro-apoptotic Bc1-xS (short form) (Boise L H et al. Cell. 1993; 74(4):597-608). High Bc1-xL/Bc1-xS ratios, promoting tumor cell survival, can be found in a number of cancer types, including human lymphoma, breast cancer, and human hepatocellular carcinoma (Minn A J et al., J Rio!
Chem. 1996;
271(10:6306-6312.44-46; Olopade 01 et al., Cancer J Sci Am. 1997; 3(4):230-237; Takehara T et al., Hepatologv. 2001; 34(1):55-61). Another example of an apoptosis-related gene that undergoes alternative splicing in cancer cells is the Fas receptor gene.
Expressed on the cell surface of many cell types, the Fas receptor is activated by the Fas ligand produced by cytotoxic T cells, which initiates a death-signaling cascade leading to apoptosis of cells expressing the Fas receptor (Bouillet P et al, Nat Rev Immunol. 2009;
9(7):514-519). There are at least 3 short mRNA variants of Fas missing the encoded transmembrane domain and the resulting translated protein variants are presumably secreted by cancer cells and act as decoy receptors for the Fas ligand, thus allowing cancer cells to escape from apoptosis (Cheng J et al., Science. 1994; 263(5154):1759-1762;
Cascino I et al., Journal of immunology. 1995; 154(6):2706-2713).
Alternative splicing of the H-Ras oncogene occurs on a previously unknown spliced exon (named as IDX) caused by an intronic mutation in the H-Ras gene (Cohen J B et al., Cell. 1989; 58(3):461-472). This mutation of the IDX splice site results in an H-Ras mRNA variant, which is more resistant to the nonsense-mediated mRNA
decay (NMD) process, and consequently overexpressed in cancers (Barbier J et al., Mol Cell Biol. 2007;
27(20):7315-7333). Alternative splicing also plays a role in promoting invasive and metastatic behavior in cancers. CD44 was among the first genes with splice variants specifically associated with metastasis, where variants containing exons 4-7 (v4-7) and 6-7 (v6-7) were shown to be expressed in a metastasizing pancreatic carcinoma cell line, but not in the corresponding parental tumor (Gunthert U et al., Cell. 1991; 65(1):13-24).
Mutational Calling Software Tools In certain aspects, a Pegasus human research pipeline at TGen.
https://github.comftgen/pegasusPipe is used. The sequences are aligned to the HG19 human genome or the HG38 human genome. In one aspect, somatic mutations are called using three separate mutational callers: Seurat, Mutect, and Strelka. All mutations that were seen in more than one of the callers were selected and used to generate peptides. The rationale behind this is that each caller has its own strengths and weaknesses. By pulling mutations that are called by multiple callers the risk of identifying false positives is reduced. The callers are available at: Mutect:https://software.broadinstitute.org/cancer/cga/mutect (Broad Institute Software);
Seurat: https://github.com/tgen/seurat (TGen Caller);
and Strelka:
https://github.com/Illumina/strelka (GNU general public license). Best practices are followed for DNA and RNA workflows. Alternatively, CLIA certified somatic calls are used with no changes to generate peptides as candidate neoantigens for further analysis.
In some embodiments, single or multiple mutation callers may be utilized to call genomic variants. For samples consisting of sequencing tumor and normal tissue the callers that may be used are: Strelka, Strelka2, VarDict, VarScan2, qSNP, Shimmer, RADIA, SOAPsnv, SomaticSniper, FaSD-somatic, Samtools, JointSNVMix, Virmid, SNVSniffer, Seurat, CaVEMan, MuTect, MuTect2, LoFreq, EBCall, deepSNV, LoLoPicker, MuSE, MutationSeq, SomaticSeq, SnooPer, FreeBayes, HapMuC, SPLINTER, Pisces, DeepSNVMiner, smCounter, DeepVariant, Cake, Tnscope, DNAscope, NeoMutate, Maftools, scABA, Sanivar, Sarek, BATCAVE, SomaticNet, CoVaCS, RegTools, xAtlas, R2D2, SiNPle, Bambino, and exactSNP. For samples consisting of tumor only sequencing callers that may be utilized are: Platypus, LumosVar, LumosVar2, SNVMix2, SNVer, OutLyzer, ISOWN, SomVarIUS, SiNVICT, FreeBayes, SNPiR, eSNV-dectect, RNAIndel, VaDir, and Cl airvoy ante.
In certain embodiments, single or multiple mutation callers recognizing splice variants may be utilized to call genomic variants. For samples consisting of sequencing tumor and normal tissue the callers that may be used are: RegTools, ASGAL, MATS (rMATS), SUPPA
(SUPPA2), Leafcutter, MAJIQ, JunctionSeq, findAS, Cufflinks/Cuffdiff, IsoformSwitchAnalyzeR, ALEXA-seq, MISO, SplicingCompass, Flux Capacitor, JuncBASE, SpliceR, FineSplice, ARH-seq, Spladder, DEXSeq, edgeR, Limma, DiffSplice, dSpliceType, SpliceDetector, HISAT2, STAR, Subread, Subjunct, PennDiff, DSGseq, AltAnalyze, Splicing Express, SpliceTrap, PSGInfer, FDM, IsoEM2, MADS+, Spanki, SpliceMap, CASPER, AV1SPA, PASA, SpliceSeq, MATT, Aspli, 1PSA, SANJUAN, VAST-Tools, SpliceV, Asprofile, DESeq2, Yanagi, ABLas, IRIS, and AS-Quant HLA Typing In some embodiments, whole exome sequencing (WES) and/or RNA sequencing from tumor and/or normal tissue may be used to identify the MHC class 1 and 2 genotypes for individual patients.
Single or multiple HLA callers may be utilized to identify the HLA types. For DNA
sequencing the HLA callers that may be utilized are: BWAkit, PHLAT, OptiType, HLAMiner, HISAT, HISAT2, xHLA, HLA-Vbseq, GATK HLA Caller, PolySolver, HLAReporter, Athlates, HLAseq, HLAssign, SOAP-HLA, STC-SEq, HapLogic, Gyper, HLATyphon, HLA-LA, HLA-PRG, MHC-PRG, Prohlatype, GraphTyper, ALPHLARD, Omixon, SNP2HLA, HLAscan, NeoEpitopePred, and Assign. For RNA sequencing the HLA callers that may be utilized are: BWAkit, seq2HLA, PHLAT, HLAProfiler, OptiType, HLAMiner, HLAForest, arcasHLA, HISAT, HISAT2, HLAseq, HLAssign, STC-Seq, HLATyphon, ALPHLARD, Omixon, and HLAscan.
In some embodiments, whole exome sequencing data may be analyzed for HLA
typing using Polysolver (polymorphic loci resolver) (Shukla et al., 2015). Polysolver is an algorithm for inferring alleles of the three major MHC class I (HLA-A, HLA-B, HLA-C) genes. For example, a patient's HLA class I alleles may be inferred from whole exome sequencing data using Polysolver. In other variations, in the absence of whole exome sequencing data, a patient's HLA class I alleles may be inferred from transcriptome sequencing data by an alternative HLA typing algorithm.
In one embodiment, HLA typing is conducted in sit/co using one or more techniques such as OptiType, run on a computing device. See Szolek, et al., OptiType:
precision HLA
typing from next-generation sequencing data, Bioinformatics. 2014 Dec 1;30(23), incorporated herein in its entirety for all purposes. A variety of other in silico techniques may also be used.
See Major, et al., HLA typing from 1000 genomes whole genome and whole exome Ilumina data, PLoS One. 2013 Nov 68(1 0:e78410; Wittig, et al., Development of a high-resolution NGS-based HLA-typing and analysis pipeline, Nucl. Acids Res. (2015).
Generation of Peptides from Tumor Mutations In some embodiments mutational data is acquired as described above in the section entitled -Detection of Tumor Mutations and/or Neoepitopes". The mutational calls may be converted to mutant protein sequences using single or multiple tools including but not limited to: Varcode, customProDB, and pyGeno. The tools will generate the peptides sequences for downstream in-vitro and in-silico HLA binding assays. Additionally, in some embodiments, the peptides will undergo testing to validate that each peptide is unique to the human proteome.
The peptides may be aligned to several different protein databases from NCBI
including: Non-redundant protein sequences, Reference proteins, model organisms, UniProtKB/Swiss-Prot, Patented protein sequences, Protein Data Bank proteins, Metagenomic proteins, and Transcriptome Shotgun Assembly proteins. Using the databases listed above rBlast may be utilized to run protein BLAST to identify proteins with 100% identity to the human proteome.
In certain aspects, Varcode software is utilized in python to predict the impact of the genome variant data. Varcode generates the wild type and mutant protein sequences from the mutation and/or neoepitopes at the desired peptide size. In certain aspects, the desired peptide size is 3,4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20 or more amino acids. In one aspect, the desired peptide size is 15 amino acids.
Varcode dependency is Pyensembl, which is a python access point to Ensembl reference genome data to generate peptides. In some embodiments, Varcode predicts the impact of each mutation on the protein. Silent mutations and mutations that are in noncoding regions on the genome are excluded. Varcode is then used to generate mutations across the peptide sequence. These variant peptides (i.e., candidate neoantigens) containing the mutations generated with Varcode are further analyzed with in silico methods and/or biochemical assays (e.g., a peptide-DNA conjugate assay) to identify which peptides bind patient-specific MHC
class I and II proteins and which are ultimately be recognized by the patient's tumor infiltrating lymphocytes (TILs).
Analysis of Neoantigens with a Peptide-DNA Conjugate Approach The peptide-DNA conjugate platform is well suited to rapidly screen large populations of diverse molecules for candidate neoantigens. In some embodiments, the present invention provides the following strategy for identification of neoantigens. According to various embodiments, a peptide-DNA conjugate method comprises a method for pooled, highly-parallel expression of proteins, each associated with a nucleic acid barcode.
In some embodiments, the peptide-DNA conjugate method comprises a method for pooled, highly-parallel in vitro expression of proteins, each covalently linked to a DNA
barcode through a puromycin-containing linkage. In other embodiments, the peptide-DNA conjugate method comprises phage display, mRNA display, or other method.
The peptide-DNA conjugate approach is a proprietary technology that can rapidly generate a large number of potential neoantigens as candidate binding agents for the patient-specific HLA proteins. The peptide-DNA conjugate approach is a method that generates peptide libraries (10-50 amino acids long) with each peptide conjugated to a unique DNA tag that can be used to monitor peptide abundance following binding experiments.
Importantly, the peptide sequences can be used in large multiplexed binding assays with upwards of 100,000 of unique programmable peptides.
Binding assays for any molecular target can be used to screen large diverse peptide-DNA conjugate libraries. A biological structure (e.g., a patient-specific HLA
proteins or fragments thereof corresponding to the patient's genotype) can be mixed with diverse peptides, separated from unbound peptides, and then queried for those that "stick." The particular libraries could be intelligently designed libraries based upon prior knowledge of the target (e.g., from exome sequencing and analysis).
The peptide-DNA conjugate platform is described in greater detail in U.S.
Patent No.
9,958,454; U.S. Patent No. 10,288,608; and U.S. Patent Application Publication No.
2016/0025726, the contents of which are hereby incorporated by reference.
In some embodiments, the peptide-DNA conjugate method is used to identifying neoantigens. In certain aspects, identification of neoantigen comprises (i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA
proteins or fragments thereof; (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs; (iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA
proteins or fragments thereof; (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA proteins or fragments thereof In some aspects, the identifying nucleic acid portion of each peptide construct comprises a polynucleotide sequence or complement thereof encoding the peptide portion of the peptide construct.
Identification of Neoantigens with Phage Display, Ribosomal display, mRNA
Display, Yeast Display, Bacterial Display, and Related Techniques In some embodiments, the polypeptides of interest are genetically encoded to facilitate identification of neoantigens. An example of a genetically encoded polypeptide library is a mRNA display library. Another example is a replicable genetic display package (rgdp) library such as a phage display library. In one embodiment, the polypeptides of interest are genetically encoded as a phage display library. In these embodiments, the nucleic acid may be comprised by the phage genome. In these embodiments, the polypeptide may be comprised by the phage coat.
In some embodiments, the invention may be used to produce a genetically encoded combinatorial library of polypeptides which are generated by translating a number of nucleic acids into corresponding polypeptides and linking molecules of said molecular scaffold to said polypeptides. The genetically encoded combinatorial library of polypeptides may be generated by phage display, yeast display, ribosomal display, bacterial display or mRNA
display.
Phage Display Techniques and methodology for performing phage display can be found in WO
2009/098450.
Different phage display systems have been developed throughout the years, making use of different phage vectors (M13 filamentous phage, lambda, T4 and T7 phage) and various phage coat proteins for covalent fusion. The M13 filamentous phage is employed most commonly. The strength of the filamentous phage display system lies within the lysogenic life cycle of this phage and the availability of M13 phagemid vectors (Webster, 1006; Hufton et al., 1999). Lysogenic phage integrate their DNA into the host cell genome, are replicated along with the bacterial cell and do not require the lysis of the bacterial cell for phage particle formation. Instead, phage particles are shed from the bacterial surface without inducing cell death (Webster, 1996). Moreover, the development of M13 phagemid vectors has allowed for excellent workability. Phagemids are plasmids containing the replication origin and packaging signal of the filamentous phage, together with the plasmid origin of replication and the gene encoding the phage coat protein coupled with the DNA insert (Webster, 1996;
Armstrong et al., 1996). For phage propagation, bacterial cells infected with phagemid need to be "superinfected" with a so-called helper phage that provides all the other essential phage components for the formation of viable phage virions. Besides excellent workability, the use of a phagemid vector system allows for monovalent display of the recombinant protein (maximally one recombinant protein per phage virion) as the helper phage contributes non-recombinant phage coat proteins (Armstrong et al., 1996).
Different M13 vector systems for phage display through various coat proteins are available (Smith and Petrenko, 1997; Barbas, 1993). Major coat protein pVIII and minor coat protein pill, are used most frequently for display purposes (Armstrong et al., 1996;
Rodi and Makowski, 1999). As the N-terminal end of both proteins is exposed at the phage surface, foreign DNA sequences are inserted upstream of the genes encoding the coat proteins. The development of phage vectors for C-terminal fusion to M13 minor coat protein pVI, of which the C-terminal end is exposed at the surface of the phage, has been an important step towards the development of cDNA phage display libraries (Hufton et al., 1999; Jespers et al., 1995).
More recently, display methods were also developed in the lytic phage systems, namely for lambda phage, T4 and T7 phage. For the formation and shedding of recombinant lytic phage virions containing recombinant coat proteins, bacterial cells need to be lysed on phage propagation (Russel, 1991). Moreover, as there are no plasmid vectors available for the lytic phage, DNA isolation and experimental approaches are more labor-intensive in comparison to working with plasmids (Sambrook et al., 1989). As both lytic and lysogenic phage life cycles employ different phage assembly strategies, both approaches allow the display of different proteins (Hufton et al., 1999). As the virion proteins of M13 filamentous phage (and thus, also the recombinant phage coat protein) are embedded into the bacterial cell membrane prior to phage virion assembly, this process puts constraints on the proteins that can be displayed at the surface of the phage; for efficient display, the cDNA
products must be able to traverse the bacterial cell membrane and need to allow for the formation of a viable and infectious virion (Webster, 1996; Russel, 1991; Rodi et al., 2002).
For lytic phage virion production on the other hand, the recombinant proteins are formed and retained within the cytosol of bacterial cells prior and during virion assembly so that the spectrum of recombinant proteins that can be displayed by lytic phage is less constrained (Hufton et al., 1999; Russel, 1991; Krumpe et al., 2006).
Phage display is described, for example, in Ladner et al., U.S. Pat. No.
5,223,409;
Smith (1985) Science 228:1315-1317; WO 92/18619; WO 91/17271; WO 92/20791; WO
92/15679; WO 93/01288; WO 92/01047; WO 92/09690; WO 90/02809; de Haard et al.
(1999) 1 Biol. Chem 274:18218-30; Hoogenboom et al. (1998) Immunotechnology 4:1-20;
Hoogenboom et al. (2000) Immunol Today 2:371-8;
Fuchs et al.
(1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum Anabod Hybridomas 3:81-85;
Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EV/B0 112:725-734;
Hawkins et al. (1992) J Mol Blot 226:889-896; Clackson et al. (1991) Nature 352:624-628;
Gram et al. (1992) Proc Nat! Acad Sci USA 89:3576-3580; Garrard et al.
(1991) Bio/Technology 9:1373-1377; Rebar et al. (1996)Methods Enzymol. 267:129-49;
Hoogenboom et al. (1991) Nue Acid Res 19:4133-4137; and Barbas et al.
(1991) PNAS 88:7978-7982.
Ribosomal Display In certain aspects, the methods described herein comprise the use of ribosomal display to identify neoantigens. Ribosomal display can be used to perform in vitro protein synthesis of a protein of interest (e.g., a candidate neoantigen). Ribosomal display can also be used to perform in vitro protein evolution to create proteins with desired properties, for example, Fab fragments that bind to a specific target molecule. Ribosomal display is a well-known technology useful for generating libraries. This entirely in vitro method allows for libraries with a diversity of 1016 members. The process results in translated proteins that are associated with their RNA progenitor which can be used, as a complex, to select for proteins with desired properties (e.g., bind to an immobilized target molecule). The RNA-protein complex that shows the desired property, e.g., high binding affinity, can then be reverse transcribed to cDNA
and the sequence amplified via PCR. The process also provides for repeated cycles of iteration or protein expression. In addition, nucleic acid mutations can be introduced efficiently into the selected nucleic acid library in subsequent cycles, leading to continuous DNA
diversification and thus, protein evolution. The end result is a nucleic acid sequence that can be used to produce a protein of interest (e.g., neoantigens that specifically bind to the patient-specific HLA
proteins, and ultimately the patent's TILs).
In the method provided herein, a protein of interest is displayed on the surface of a ribosome from which the protein of interest is being translated. Briefly, a library of RNA
molecules is translated in an in vitro translation system to the 3' end of the RNA molecule, such that the ribosome does not fall off This is accomplished by not incorporating a functional stop codon in the RNA template. Normally, the stop codon is recognized by release factors that trigger detachment of the nascent polypeptide from the ribosome. In ribosomal display, the peptide emerges from the ribosome, but does not fall free of the complex. This allows, for example, the nascent polypeptide to associate with another polypeptide to form a functional dimer. In some instances, there is an additional folding step in an oxidizing environment (important for forming disulfide bonds).
The whole complex of folded protein of interest, ribosome and RNA, which is stable for several days, can then be screened for desired properties, such as specific binding to a binding pair ligand by the translated protein of interest. The RNA encoding the selected protein of interest can be reverse transcribed into single stranded cDNA which can be converted to double-stranded DNA and amplified by PCR, providing the coding sequence of the selected protein (e.g., a neoantigen). The reverse transcription reaction can be performed on mRNA associated in the ribosomal display complex, or the mRNA can be isolated from the ribosomal display complex then used in the reverse transcription step.
Suitable methods for disruption/dissociation of ribosome complexes are known in the art and include EDTA
treatment and/or phenol extraction.
In general, nucleic acid (DNA) constructs for ribosomal display contain a promoter (T7, SP6 or T3), a translation initiation signal such as a Shine-Dalgarno (prokaryotic) or Kozak (eukaryotic) sequence, initiation codon, and coding sequence of the protein of interest (e.g., \in or Vi. chain domain). One or more nucleic acid sequences encoding one or more detection tags may be included to provide for production of a protein further comprising one or more detection tags (e.g., histidine tag). To enable the complete nascent protein to be displayed and fold into its active conformation, a spacer domain of at least 23-30 amino acids length can be added at the C terminus, to allow the protein to exit completely from the ribosome. The spacer can provide a known sequence for the design of primers for RT-PCR recovery of the DNA
sequences.
To remove the stop codon from DNA, a 3' primer lacking the stop codon can be used during PCR construction. Constructs designed for bacterial-based display systems can incorporate sequences containing stem-loop structures at the 5' and 3' ends of the DNA to stabilize mRNA against degradation by RNase activities in bacterial cell-free systems.
The mRNA translation system used in the methods described herein may be any suitable available system. A prokaryotic or eukaryotic translation system may be used, for example crude E. coli lysate (commercially available from e.g. Promega Corp., Madison, Wis.;
Agilent Technologies, Santa Clara, Calif; GE Healthcare Biosciences, Pittsburgh, Pa.; Life Technologies, Carlsbad, Calif), a reconstituted ribosome system such as PURE
(see, e.g., Shimizu et al., Nat. Biotechnol., 19:751-755 (2001)), or a cell free protein synthesis system as described below.
The PURE system can include about 32 individually purified components used for in vitro protein biosynthesis (e.g., initiation, elongation and termination). In some embodiments, the components include initiation factors (e.g., IF1, IF2, IF3), elongation factors (e.g., EF-G, EF-Tu, EF-Ts), release factors (e.g., RF1, RF3), a termination factor (e.g., RRF), 20 aminoacyl-tRNA synthetases, methionyl-tRNA transformylase, T7 RNA polymerase, ribosomes, tRNAs, NTPs, creatine phosphate, 10-formy1-5,6,7,8-tetrahydrofolic acid, 20 amino acids, creatine kinase, myokinase, nucleoside-diphosphate kinase and pyrophosphatase.
Ribosomal display has been used to successfully generate antibody fragments with high affinity for their target. Detailed description of ribosomal display is found in, e.g., Hanes, Proc. Natl. Acad. Sci. USA, 95: 14130-14135 (1998); Schaffitzel et al., I
Immunological Methods, 231:119-135 (1999); He et al.,i Immunological Methods, 231, 105-117 (1999);
Roberts R W, Current Opinion in Chemical Biology, 3: 268-273 (1999).
Other Display Methods for In Vitro Selection Other in vitro library display methods can be used in the methods described herein, such as, but not limited to, mRNA display, bicistronic display, P2A display, and CIS display (cis-activity display).
mRNA Display In mRNA display, each member of the RNA library is directly attached to the protein of interest it encodes by a stable covalent linkage to puromycin, an antibiotic that can mimic the aminoacyl end of tRNA (see, e.g., Robert R W and Szostak J W, Proc. Natl.
Acad. Sci.
(ISA, 94:12297-12302 (1997)). Puromycin is an aminonucleoside antibiotic, active in either prokaryotes or eukaryotes, derived from Streptomyces alboniger Protein synthesis is inhibited by premature chain termination during translation taking place in the ribosome. Part of the molecule acts as an analog of the 3' end of a tyrosyl-tRNA, where a part of its structure mimics a molecule of adenosine and another part mimics a molecule of tyrosine. It enters the A site and transfers to the growing chain, causing the formation of a puromycylated nascent chain and premature chain release. The 3' position contains an amide linkage instead of the normal ester linkage of tRNA, making the molecule much more resistant to hydrolysis and stopping procession along the ribosome.
Other puromycin analog inhibitors of protein synthesis include 0-demethylpuromycin, 0-prop argyl-puromy ci n, 9- {3 '-deoxy-3 '4(4-m ethy -L-ph enyl al anypamino] 43-D-ribofuranosy1}-6-(N,N'-dimethylamino)purine [L-(4-Me)-Phe-PANS] and 6-dimethylamino-943-(p-azido-L-beta-phenylalanylamino)-3-deoxy -beta-rib ofurano syl] purine.
Members of the RNA library can be ligated to puromycin via a linker such as, but not limited to, a polynucleotide or a chemical linker, e.g., polyethylene glycol (Fukuda et al., Nucleic Acid Research, 34(19):e127 (2006)). In some embodiments, the polynucleotide linker comprising RNA is linked at the 3' terminal end to puromycin. In other embodiments, the PEG liker is linked to puromycin.
As puromycin that is linked to the 3' terminal end of a RNA molecule enters a ribosome, it establishes a covalent bond to the nascent protein (encoded by the RNA
molecule) as a result of peptidyl transferase activity in the ribosome. In turn, a stable amide linkage forms between the protein and the 0-methyl tyrosine portion of puromycin.
The RNA library of RNA-puromycin fusions can undergo in vitro translation, as described herein, to generate RNA-puromycin-protein complexes (e.g., RNA-puromycin-neoantigen complexes). In some embodiments, the RNA-puromycin fusions comprise RNA
molecules encoding candidate neoantigens identified by exome analysis of tumor cells and wild-type cells from a patient.
Affinity selection can be performed on the mRNA-displayed protein library to screen for proteins having desired properties, such a specific binding to a binding pair ligand.
The mRNA display can be performed in solution or on a solid support. The selected mRNA-displayed protein of interest can be purified by standard methods known in the art such as affinity chromatography. The mRNA can be cloned, PCR amplified, and/or sequenced to determine the coding sequence of the selected protein of interest. In one embodiment, the selected mRNA-displayed library contains a population of neoantigens that bind to the patient-specific HLA proteins or fragments thereof, and ultimately the patient's TILs.
In some aspects, members of a library of nucleic acid members are linked to puromycin, where each member encodes a prospective protein of interest having a primary amino acid sequence different from the other proteins encoded by the other nucleic acid members.
The mRNA display system can contain a population or mixture of different complexes such that each complex has a different mRNA linked to puromycin, the ribosome, and a prospective protein of interest.
Biscistronic DNA Display Bicistronic DNA display can be employed for in vitro selection of proteins of interest (see, e.g., Sumida et al., Nucleic Acid Research, 37(22):e147 (2009)). The method is based on complexing in vitro translated proteins of interest to their encoding DNA, which used to determine the sequence of the protein of interest. Typically, a DNA template containing multiple ORFs that can be linked to the protein it encodes is generated. In addition, the coupled transcription/translation reaction is compartmentalized in a water-in-oil emulsion (e.g., micelle).
In some instances, when multiple ORFs are used, they can be separated by ribosomal binding sides. In some embodiments, the coding sequence of the protein of interest is fused to the coding sequence of streptavidin. In some embodiments, the DNA
template is biotinylated through a linker. The linker can be cleavable.
During in vitro transcription/translation, the protein can be expressed in a micelle. In one non-limiting illustrative embodiment, the DNA template contains the coding sequence of a candidate neoantigen, and the candidate neoantigen is expressed in a micelle. In embodiments, a candidate neoantigen forms and is associated with the DNA
encoding the candidate neoantigen through a linkage, such as a streptavidin-biotin link.
The DNA displayed protein of interest, such as a candidate neoantigen, can be recovered from the emulsion and screened by affinity selection. The DNA template of the selected DNA-displayed protein of interest can be cleaved from the complex by methods such as UV
irradiation and then PCR amplified, cloned, and/or sequenced.
In some embodiments, the methods provided herein include generating a library of nucleic acid members, each member encoding a prospective protein of interest (i.e., a candidate neoantigen) having a primary amino acid different from the other proteins encoded by the other nucleic acid members. In some embodiments, the library comprises DNA members, and the method includes transcribing the library into RNA and translating the RNA in a cell free protein synthesis system to generate a bicistronic DNA display system in a water-in-oil emulsion. In some embodiments, the bicistronic DNA display system contains a population of proteins of interest that are selected for specific binding to a binding pair ligand. In one embodiment, the bicistronic DNA display system contains a population of candidate neoantigens, wherein each candidate neoantigen is associated with a DNA molecule encoding the candidate neoantigen.
P2A DNA Display In P2A DNA display, which utilizes the cis-activity of the endonuclease P2A, a fusion protein of P2A and a protein of interest binds to the same DNA molecule from which it is expressed (see, e.g., Reiersen et al., Nucleic Acids Research, 33(1): el 0).
The DNA template can contain the coding sequence encoding the protein of interest genetically fused to the coding sequence of P2A, a promoter, and an origin of replication. The coding sequence of P2A can be obtained and a genetic fusion with the protein of interest can be constructed by standard methods known to those in the art.
In some embodiments, P2A DNA display is used to select a protein of interest.
The protein of interest can be selected by generating a library of fusion proteins, where each member of the library comprises a fusion protein between P2A and a protein of interest, and selecting proteins of interest based on a desired property, for example, specific binding to a binding pair ligand. The library can be constructed from a library of nucleic acid members, where each member comprises a DNA template encoding a different protein of interest (i.e., each protein of interest has a primary amino acid sequence that is different from other proteins encoded by other members of the nucleic acid library) that is genetically fused to the coding sequence of P2A.
In some embodiments, the P2A DNA-displayed library can be screened by affinity selection strategies, e.g., in solution or on a solid support. The selected protein of interest can be purified by, e.g., affinity chromatography, and the complexed DNA can be PCR amplified, cloned and/or sequenced.
CIS Display Similar to P2A DNA display, CIS display involves a DNA-based approach to directly link in vitro transcribed/translated proteins to the DNA molecules that encode them (see, e.g., Odegrip et al., Proc. Natl. Acad. Sc,. USA, 101(9):2806-2810). This method uses RepA, a DNA
replication initiator protein, to non-covalently bind to the DNA molecule from which it is expressed if the DNA molecule has a CIS element. The DNA molecule can be created to encode proteins of interest (e.g., candidate neoantigens) in addition to RepA.
In some embodiments, CIS display is used to select a protein of interest. The protein of interest can be selected by generating a DNA library of fusion proteins, where each member comprises a fusion protein between RepA and a protein of interest, and selecting proteins of interest based on a desired property, for example, specific binding to a binding pair ligand. The library can be constructed from a DNA library, where each member of the library comprises a DNA template encoding a different protein of interest (i.e., each protein of interest has a primary amino acid sequence that is different from other proteins encoded by other members of the nucleic acid library) that is genetically fused to the coding sequence of RepA.
In some embodiments, members of the DNA library contain a coding sequence of the protein of interest, a coding sequence of RepA, a CIS element, an origin of replication and a promoter, wherein the coding sequence of the protein of interest is genetically fused to the coding sequence of RepA. The CIS element can be genetically linked to the RepA
coding sequence.
In some embodiments, the library contains a fusion protein between RepA and a protein of interest, and a DNA molecule encoding the fusion protein.
The RepA DNA-displayed library can be screened by affinity selection strategies, e.g., in solution or on a solid support. The selected protein of interest can be purified by, e.g., affinity chromatography, and the complexed DNA can be PCR amplified, cloned and/or sequenced.
Cell-Free Protein Synthesis ((7FPS) In order to express the biologically active proteins of interest described herein (i.e., neoantigens), a cell free protein synthesis system can be used. Cell extracts have been developed that support the synthesis of proteins in vitro from purified mRNA
transcripts or from mRNA transcribed from DNA during the in vitro synthesis reaction.
CFPS of polypeptides in a reaction mix comprises bacterial extracts and/or defined reagents. The reaction mix comprises at least ATP or an energy source; a template for production of the macromolecule, e.g., DNA, mRNA, etc.; amino acids, and such co-factors, enzymes and other reagents that are necessary for polypeptide synthesis, e.g., ribosomes, tRNA, polymerases, transcriptional factors, aminoacyl synthetases, elongation factors, initiation factors, etc. In one embodiment of the invention, the energy source is a homeostatic energy source. Also included may be enzyme(s) that catalyze the regeneration of ATP from high-energy phosphate bonds, e.g., acetate kinase, creatine kinase, etc. Such enzymes may be present in the extracts used for translation, or may be added to the reaction mix. Such synthetic reaction systems are well-known in the art, and have been described in the literature.
The templates for cell-free protein synthesis can be either mRNA or DNA. The template can comprise sequences for any particular gene of interest, and may encode a full-length polypeptide or a fragment of any length thereof Nucleic acids that serve as protein synthesis templates are optionally derived from a natural source or they can be synthetic or recombinant. For example, DNAs can be recombinant DNAs, e.g., plasmids, viruses or the like.
The term -reaction mix" as used herein, refers to a reaction mixture capable of catalyzing the synthesis of polypeptides from a nucleic acid template. The reaction mixture comprises extracts from bacterial cells, e.g., E. coil S30 extracts. S30 extracts are well known in the art, and are described in, e.g., Lesley, S. A., et al. (1991), 1 Biol.
Chem. 266, 2632-8.
The synthesis can be performed under either aerobic or anaerobic conditions.
In some embodiments, the bacterial extract is dried. The dried bacterial extract can be reconstituted in milli-Q water (e.g., reverse osmosis water) at 110% of the original solids as determined by measuring the percent solids of the starting material. In one embodiment, an accurately weighed aliquot of dried extract, representing 110% of the original solids of 10 mL
of extract, is added to 10 mL of Milli-Q water in a glass beaker with a stir bar on a magnetic stirrer. The resulting mixture is stirred until the powder is dissolved. Once dissolved, the material is transferred to a 15 mL Falcon tube and stored at ¨80 C unless used immediately.
The volume percent of extract in the reaction mix will vary, where the extract is usually at least about 10% of the total volume; more usually at least about 20%; and in some instances, may provide for additional benefit when provided at least about 50%; or at least about 60%;
and usually not more than about 75% of the total volume.
The general system includes a nucleic acid template that encodes a protein of interest.
The nucleic acid template is an RNA molecule (e.g., mRNA) or a nucleic acid that encodes an mRNA (e.g., RNA, DNA) and be in any form (e.g., linear, circular, supercoiled, single stranded, double stranded, etc.). Nucleic acid templates guide production of the desired protein.
To maintain the template, cells that are used to produce the extract can be selected for reduction, substantial reduction or elimination of activities of detrimental enzymes or for enzymes with modified activity. Bacterial cells with modified nuclease or phosphatase activity (e.g., with at least one mutated phosphatase or nuclease gene or combinations thereof) can be used for synthesis of cell extracts to increase synthesis efficiency. For example, an E. coli strain used to make an S30 extract for CFPS can be RNase E or RNase A deficient (for example, by mutation).
In a generic CFPS reaction, a gene encoding a protein of interest is expressed in a transcription buffer, resulting in mRNA that is translated into the protein of interest in a CFPS
extract and a translation buffer. The transcription buffer, cell-free extract and translation buffer can be added separately, or two or more of these solutions can be combined before their addition, or added contemporaneously.
To synthesize a protein of interest in vitro, a CFPS extract at some point comprises a mRNA molecule that encodes the protein of interest. In some CFPS systems, mRNA is added exogenously after being purified from natural sources or prepared synthetically in vitro from cloned DNA using RNA polymerases such as RNA polymerase II, SP6 RNA
polymerase, T3 RNA polymerase, T7 RNA polymerase, RNA polymerase III and/or phage derived RNA
polymerases. In other systems, the mRNA is produced in vitro from a template DNA; both transcription and translation occur in this type of CFPS reaction. In some embodiments, the transcription and translation systems are coupled or comprise complementary transcription and translation systems, which carry out the synthesis of both RNA and protein in the same reaction. In such in vitro transcription and translation systems, the CFPS
extracts contain all the components (exogenous or endogenous) necessary both for transcription (to produce mRNA) and for translation (to synthesize protein) in a single system.
A cell free protein synthesis reaction mixture comprises the following components: a template nucleic acid, such as DNA, that comprises a gene of interest operably linked to at least one promoter and, optionally, one or more other regulatory sequences (e.g., a cloning or expression vector containing the gene of interest) or a PCR fragment; an RNA
polymerase that recognizes the promoter(s) to which the gene of interest is operably linked and, optionally, one or more transcription factors directed to an optional regulatory sequence to which the template nucleic acid is operably linked; ribonucleotide triphosphates (rNTPs);
optionally, other transcription factors and co-factors therefor; ribosomes; transfer RNA (tRNA);
other or optional translation factors (e.g., translation initiation, elongation and termination factors) and co-factors therefore; one or more energy sources, (e.g., ATP, GTP);
optionally, one or more energy regenerating components (e.g., PEP/pyruvate kinase, AP/acetate kinase or creatine phosphate/creatine kinase); optionally factors that enhance yield and/or efficiency (e.g., nucleases, nuclease inhibitors, protein stabilizers, chaperones) and co-factors therefore; and;
optionally, solubilizing agents. The reaction mix further comprises amino acids and other materials specifically required for protein synthesis, including salts (e.g., potassium, magnesium, ammonium, and manganese salts of acetic acid, glutamic acid, or sulfuric acids), polymeric compounds (e.g., polyethylene glycol, dextran, diethyl aminoethyl dextran, quaternary aminoethyl and aminoethyl dextran, etc.), cyclic AMP, inhibitors of protein or nucleic acid degrading enzymes, inhibitors or regulators of protein synthesis, oxidation/reduction adjuster (e.g., DTI, ascorbic acid, glutathione, and/or their oxides), non-denaturing surfactants (e.g., Triton X-100), buffer components, spermine, spermidine, putrescine, etc. Components of CFPS reactions are discussed in more detail in U.S. Pat. Nos.
7,338,789 and 7,351,563, and U.S. App. Pub. No. 2010/0184135, the disclosures of which are incorporated by reference in its entirety for all purposes.
Depending on the specific enzymes present in the extract, for example, one or more of the many known nuclease, polymerase or phosphatase inhibitors can be selected and advantageously used to improve synthesis efficiency.
Protein and nucleic acid synthesis typically requires an energy source. Energy is required for initiation of transcription to produce mRNA (e.g., when a DNA
template is used and for initiation of translation high energy phosphate for example in the form of GTP is used).
Each subsequent step of one codon by the ribosome (three nucleotides; one amino acid) requires hydrolysis of an additional GTP to GDP. ATP is also typically required. For an amino acid to be polymerized during protein synthesis, it must first be activated.
Significant quantities of energy from high energy phosphate bonds are thus required for protein and/or nucleic acid synthesis to proceed.
An energy source is a chemical substrate that can be enzymatically processed to provide energy to achieve desired chemical reactions. Energy sources that allow release of energy for synthesis by cleavage of high-energy phosphate bonds such as those found in nucleoside triphosphates, e.g., ATP, are commonly used. Any source convertible to high energy phosphate bonds is especially suitable. ATP, GTP, and other triphosphates can normally be considered as equivalent energy sources for supporting protein synthesis.
To provide energy for the synthesis reaction, the system can include added energy sources such as glucose, pyruvate, phosphoenolpyruvate (PEP), carbamoyl phosphate, acetyl phosphate, creatine phosphate, phosphopyruvate, glyceral dehyde-3-phosph ate, Phosphoglycerate and glucose-6-phosphate that can generate or regenerate high-energy triphosphate compounds such as ATP, GTP, other NTPs, etc.
When sufficient energy is not initially present in the synthesis system, an additional source of energy is preferably supplemented. Energy sources can also be added or supplemented during the in vitro synthesis reaction.
In some embodiments, the cell-free protein synthesis reaction is performed using the PAN0x-SP system comprising NTPs, E. coil tRNA, amino acids, Mg' acetate, Mg' glutamate, K+ acetate, IC glutamate, folinic acid, Tris pH 8.2, DTT, pyruvate kinase, T7 RNA polymerase, disulfide isomerase, phosphoenol pyruvate (PEP), NAD, CoA, Na + oxalate, putrescine, spermidine, and S30 extract.
In some instances, the cell-free synthesis reaction does not require the addition of commonly secondary energy sources, yet uses co-activation of oxidative phosphorylation and protein synthesis. In some instances, CFPS is performed in a reaction such as the Cytomim (cytoplasm mimic) system. The Cytomim system is defined as a reaction condition performed in the absence of polyethylene glycol with optimized magnesium concentration.
This system does not accumulate phosphate, which is known to inhibit protein synthesis.
The presence of an active oxidative phosphorylation pathway can be tested using inhibitors that specifically inhibit the steps in the pathway, such as electron transport chain inhibitors. Examples of inhibitors of the oxidative phosphorylation pathway include toxins such as cyanide, carbon monoxide, azide, carbonyl cyanide m-chlorophenyl hydrazone (CCCP), and 2,4-dinitrophenol, antibiotics such as oligomycin, pesticides such as rotenone, and competitive inhibitors of succinate dehydrogenase such as malonate and oxaloacetate.
In some embodiments, the cell-free protein synthesis reaction is performed using the Cytomim system comprising NTPs, E. coil tRNA, amino acids, Mg2+ acetate, Mg2+
glutamate, K+ acetate, K+ glutamate, folinic acid, Tris pH 8.2, DTT, pyruvate kinase, T7 RNA polymerase, disulfide isomerase, sodium pyruvate, NAD, CoA, Na + oxalate, putrescine, spermidine, and S30 extract. In some embodiments, the energy substrate for the Cytomim system is pyruvate, glutamic acid, and/or glucose. In some embodiments of the system, the nucleoside triphosphates (NTPs) are replaced with nucleoside monophosphates (NMPs).
The cell extract can be treated with iodoacetamide in order to inactivate enzymes that can reduce disulfide bonds and impair proper protein folding. In some embodiments, the cell extract comprises an exogenous protein chaperone. The protein chaperone can be expressed by the bacterial strain used to make the cell free extract, or the protein chaperone can be added to the cell extract Non-limiting examples of exogenous protein chaperones include disulfide bond isomerase (PDI), such as, but not limited to E. coil DsbC, and peptidyl prolyl cis-trans isomerase (PPIase), such as but not limited to FkpA. In some embodiments, the extract comprises both a PDI and a PPIase, e.g., both DsbC and FkpA. Glutathione disulfide (GSSG) and/or glutathione (GSH) can also be added to the extract at a ratio that promotes proper protein folding and prevents the formation of aberrant protein disulfides.
In some embodiments, the CFPS reaction includes inverted membrane vesicles to perform oxidative phosphorylation. These vesicles can be formed during the high pressure homogenization step of the preparation of cell extract process, as described herein, and remain in the extract used in the reaction mix.
Methods of preparing a cell extract are described in. e.g., Zawada, J.
"Preparation and Testing of E. coil S30 In Vitro Transcription Translation Extracts", Douthwaite, J. A. and Jackson, R. H. (eds.), Ribosomal display and Related Technologies: Methods and Protocols, Methods in Molecular Biology, vol. 805, pp. 31-41 (Humana Press, 2012); Jewett et al., Molecular Systems Biology: 4, 1-10 (2008); Shin J. and Norieaux V., I
Biol. Eng., 4:8 (2010). Briefly, a bacterial culture is grown and harvested; suspended in an appropriate buffer (e.g., S30 buffer), and homogenized to lyse the cells.
The cell-free extract can be thawed to room temperature before use in the CFPS
reaction. The extract can be incubated with 50 p.M iodoacetamide for 30 minutes when synthesizing protein with disulfide bonds. In some embodiments, the CFPS
reaction includes about 30% (v/v) iodoacetamide-treated extract with about 8 mM magnesium glutamate, about mM ammonium glutamate, about 130 mM potassium glutamate, about 35 mM sodium pyruvate, about 1.2 mM AMP, about 0.86 mM each of GMP, UMP, and CMP, about 2 mM
amino acids (about 1 mIVI for tyrosine), about 4 mM sodium oxalate, about 0.5 mIVI putrescine, 5 about 1.5 mM spermidine, about 16.7 mM potassium phosphate, about 100 mM T7 RNA
polymerase, about 2-10 ng/mL plasmid DNA template, about 1-10 plVI E. coli DsbC, and a total concentration of about 2 mM oxidized (GSSG) glutathione. Optionally, the cell free extract can include 1 mM of reduced (GSH).
Generating a Lys ate
10 The methods and systems described herein can use a cell lysate for in vitro translation of a target protein of interest. For convenience, the organism used as a source for the lysate may be referred to as the source organism or host cell. Host cells may be bacteria, yeast, mammalian or plant cells, or any other type of cell capable of protein synthesis. A lysate comprises components that are capable of translating messenger ribonucleic acid (mRNA) encoding a desired protein, and optionally comprises components that are capable of transcribing DNA encoding a desired protein. Such components include, for example, DNA-directed RNA polymerase (RNA polymerase), any transcription activators that are required for initiation of transcription of DNA encoding the desired protein, transfer ribonucleic acids (tRNAs), aminoacyl-tRNA synthetases, 70S ribosomes, N''-formyltetrahydrofolate, formylmethionine-tRNAtmel synthetase, peptidyl transferase, initiation factors such as IF-I, IF-2, and IF-3, elongation factors such as EF-Tu, EF-Ts, and EF-G, release factors such as RF-1, RF-2, and RF-3, and the like.
An embodiment uses a bacterial cell from which a lysate is derived. A
bacterial lysate derived from any strain of bacteria can be used in the methods of the invention.
The bacterial lysate can be obtained as follows. The bacteria of choice are grown to log phase in any of a number of growth media and under growth conditions that are well known in the art and easily optimized by a practitioner for growth of the particular bacteria. For example, a natural environment for synthesis utilizes cell lysates derived from bacterial cells grown in medium containing glucose and phosphate, where the glucose is present at a concentration of at least about 0.25% (weight/volume), more usually at least about 1%; and usually not more than about 4%, more usually not more than about 2%. An example of such media is 2YTPG
medium, however one of skill in the art will appreciate that many culture media can be adapted for this purpose, as there are many published media suitable for the growth of bacteria such as E. coli, using both defined and undefined sources of nutrients. Cells that have been harvested overnight can be lysed by suspending the cell pellet in a suitable cell suspension buffer, and disrupting the suspended cells by sonication, breaking the suspended cells in a French press, continuous flow high pressure homogenization, or any other method known in the art useful for efficient cell lysis. The cell lysate is then centrifuged or filtered to remove large DNA
fragments and cell debris.
The bacterial strain used to make the cell lysate generally has reduced nuclease and/or phosphatase activity to increase cell free synthesis efficiency. For example, the bacterial strain used to make the cell free extract can have mutations in the genes encoding the nucleases RNase E and RNase A. The strain may also have mutations to stabilize components of the cell synthesis reaction such as deletions in genes such as tnaA, speA, sdaA or gshA, which prevent degradation of the amino acids tryptophan, arginine, serine and cysteine, respectively, in a cell-free synthesis reaction. Additionally, the strain may have mutations to stabilize the protein products of cell-free synthesis such as knockouts in the proteases ompT or lonP.
DIVA Expression Cassette without Stop Codon In some embodiments, the nucleic acid template used in the ribosomal display reaction system comprises a DNA expression cassette that is capable of expressing an RNA encoding the protein of interest, where the RNA lacks an operable stop codon. To remove the stop codon from the protein coding region in the expression cassette, a PCR primer lacking the stop codon can be used to amplify the coding region for the protein of interest, such that the entire coding region from the translation start to the sequence encoding the C-terminal amino acid is amplified.
MHC Binding Assay with Neoantigen Library The major histocompatibility complex (MHC) is a collection of genes encoding glycoproteins called MHC proteins. The primary function of an MHC protein in vivo is to present antigen in a form capable of being recognized by a TCR. An MHC protein is bound to an antigen in the form of an antigenic peptide to form an MHC-peptide complex.
MHC proteins, also known as human leukocyte antigen (HLA) in humans and H-2 region in mice, are classified in two categories: class I and class II MHC
proteins. These proteins are comprised of a cluster of highly polymorphic genes. Specifically, human HLA-A, HLA-B, and HLA-C are known as class I MHC molecules, whereas human HLA-DP, HLA-DQ and HLA-DR are known as class II MHC molecules. The HLA loci include HLA-DP, HLA-DN, HLA-DM, HLA-DO, HLA-DQ, HLA-DR, HLA-A, HLA-B and HLA-C. Each of these loci contains different alleles in the human population. The different subtypes encoded by these allelic variants are intended to be within the scope of the invention.
An MHC class II protein is a heterodimeric integral membrane protein comprising one a and one f3 chain in noncovalent association. The a chain has two extracellular domains (ai and a2), and a transmembrane (TM) and a cytoplasmic (CYT) domain. The 13 chain contains two extracellular domains (131 and 02), and a TM and CYT domain. An MHC class I
protein is an integral membrane protein comprising a glycoprotein heavy chain having three extracellular domains (i.e., Cu, a2 and a3), and a TM and CYT domain. The heavy chain is noncovalently associated with a soluble subunit called 132-microglobulin (132m).
In some embodiments, the binding assay (e.g., the MHC-peptide-DNA conjugate assay) of the present invention employs the use of a spaceholder molecule linked to the MHC class II
component, e.g., the 13 chain, by a processable linker. A spaceholder molecule of the present invention may be any peptide that is capable of binding to a peptide binding groove of an MHC
protein in such a manner that binding of any other peptide in the peptide binding groove is hindered. Preferably, the spaceholder molecule binds within the peptide binding groove with intermediate affinity, and more preferably with low affinity, at approximately neutral pH. In one embodiment, the length of a spaceholder molecule extends from about 5 to about 40 amino acid residues, more preferably from about 6 to about 30 amino acid residues, 8 to about 20 amino acid residues and even more preferably from about 12 to 15 amino acids residues. In a further embodiment, a spaceholder molecule is about 13 amino acids residues.
Examples of suitable spaceholder molecules include, without limitation, (in single letter amino acid code) PVSKMRMATPLLMQA (SEQ ID NO: 25), also known as CLIP; AAMAAAAAAAMAA
(SEQ ID NO: 26); AAMAAAAAAAAAA (SEQ ID NO: 27); AAFAAAAAAAAAA (SEQ ID
NO: 28); ASMSAASAASMAA (SEQ ID NO: 29), and functional equivalents thereof In one embodiment, the spaceholder molecule will have the consensus sequence AAXAAAAAAAXAA (SEQ ID NO: 30), wherein X is any amino acid. The ability of maintaining a spaceholder molecule within the binding groove of the MHC class II molecule prevents "empty" molecules from forming. The formation of -empty" MHC class II
molecules has been a major limiting factor due to the tendency of these "empty-molecules to aggregate, thus making isolation of functional MHC class II components difficult.
The spaceholder molecule of the present invention may be covalently linked to the MHC molecule by a linker having an amino acid sequence that contains a target site for an enzyme capable of cleaving proteins. Such linkers are referred to herein as -processable linkers". Examples of processable linkers of the present invention include linkers containing target sites for enzymes such as collagenases, metalloproteases, serine proteases, cysteine proteases, kallikriens, thrombin, and plasminogen activators. A preferred processable linker of the present invention includes a linker having a thrombin cleavage site.
Suitable linkers useful in the present invention can also be designed using various methods. For example, X-ray crystallographic data of an MHC protein can be used to design a linker of suitable length and charge such that the linker does not interfere with the binding of the spaceholder molecule to the peptide binding groove of the MHC class II
component. Such methods are included in the present invention.
The length of a linker of the present invention is preferably sufficiently short (i.e., small enough in size) such that the linker does not substantially inhibit binding between the spaceholder molecule and the MHC class II component. The length of a linker of the present invention may range from about 1 amino acid residue to about 40 amino acid residues, more preferably from about 5 amino acid residues to about 30 amino acid residues, and even more preferably from about 8 amino acid residues to about 20 amino acid residues.
The cleavage of the linker facilitates the release of the spaceholder molecule thereby freeing the peptide binding groove. The MHC class II component may then be incubated with the library of candidate neoantigens (e.g., a peptide-DNA conjugate library of peptides designed from exome analysis of tumor and wild-type cells) to facilitate the binding of the antigen peptide molecule to the MHC class II component. After sufficient time to allow binding, which can be readily determined by one skilled in the art, the MEC
class II component which has bound to the antigen peptide molecule is recovered.
In certain embodiments, the step of cleaving the linker and incubating with the antigen peptide molecule is repeated using different antigen peptide molecules. The advantage of repeating these steps is to allow for the formation of a number of MHC class II components that recognize several antigenic epitopes. Furthermore, these steps can be carried out using MHC class II molecules constructed with varying allelic forms of the MHC class II genes. This feature of the assay therefore allows for the generation of several MHC class II components which are specific for a number of different MHC allelic genotypes.
Alternatively, the binding assay (e.g., the MHC-peptide-DNA conjugate assay) of the present invention employs a phage display system (see, for example, Hammer J
et al., Promiscuous and allele-specific anchors in HLA-DR-binding peptides, Cell (1993) 74(1):197-203). MHC II components are expressed with phage display. The phages expressing the MEC
II components are then incubated with the library of candidate neoantigens (e.g., a peptide-DNA conjugate library of peptides designed from exome analysis of tumor and wild-type cells) to facilitate the binding of the antigen peptide molecule to the MHC class II
component. After sufficient time to allow binding, which can be readily determined by one skilled in the art, the MHC class II component which has bound to the antigen peptide molecule is recovered.
In certain aspects, an in silico analysis is used to determine specific binding between neoantigens and MHC class I proteins or fragments thereof The in silico analysis comprises applying a computational algorithm to predict relative binding to MHC I
proteins based on the peptide sequences of the neoantigens. Tools such as netMHCpan are used for prediction of binding of peptides/neoantigens to the MHC proteins (see Jurtz et al, NetMHCpan-4.0:
Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data, J Immunol (2017) 199(9):3360-3368). The input to this analysis is the peptide sequences and the MHC alleles of interest, and the output is a predicted binding affinity.
In certain aspects, neoantigens demonstrating binding with MHC class I
molecules or MHC class II molecules in an MHC binding assay or in silico are pooled to form a peptide mixture. This peptide mixture or oligoneucleotides encoding for the peptides from the peptide mixture can then he administered directly to the patient Vaccine Administration The administration of the peptides or oligonucleotides according to the methods provided herein can be carried out in any suitable manner for administering peptides or oligonucleotides, including but not limited to injection, transfusion, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, intrathecally, by intravenous or intralymphatic injection, or intraperitoneally. In some embodiments, the neoantigens or oligonucleotides are administered into a cavity formed by the resection of tumor tissue (i.e. intracavity delivery) or directly into a tumor prior to resection (i.e. intratumoral delivery). In one embodiment, the peptides or oligonucleotides are administered by intravenous injection.
In an embodiment, the invention includes a method of treating a cancer with one or more neoantigen peptide or with one or more oligonucleotide each having a nucleic acid sequence that encodes a neoantigen peptide, wherein a patient is pre-treated with non-myeloablative chemotherapy prior to the neoantigens treatment or oligonucleotide treatment according to the invention.
Methods of Treating Cancer The cancer treated by the disclosed compositions and methods can be any solid tumor.
The cancer can also be metastatic and/or recurrent. Non-limiting examples of cancers include acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, cervical cancer, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, soft tissue cancer, testicular cancer, thyroid cancer, ureter cancer, urinary bladder cancer, and digestive tract cancer such as, e.g., esophageal cancer, gastric cancer, pancreatic cancer, stomach cancer, small intestine cancer, gastrointestinal carcinoid tumor, cancer of the oral cavity, colorectal cancer, and hepatobiliary cancer.
Triple Negative Breast Cancers (TNBCs), representing about 15% of all breast cancers, are highly aggressive type of tumors that lack estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (HER2) gene amplification. TNBCs do not respond to hormonal therapy such as tamoxifen or aromatase inhibitors or therapies that target HER2 receptors, such as Herceptin (trastuzumab). Because of limited targets that are available for TNBCs, currently there is an intense interest in finding new targets and thus personalized medications that can treat this type of breast cancer. Therefore, in some embodiments, the cancer is a triple negative breast cancer (TNBC).
Combination Cancer Therapies The disclosed compositions and methods can be used in combination with other cancer immunotherapies. There are two distinct types of immunotherapy: passive immunotherapy uses components of the immune system to direct targeted cytotoxic activity against cancer cells, without necessarily initiating an immune response in the patient, while active immunotherapy actively triggers an endogenous immune response. Passive strategies include the use of the monoclonal antibodies (mAbs) produced by B cells in response to a specific antigen. The development of hybridoma technology in the 1970s and the identification of tumor-specific antigens permitted the pharmaceutical development of mAbs that could specifically target tumor cells for destruction by the immune system. Thus far, mAbs have been the biggest success story for immunotherapy; the top three best-selling anticancer drugs in 2012 were mAbs. Among them is rituximab (Rituxan, Genentech), which binds to the CD20 protein that is highly expressed on the surface of B cell malignancies such as non-Hodgkin's lymphoma (NHL). Rituximab is approved by the FDA for the treatment of NHL and chronic lymphocytic leukemia (CLL) in combination with chemotherapy. Another important mAb is trastuzumab (Herceptin; Genentech), which revolutionized the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer by targeting the expression of HER2.
Generating optimal "killer" CD8 T cell responses also requires T cell receptor activation plus co-stimulation, which can be provided through ligation of tumor necrosis factor receptor family members, including 0X40 (CD134) and 4-1BB (CD137). 0X40 is of particular interest as treatment with an activating (agonist) anti-0X40 mAb augments T
cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors.
Numerous anti-cancer drugs are available for combination with the present method and compositions. The following is anon-exhaustive lists of anti-cancer (anti-neoplastic) drugs that can be used in conjunction with or without irradiation: Acivicin; Aclarubicin;
Acodazole Hydrochloride; AcrQnine; Adozelesin; Aldesleukin; Altretamine; Ambomycin;
Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase;
Asperlin;
Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide;
Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; B1 eomycin Sulfate; Brequinar Sodium;
Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer;
Carboplatin;
Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil;
Cirolemycin;
Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine;
Dacarbazine;
Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin;
Dezaguanine;
Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride;
Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin;
Edatrexate;
Eflomithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropidine;
Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine;
Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate;
Etoprine;
Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate;
Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine;
Gemcitabine Hydrochloride; Gold Au 198; Hy droxy urea; Idarubicin Hydrochloride; Ifos fami de; Ilmofosine;
Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole;
Leuprolide Acetate;
Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride;
Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate;
Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium;
Metoprine; Meturedepa; Mitindomi de; Mitocarcin; Mitocromin; Mitogillin;
Mitomalcin;
Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid;
Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase;
Peliomycin;
Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman; Piposulfan;
Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin;
Prednimustine;
Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin;
Riboprine;
Rogletimide; Safmgol; Safingol Hydrochloride; Semustine; Simtrazene;
Sparfosate Sodium;
Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin;
Streptonigrin;
Streptozocin; Strontium Chloride Sr 89; Sulofenur; Talisomycin; Taxane;
Taxoid; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide;
Teroxirone;
Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine;
Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate;
Trimetrexate;
Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil Mustard; Uredepa;
Vapreotide; Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine;
Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate;
Vinorelbine Tartrate;
Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin;
Zorubicin Hydrochloride.
The disclosed compositions and methods can be used in combination with one or more immune checkpoint inhibitors. By immune checkpoint inhibitor it is meant a compound that inhibits a protein in the checkpoint signally pathway. Proteins in the checkpoint signally pathway include for example, CD27, CD28, CD40, CD 122, CD137, 0X40, GITR, ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, MR, LAG3, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, Lain, CD244, HAVCR2, CD200, CD200R1, CD200R2, CD200R4, LILRB4, PILRA, ICOSL, 4-1BB or VISTA. Immune checkpoint inhibitors are known in the art.
For example, the immune checkpoint inhibitor can be a small molecule. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules.
Alternatively, the immune checkpoint inhibitor is an antibody or fragment thereof For example, the antibody or fragment thereof is specific to a protein in the checkpoint signaling pathway, such as CD27, CD28, CD40, CD 122, CD137, 0X40, GITR, ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, MR, LAG3, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, Lain, CD244, HAVCR2, CD200, CD200RI, CD200R2, CD200R4, LILRB4, PILRA, ICOSL, 4-1BB or VISTA.
Exemplary, anti-immune checkpoint antibodies include for example ipiliumab (anti-CTLA-4), penbrolizumab (anti-PD-L1), nivolumab (anti-PD-L1), atezolizumab (anti-PD-L1), and duralumab (anti-PD-L1).
The present invention is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents, and published patent applications cited throughout this application, as well as the Figures, are incorporated herein by reference in their entirety for all purposes.
EXAMPLES
Example 1. Overview of Neoantigen Vaccines The Inventors have developed a differentiated peptide vaccine approach (FIGs.
1 and 2) in which a novel peptide:MHC screening technology (i.e., "peptide-DNA
conjugate assay"
or "PepSeq") or related methodology (e.g., ribosomal display) is applied to predict personalized immunogenic neoantigens from genomic analysis. Peptides are designed corresponding to the patient's neoantigens, and then these peptides are administered to the patient. One or more oligonucleotides may be manufactured having the nucleic acid sequence that encodes a peptide corresponding to a neoantigen. The oligonucleotides may be administered to the patient.
The peptide-DNA conjugate assay provides a method for efficient synthesis and analysis of large libraries of DNA-barcoded peptides (see FIG. 3).
Example 2. A Method for the Identification of Neoantigens from Human Tumors The following methods enable the identification of neoantigens from human tumors.
Freshly-resected tumor specimens from human patients with various malignancies will each be split into 2 samples. The first sample will be used to extract DNA and RNA, enabling whole exome sequencing and RNAseq. Together with a germline sample (e.g., blood or cheek swab), this will enable the identification of somatic variants and quantification of the expression of the associated proteins.
Following analysis of the sequencing data, the tumor genomic information will be used to design libraries of overlapping peptides covering candidate mutations and their wild-type counterparts. DNA-encoded libraries of these peptides will be synthesized in a highly-parallel fashion using the peptide-DNA conjugate platform or a phage display platform, for example, and assayed in parallel against a panel of commonly-expressed human MEC class II proteins.
In parallel, in silico models of MHC class I binding will be applied to identify a second subset of candidate neoantigens. The resulting data will enable prioritization of a subset of putative class I or II-restricted neoantigens for downstream attention.
Using the candidate neoantigens identified by the peptide-DNA conjugate assay or a phage display platform and/or in silico prediction approach, two parallel approaches for enriching neoantigens will be pursued. In the first approach, selective expansion of neoantigen-reactive T cells will be accomplished by culturing TILs isolated from the tumors (without tumor cells) with peptides representing the shortlisted (i.e., prioritized) neoantigen sequences, in the presence of cytokines.
In addition, fluorescently-labeled peptide:MHC probes corresponding to the shortlisted sequences (and perhaps in combination with cellular exhaustion markers) will be used to isolate neoantigen-reactive T cells by fluorescence-activated cell sorting. In each case, in vitro activation assays will be used to measure the activity of the cellular product against autologous tumor cells, including possibly the use of in vitro-derived tumor organoids.
Example 3. An Alternative Method for the Identification Neoantigens from Human Tumors Freshly-resected tumor specimens from human patients are used to extract DNA
and RNA, enabling whole exome sequencing and RNAseq. Together with a germline sample (blood or cheek swab), this enables the identification of somatic variants and quantification of the expression of the associated proteins.
Following analysis of the sequencing data, the tumor genomic information is used to design libraries of overlapping peptides covering candidate mutations and their wild-type counterparts. DNA-encoded libraries of these peptides are synthesized in a highly-parallel fashion using the peptide-DNA conjugate platform, and assayed in parallel against a MHC
class II (DR, DP, and DQ) specific for the patient. This process enables the rapid, high-confidence identification of candidate neoantigen peptide:MHCs by selectivity and by affinity.
In parallel, in silico analysis may be performed on the peptide library applying a computational algorithm to predict relative binding to MHC class I proteins based on the peptide sequences of the neoantigens. As a result, a small set of targeted neoantigens from among the typically large catalog of peptide-changing somatic tumor variants is selected.
Example 4. Collection of Samples from Human Patients and Mice Several human patients enrolled in a clinical trial to test the efficacy of a NeoTIL
therapy. The patients had been diagnosed with lung cancer, colorectal cancer, melanoma, breast cancer, and colon cancer. In addition, a BALB/c mouse model of colon cancer was used for the collection of tumor infiltrating lymphocytes (TILs).
Tumor biopsies were collected from each human patient and from the mice. The numbers of isolated tumor cells, peripheral blood mononuclear cells, and TILs were determined for each human patient. In addition, the MHC alleles and number of mutations were identified for each human patient and for the BALB/c mouse model of colon cancer (see Table 1).
Table 1. Identification of MHC alleles and mutations for each human patient and for the BALB/c mouse model of colon cancer.
Patient Cancer Biopsy Number of Species ID Type Site MHC Alleles Mutations primary human TG00006 lung lung DRB1*07:01 DRB1*11:03 83 metastati c human TG00013 melanoma back DRB1*03:01 DRB1*01:02 374 colon BALB/c cancer mouse Mouse model N/A 1(A)d 1506 Example 5. Exome Sequencing, Peptide Library Design, and Binding Assays with Human Samples Whole exome sequencing of tumor exomes and exomes from normal cells was used to design a peptide-DNA conjugate library as outlined in FIGs. 4 and 5. Peptides in the peptide-DNA conjugate library overlapped in sequence and contained wild-type residues ("W") and mutant residues ("M") (see FIG. 5).
For human patients TG00006 and TG00013 a binding assay was performed as shown in FIG. 6 using the methods outlined in Day et al., J Clin Invest.
2003;112(6):831-842. The binding assay identified peptides with high affinity for the particular human leukocyte antigen serotypes present in each patient (see the larger data points in the upper left-hand comer of each graph shown in FIG. 7). Additional analyses with the binding assay using peptide libraries for human patient TG00013 are shown in FIGS. 8A and 8B.
The nucleic acids encoding the peptides with high affinity for the HLA
complexes were isolated with the peptide constructs identified using the peptide-DNA
conjugate assay. These nucleic acids were sequenced, and the corresponding amino acid sequences are presented in FIG. 9 for human patient TG00013. Comparison of MHC-peptide-DNA conjugate assay results with in silico predictions can be used to identify and confirm neoantigens and/or neoepitopes as shown in FIG. 10.
Several additional human patients with various forms of cancer including lung cancer, melanoma, pancreatic cancer, colorectal cancer, adenocarcinoma of the stomach, uveal melanoma, basal cell carcinoma Merkel cell carcinoma, and cholangiocarcinoma were evaluated by collecting tumor infiltrating lymphocytes (TILs) and generating peptides to activate and educate these TILs to enhance recognition of neoantigens and anti-tumor activity (see FIG. 11). A non-limiting example of a process for manufacturing the peptide vaccines is outlined in FIG. 12.
Example 6. Peripheral Blood Mononuclear Cell Activation with Peptides A peripheral blood mononuclear cell (PBMC) is any peripheral blood cell having a round nucleus. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes, whereas erythrocytes and platelets have no nuclei, and granulocytes (neutrophils, basophils, and eosinophils) have multi-lobed nuclei. In humans, lymphocytes make up the majority of the PBMC population, followed by monocytes, and only a small percentage of dendritic cells.
PBMCs can be extracted from whole blood using FICOLL , a hydrophilic polysaccharide that separates layers of blood, and gradient centrifugation, which will separate the blood into a top layer of plasma, followed by a layer of PBMCs and a bottom fraction of polymorphonuclear cells (such as neutrophils and eosinophils) and erythrocytes.
To test the efficiency of a peptide vaccine generated as disclosed herein, an immune infiltration assays was performed on patient-derived tumor organoids. Briefly, tumor cells isolated from the original specimen were cultured in ultra-low affinity (ULA) plate to form 3D
structures (organoids). Organoids are known to recapitulate the phenotypic characteristic of the tissue of origin, including the antigenic potential. Following co-culture of PBMCs with tumor organoids derived from the same patient, the level of PBMC infiltration into the organoid is quantified by z-stacking imaging.
PBMCs were stained with Invitrogen CELLTRACKERTm CM-DiI, a red fluorescent dye well suited for monitoring multigenerational cell movement or location to facilitate the quantification of PBMC infiltration into the organoids. The following treatments were administered to the organoids: 1) PBMCs; 2) PBMCs + IL-2; 3) PBMCs + IL-2 +
peptide vaccine ("PEP"); and 4) PBMCs + DMSO (vehicle). PBMC infiltration into the organoids was quantified 24 hr, and 48 hr after administration. As shown in the bar graphs in FIG. 13, after only 24 hours the PBMCs in combination the IL-2 and the peptide demonstrated significant infiltration of the organoids.
Example 7. Peptide Vaccine Study A study to evaluate the safety and efficacy of peptide vaccines produced as disclosed herein is outlined in FIG. 14. The study is conducted in patients with advanced or metastatic cancers with the key inclusion criteria and key exclusion criteria listed in FIG. 14. The study has the following objectives:
= To evaluate the safety of administering the peptide vaccines;
= To observe anti-tumor activity, as assessed by objective response rate (ORR) and clinical benefit rate (CBR);
= To evaluate the duration of any observed response (DOR);
= To evaluate progression-free survival (PFS) and overall survival (OS) for all enrolled patients;
= To characterize vaccine-induced immune responses by evaluating several criteria, including antigen-specific CDS+ and CD4+ T-cell responses in peripheral blood before, during, and after vaccine treatment;
= To evaluate exploratory biomarkers in peripheral blood and tumor biopsies, such as programmed death ligand 1 (PD-L1) expression, abundance and phenotypes of tumor-infiltrating lymphocytes (TILs) and myeloid cells, somatic mutational load, and neoantigen load.
The duration of treatment with the peptide vaccine will be about 12 weeks.
During the Vaccination Treatment Period, safety, functional, and immunological assessments will be conducted. Safety and functional assessments will be conducted 30 days ( 7 days) after the last dose.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.
An embodiment uses a bacterial cell from which a lysate is derived. A
bacterial lysate derived from any strain of bacteria can be used in the methods of the invention.
The bacterial lysate can be obtained as follows. The bacteria of choice are grown to log phase in any of a number of growth media and under growth conditions that are well known in the art and easily optimized by a practitioner for growth of the particular bacteria. For example, a natural environment for synthesis utilizes cell lysates derived from bacterial cells grown in medium containing glucose and phosphate, where the glucose is present at a concentration of at least about 0.25% (weight/volume), more usually at least about 1%; and usually not more than about 4%, more usually not more than about 2%. An example of such media is 2YTPG
medium, however one of skill in the art will appreciate that many culture media can be adapted for this purpose, as there are many published media suitable for the growth of bacteria such as E. coli, using both defined and undefined sources of nutrients. Cells that have been harvested overnight can be lysed by suspending the cell pellet in a suitable cell suspension buffer, and disrupting the suspended cells by sonication, breaking the suspended cells in a French press, continuous flow high pressure homogenization, or any other method known in the art useful for efficient cell lysis. The cell lysate is then centrifuged or filtered to remove large DNA
fragments and cell debris.
The bacterial strain used to make the cell lysate generally has reduced nuclease and/or phosphatase activity to increase cell free synthesis efficiency. For example, the bacterial strain used to make the cell free extract can have mutations in the genes encoding the nucleases RNase E and RNase A. The strain may also have mutations to stabilize components of the cell synthesis reaction such as deletions in genes such as tnaA, speA, sdaA or gshA, which prevent degradation of the amino acids tryptophan, arginine, serine and cysteine, respectively, in a cell-free synthesis reaction. Additionally, the strain may have mutations to stabilize the protein products of cell-free synthesis such as knockouts in the proteases ompT or lonP.
DIVA Expression Cassette without Stop Codon In some embodiments, the nucleic acid template used in the ribosomal display reaction system comprises a DNA expression cassette that is capable of expressing an RNA encoding the protein of interest, where the RNA lacks an operable stop codon. To remove the stop codon from the protein coding region in the expression cassette, a PCR primer lacking the stop codon can be used to amplify the coding region for the protein of interest, such that the entire coding region from the translation start to the sequence encoding the C-terminal amino acid is amplified.
MHC Binding Assay with Neoantigen Library The major histocompatibility complex (MHC) is a collection of genes encoding glycoproteins called MHC proteins. The primary function of an MHC protein in vivo is to present antigen in a form capable of being recognized by a TCR. An MHC protein is bound to an antigen in the form of an antigenic peptide to form an MHC-peptide complex.
MHC proteins, also known as human leukocyte antigen (HLA) in humans and H-2 region in mice, are classified in two categories: class I and class II MHC
proteins. These proteins are comprised of a cluster of highly polymorphic genes. Specifically, human HLA-A, HLA-B, and HLA-C are known as class I MHC molecules, whereas human HLA-DP, HLA-DQ and HLA-DR are known as class II MHC molecules. The HLA loci include HLA-DP, HLA-DN, HLA-DM, HLA-DO, HLA-DQ, HLA-DR, HLA-A, HLA-B and HLA-C. Each of these loci contains different alleles in the human population. The different subtypes encoded by these allelic variants are intended to be within the scope of the invention.
An MHC class II protein is a heterodimeric integral membrane protein comprising one a and one f3 chain in noncovalent association. The a chain has two extracellular domains (ai and a2), and a transmembrane (TM) and a cytoplasmic (CYT) domain. The 13 chain contains two extracellular domains (131 and 02), and a TM and CYT domain. An MHC class I
protein is an integral membrane protein comprising a glycoprotein heavy chain having three extracellular domains (i.e., Cu, a2 and a3), and a TM and CYT domain. The heavy chain is noncovalently associated with a soluble subunit called 132-microglobulin (132m).
In some embodiments, the binding assay (e.g., the MHC-peptide-DNA conjugate assay) of the present invention employs the use of a spaceholder molecule linked to the MHC class II
component, e.g., the 13 chain, by a processable linker. A spaceholder molecule of the present invention may be any peptide that is capable of binding to a peptide binding groove of an MHC
protein in such a manner that binding of any other peptide in the peptide binding groove is hindered. Preferably, the spaceholder molecule binds within the peptide binding groove with intermediate affinity, and more preferably with low affinity, at approximately neutral pH. In one embodiment, the length of a spaceholder molecule extends from about 5 to about 40 amino acid residues, more preferably from about 6 to about 30 amino acid residues, 8 to about 20 amino acid residues and even more preferably from about 12 to 15 amino acids residues. In a further embodiment, a spaceholder molecule is about 13 amino acids residues.
Examples of suitable spaceholder molecules include, without limitation, (in single letter amino acid code) PVSKMRMATPLLMQA (SEQ ID NO: 25), also known as CLIP; AAMAAAAAAAMAA
(SEQ ID NO: 26); AAMAAAAAAAAAA (SEQ ID NO: 27); AAFAAAAAAAAAA (SEQ ID
NO: 28); ASMSAASAASMAA (SEQ ID NO: 29), and functional equivalents thereof In one embodiment, the spaceholder molecule will have the consensus sequence AAXAAAAAAAXAA (SEQ ID NO: 30), wherein X is any amino acid. The ability of maintaining a spaceholder molecule within the binding groove of the MHC class II molecule prevents "empty" molecules from forming. The formation of -empty" MHC class II
molecules has been a major limiting factor due to the tendency of these "empty-molecules to aggregate, thus making isolation of functional MHC class II components difficult.
The spaceholder molecule of the present invention may be covalently linked to the MHC molecule by a linker having an amino acid sequence that contains a target site for an enzyme capable of cleaving proteins. Such linkers are referred to herein as -processable linkers". Examples of processable linkers of the present invention include linkers containing target sites for enzymes such as collagenases, metalloproteases, serine proteases, cysteine proteases, kallikriens, thrombin, and plasminogen activators. A preferred processable linker of the present invention includes a linker having a thrombin cleavage site.
Suitable linkers useful in the present invention can also be designed using various methods. For example, X-ray crystallographic data of an MHC protein can be used to design a linker of suitable length and charge such that the linker does not interfere with the binding of the spaceholder molecule to the peptide binding groove of the MHC class II
component. Such methods are included in the present invention.
The length of a linker of the present invention is preferably sufficiently short (i.e., small enough in size) such that the linker does not substantially inhibit binding between the spaceholder molecule and the MHC class II component. The length of a linker of the present invention may range from about 1 amino acid residue to about 40 amino acid residues, more preferably from about 5 amino acid residues to about 30 amino acid residues, and even more preferably from about 8 amino acid residues to about 20 amino acid residues.
The cleavage of the linker facilitates the release of the spaceholder molecule thereby freeing the peptide binding groove. The MHC class II component may then be incubated with the library of candidate neoantigens (e.g., a peptide-DNA conjugate library of peptides designed from exome analysis of tumor and wild-type cells) to facilitate the binding of the antigen peptide molecule to the MHC class II component. After sufficient time to allow binding, which can be readily determined by one skilled in the art, the MEC
class II component which has bound to the antigen peptide molecule is recovered.
In certain embodiments, the step of cleaving the linker and incubating with the antigen peptide molecule is repeated using different antigen peptide molecules. The advantage of repeating these steps is to allow for the formation of a number of MHC class II components that recognize several antigenic epitopes. Furthermore, these steps can be carried out using MHC class II molecules constructed with varying allelic forms of the MHC class II genes. This feature of the assay therefore allows for the generation of several MHC class II components which are specific for a number of different MHC allelic genotypes.
Alternatively, the binding assay (e.g., the MHC-peptide-DNA conjugate assay) of the present invention employs a phage display system (see, for example, Hammer J
et al., Promiscuous and allele-specific anchors in HLA-DR-binding peptides, Cell (1993) 74(1):197-203). MHC II components are expressed with phage display. The phages expressing the MEC
II components are then incubated with the library of candidate neoantigens (e.g., a peptide-DNA conjugate library of peptides designed from exome analysis of tumor and wild-type cells) to facilitate the binding of the antigen peptide molecule to the MHC class II
component. After sufficient time to allow binding, which can be readily determined by one skilled in the art, the MHC class II component which has bound to the antigen peptide molecule is recovered.
In certain aspects, an in silico analysis is used to determine specific binding between neoantigens and MHC class I proteins or fragments thereof The in silico analysis comprises applying a computational algorithm to predict relative binding to MHC I
proteins based on the peptide sequences of the neoantigens. Tools such as netMHCpan are used for prediction of binding of peptides/neoantigens to the MHC proteins (see Jurtz et al, NetMHCpan-4.0:
Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data, J Immunol (2017) 199(9):3360-3368). The input to this analysis is the peptide sequences and the MHC alleles of interest, and the output is a predicted binding affinity.
In certain aspects, neoantigens demonstrating binding with MHC class I
molecules or MHC class II molecules in an MHC binding assay or in silico are pooled to form a peptide mixture. This peptide mixture or oligoneucleotides encoding for the peptides from the peptide mixture can then he administered directly to the patient Vaccine Administration The administration of the peptides or oligonucleotides according to the methods provided herein can be carried out in any suitable manner for administering peptides or oligonucleotides, including but not limited to injection, transfusion, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, intrathecally, by intravenous or intralymphatic injection, or intraperitoneally. In some embodiments, the neoantigens or oligonucleotides are administered into a cavity formed by the resection of tumor tissue (i.e. intracavity delivery) or directly into a tumor prior to resection (i.e. intratumoral delivery). In one embodiment, the peptides or oligonucleotides are administered by intravenous injection.
In an embodiment, the invention includes a method of treating a cancer with one or more neoantigen peptide or with one or more oligonucleotide each having a nucleic acid sequence that encodes a neoantigen peptide, wherein a patient is pre-treated with non-myeloablative chemotherapy prior to the neoantigens treatment or oligonucleotide treatment according to the invention.
Methods of Treating Cancer The cancer treated by the disclosed compositions and methods can be any solid tumor.
The cancer can also be metastatic and/or recurrent. Non-limiting examples of cancers include acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, cervical cancer, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, soft tissue cancer, testicular cancer, thyroid cancer, ureter cancer, urinary bladder cancer, and digestive tract cancer such as, e.g., esophageal cancer, gastric cancer, pancreatic cancer, stomach cancer, small intestine cancer, gastrointestinal carcinoid tumor, cancer of the oral cavity, colorectal cancer, and hepatobiliary cancer.
Triple Negative Breast Cancers (TNBCs), representing about 15% of all breast cancers, are highly aggressive type of tumors that lack estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (HER2) gene amplification. TNBCs do not respond to hormonal therapy such as tamoxifen or aromatase inhibitors or therapies that target HER2 receptors, such as Herceptin (trastuzumab). Because of limited targets that are available for TNBCs, currently there is an intense interest in finding new targets and thus personalized medications that can treat this type of breast cancer. Therefore, in some embodiments, the cancer is a triple negative breast cancer (TNBC).
Combination Cancer Therapies The disclosed compositions and methods can be used in combination with other cancer immunotherapies. There are two distinct types of immunotherapy: passive immunotherapy uses components of the immune system to direct targeted cytotoxic activity against cancer cells, without necessarily initiating an immune response in the patient, while active immunotherapy actively triggers an endogenous immune response. Passive strategies include the use of the monoclonal antibodies (mAbs) produced by B cells in response to a specific antigen. The development of hybridoma technology in the 1970s and the identification of tumor-specific antigens permitted the pharmaceutical development of mAbs that could specifically target tumor cells for destruction by the immune system. Thus far, mAbs have been the biggest success story for immunotherapy; the top three best-selling anticancer drugs in 2012 were mAbs. Among them is rituximab (Rituxan, Genentech), which binds to the CD20 protein that is highly expressed on the surface of B cell malignancies such as non-Hodgkin's lymphoma (NHL). Rituximab is approved by the FDA for the treatment of NHL and chronic lymphocytic leukemia (CLL) in combination with chemotherapy. Another important mAb is trastuzumab (Herceptin; Genentech), which revolutionized the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer by targeting the expression of HER2.
Generating optimal "killer" CD8 T cell responses also requires T cell receptor activation plus co-stimulation, which can be provided through ligation of tumor necrosis factor receptor family members, including 0X40 (CD134) and 4-1BB (CD137). 0X40 is of particular interest as treatment with an activating (agonist) anti-0X40 mAb augments T
cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors.
Numerous anti-cancer drugs are available for combination with the present method and compositions. The following is anon-exhaustive lists of anti-cancer (anti-neoplastic) drugs that can be used in conjunction with or without irradiation: Acivicin; Aclarubicin;
Acodazole Hydrochloride; AcrQnine; Adozelesin; Aldesleukin; Altretamine; Ambomycin;
Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase;
Asperlin;
Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide;
Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; B1 eomycin Sulfate; Brequinar Sodium;
Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer;
Carboplatin;
Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil;
Cirolemycin;
Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine;
Dacarbazine;
Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin;
Dezaguanine;
Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride;
Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin;
Edatrexate;
Eflomithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropidine;
Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine;
Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate;
Etoprine;
Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate;
Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine;
Gemcitabine Hydrochloride; Gold Au 198; Hy droxy urea; Idarubicin Hydrochloride; Ifos fami de; Ilmofosine;
Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole;
Leuprolide Acetate;
Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride;
Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate;
Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium;
Metoprine; Meturedepa; Mitindomi de; Mitocarcin; Mitocromin; Mitogillin;
Mitomalcin;
Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid;
Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase;
Peliomycin;
Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman; Piposulfan;
Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin;
Prednimustine;
Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin;
Riboprine;
Rogletimide; Safmgol; Safingol Hydrochloride; Semustine; Simtrazene;
Sparfosate Sodium;
Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin;
Streptonigrin;
Streptozocin; Strontium Chloride Sr 89; Sulofenur; Talisomycin; Taxane;
Taxoid; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide;
Teroxirone;
Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine;
Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate;
Trimetrexate;
Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil Mustard; Uredepa;
Vapreotide; Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine;
Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate;
Vinorelbine Tartrate;
Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin;
Zorubicin Hydrochloride.
The disclosed compositions and methods can be used in combination with one or more immune checkpoint inhibitors. By immune checkpoint inhibitor it is meant a compound that inhibits a protein in the checkpoint signally pathway. Proteins in the checkpoint signally pathway include for example, CD27, CD28, CD40, CD 122, CD137, 0X40, GITR, ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, MR, LAG3, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, Lain, CD244, HAVCR2, CD200, CD200R1, CD200R2, CD200R4, LILRB4, PILRA, ICOSL, 4-1BB or VISTA. Immune checkpoint inhibitors are known in the art.
For example, the immune checkpoint inhibitor can be a small molecule. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules.
Alternatively, the immune checkpoint inhibitor is an antibody or fragment thereof For example, the antibody or fragment thereof is specific to a protein in the checkpoint signaling pathway, such as CD27, CD28, CD40, CD 122, CD137, 0X40, GITR, ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, MR, LAG3, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, Lain, CD244, HAVCR2, CD200, CD200RI, CD200R2, CD200R4, LILRB4, PILRA, ICOSL, 4-1BB or VISTA.
Exemplary, anti-immune checkpoint antibodies include for example ipiliumab (anti-CTLA-4), penbrolizumab (anti-PD-L1), nivolumab (anti-PD-L1), atezolizumab (anti-PD-L1), and duralumab (anti-PD-L1).
The present invention is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents, and published patent applications cited throughout this application, as well as the Figures, are incorporated herein by reference in their entirety for all purposes.
EXAMPLES
Example 1. Overview of Neoantigen Vaccines The Inventors have developed a differentiated peptide vaccine approach (FIGs.
1 and 2) in which a novel peptide:MHC screening technology (i.e., "peptide-DNA
conjugate assay"
or "PepSeq") or related methodology (e.g., ribosomal display) is applied to predict personalized immunogenic neoantigens from genomic analysis. Peptides are designed corresponding to the patient's neoantigens, and then these peptides are administered to the patient. One or more oligonucleotides may be manufactured having the nucleic acid sequence that encodes a peptide corresponding to a neoantigen. The oligonucleotides may be administered to the patient.
The peptide-DNA conjugate assay provides a method for efficient synthesis and analysis of large libraries of DNA-barcoded peptides (see FIG. 3).
Example 2. A Method for the Identification of Neoantigens from Human Tumors The following methods enable the identification of neoantigens from human tumors.
Freshly-resected tumor specimens from human patients with various malignancies will each be split into 2 samples. The first sample will be used to extract DNA and RNA, enabling whole exome sequencing and RNAseq. Together with a germline sample (e.g., blood or cheek swab), this will enable the identification of somatic variants and quantification of the expression of the associated proteins.
Following analysis of the sequencing data, the tumor genomic information will be used to design libraries of overlapping peptides covering candidate mutations and their wild-type counterparts. DNA-encoded libraries of these peptides will be synthesized in a highly-parallel fashion using the peptide-DNA conjugate platform or a phage display platform, for example, and assayed in parallel against a panel of commonly-expressed human MEC class II proteins.
In parallel, in silico models of MHC class I binding will be applied to identify a second subset of candidate neoantigens. The resulting data will enable prioritization of a subset of putative class I or II-restricted neoantigens for downstream attention.
Using the candidate neoantigens identified by the peptide-DNA conjugate assay or a phage display platform and/or in silico prediction approach, two parallel approaches for enriching neoantigens will be pursued. In the first approach, selective expansion of neoantigen-reactive T cells will be accomplished by culturing TILs isolated from the tumors (without tumor cells) with peptides representing the shortlisted (i.e., prioritized) neoantigen sequences, in the presence of cytokines.
In addition, fluorescently-labeled peptide:MHC probes corresponding to the shortlisted sequences (and perhaps in combination with cellular exhaustion markers) will be used to isolate neoantigen-reactive T cells by fluorescence-activated cell sorting. In each case, in vitro activation assays will be used to measure the activity of the cellular product against autologous tumor cells, including possibly the use of in vitro-derived tumor organoids.
Example 3. An Alternative Method for the Identification Neoantigens from Human Tumors Freshly-resected tumor specimens from human patients are used to extract DNA
and RNA, enabling whole exome sequencing and RNAseq. Together with a germline sample (blood or cheek swab), this enables the identification of somatic variants and quantification of the expression of the associated proteins.
Following analysis of the sequencing data, the tumor genomic information is used to design libraries of overlapping peptides covering candidate mutations and their wild-type counterparts. DNA-encoded libraries of these peptides are synthesized in a highly-parallel fashion using the peptide-DNA conjugate platform, and assayed in parallel against a MHC
class II (DR, DP, and DQ) specific for the patient. This process enables the rapid, high-confidence identification of candidate neoantigen peptide:MHCs by selectivity and by affinity.
In parallel, in silico analysis may be performed on the peptide library applying a computational algorithm to predict relative binding to MHC class I proteins based on the peptide sequences of the neoantigens. As a result, a small set of targeted neoantigens from among the typically large catalog of peptide-changing somatic tumor variants is selected.
Example 4. Collection of Samples from Human Patients and Mice Several human patients enrolled in a clinical trial to test the efficacy of a NeoTIL
therapy. The patients had been diagnosed with lung cancer, colorectal cancer, melanoma, breast cancer, and colon cancer. In addition, a BALB/c mouse model of colon cancer was used for the collection of tumor infiltrating lymphocytes (TILs).
Tumor biopsies were collected from each human patient and from the mice. The numbers of isolated tumor cells, peripheral blood mononuclear cells, and TILs were determined for each human patient. In addition, the MHC alleles and number of mutations were identified for each human patient and for the BALB/c mouse model of colon cancer (see Table 1).
Table 1. Identification of MHC alleles and mutations for each human patient and for the BALB/c mouse model of colon cancer.
Patient Cancer Biopsy Number of Species ID Type Site MHC Alleles Mutations primary human TG00006 lung lung DRB1*07:01 DRB1*11:03 83 metastati c human TG00013 melanoma back DRB1*03:01 DRB1*01:02 374 colon BALB/c cancer mouse Mouse model N/A 1(A)d 1506 Example 5. Exome Sequencing, Peptide Library Design, and Binding Assays with Human Samples Whole exome sequencing of tumor exomes and exomes from normal cells was used to design a peptide-DNA conjugate library as outlined in FIGs. 4 and 5. Peptides in the peptide-DNA conjugate library overlapped in sequence and contained wild-type residues ("W") and mutant residues ("M") (see FIG. 5).
For human patients TG00006 and TG00013 a binding assay was performed as shown in FIG. 6 using the methods outlined in Day et al., J Clin Invest.
2003;112(6):831-842. The binding assay identified peptides with high affinity for the particular human leukocyte antigen serotypes present in each patient (see the larger data points in the upper left-hand comer of each graph shown in FIG. 7). Additional analyses with the binding assay using peptide libraries for human patient TG00013 are shown in FIGS. 8A and 8B.
The nucleic acids encoding the peptides with high affinity for the HLA
complexes were isolated with the peptide constructs identified using the peptide-DNA
conjugate assay. These nucleic acids were sequenced, and the corresponding amino acid sequences are presented in FIG. 9 for human patient TG00013. Comparison of MHC-peptide-DNA conjugate assay results with in silico predictions can be used to identify and confirm neoantigens and/or neoepitopes as shown in FIG. 10.
Several additional human patients with various forms of cancer including lung cancer, melanoma, pancreatic cancer, colorectal cancer, adenocarcinoma of the stomach, uveal melanoma, basal cell carcinoma Merkel cell carcinoma, and cholangiocarcinoma were evaluated by collecting tumor infiltrating lymphocytes (TILs) and generating peptides to activate and educate these TILs to enhance recognition of neoantigens and anti-tumor activity (see FIG. 11). A non-limiting example of a process for manufacturing the peptide vaccines is outlined in FIG. 12.
Example 6. Peripheral Blood Mononuclear Cell Activation with Peptides A peripheral blood mononuclear cell (PBMC) is any peripheral blood cell having a round nucleus. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes, whereas erythrocytes and platelets have no nuclei, and granulocytes (neutrophils, basophils, and eosinophils) have multi-lobed nuclei. In humans, lymphocytes make up the majority of the PBMC population, followed by monocytes, and only a small percentage of dendritic cells.
PBMCs can be extracted from whole blood using FICOLL , a hydrophilic polysaccharide that separates layers of blood, and gradient centrifugation, which will separate the blood into a top layer of plasma, followed by a layer of PBMCs and a bottom fraction of polymorphonuclear cells (such as neutrophils and eosinophils) and erythrocytes.
To test the efficiency of a peptide vaccine generated as disclosed herein, an immune infiltration assays was performed on patient-derived tumor organoids. Briefly, tumor cells isolated from the original specimen were cultured in ultra-low affinity (ULA) plate to form 3D
structures (organoids). Organoids are known to recapitulate the phenotypic characteristic of the tissue of origin, including the antigenic potential. Following co-culture of PBMCs with tumor organoids derived from the same patient, the level of PBMC infiltration into the organoid is quantified by z-stacking imaging.
PBMCs were stained with Invitrogen CELLTRACKERTm CM-DiI, a red fluorescent dye well suited for monitoring multigenerational cell movement or location to facilitate the quantification of PBMC infiltration into the organoids. The following treatments were administered to the organoids: 1) PBMCs; 2) PBMCs + IL-2; 3) PBMCs + IL-2 +
peptide vaccine ("PEP"); and 4) PBMCs + DMSO (vehicle). PBMC infiltration into the organoids was quantified 24 hr, and 48 hr after administration. As shown in the bar graphs in FIG. 13, after only 24 hours the PBMCs in combination the IL-2 and the peptide demonstrated significant infiltration of the organoids.
Example 7. Peptide Vaccine Study A study to evaluate the safety and efficacy of peptide vaccines produced as disclosed herein is outlined in FIG. 14. The study is conducted in patients with advanced or metastatic cancers with the key inclusion criteria and key exclusion criteria listed in FIG. 14. The study has the following objectives:
= To evaluate the safety of administering the peptide vaccines;
= To observe anti-tumor activity, as assessed by objective response rate (ORR) and clinical benefit rate (CBR);
= To evaluate the duration of any observed response (DOR);
= To evaluate progression-free survival (PFS) and overall survival (OS) for all enrolled patients;
= To characterize vaccine-induced immune responses by evaluating several criteria, including antigen-specific CDS+ and CD4+ T-cell responses in peripheral blood before, during, and after vaccine treatment;
= To evaluate exploratory biomarkers in peripheral blood and tumor biopsies, such as programmed death ligand 1 (PD-L1) expression, abundance and phenotypes of tumor-infiltrating lymphocytes (TILs) and myeloid cells, somatic mutational load, and neoantigen load.
The duration of treatment with the peptide vaccine will be about 12 weeks.
During the Vaccination Treatment Period, safety, functional, and immunological assessments will be conducted. Safety and functional assessments will be conducted 30 days ( 7 days) after the last dose.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.
Claims
PCT/US2022/022074What is claimed is:
1. A method of treating cancer in a patient, the method comprising:
obtaining tumor cells from a tumor resected from the patient;
detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient;
identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient;
generating one or more peptides based on the neoantigens; and administering to the patient a therapeutically effective amount of the one or more peptides.
The method of cl aim 1 , wherein detecting the plurality of pati ent-specific tumor mutations comprises genomic profiling with next generation sequencing of a targeted gene panel.
3. The method of claim 2, wherein the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
4. The method of any one of claims 1 to 3, wherein the genomic analysis comprises identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
5. The method of any one of claims 1 to 4, wherein the plurality of patient-specific tumor mutations comprises a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof; and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which binds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
6.
The method of any one of claims 1 to 5, further comprising identifying Major Histocompatibility Complex (MHC) class 1 and 2 genotypes of the patient.
7.
The method of claim 6, wherein identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
8.
The method of any one of claims 1 to 7, wherein identifying the neoantigens comprises:
(i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA proteins or fragments thereof (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs;
(iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA proteins or fragments thereof; and (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA
proteins or fragments thereof 9.
The method of claim 8, wherein the library of peptide constructs comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
1 O.
The method of claim 9, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
11. The method of any one of claims 1 to 7, wherein identifying the neoantigens comprises:
(i) generating a genetically encoded combinatorial libraiy of polypeptides with phage display, ribosomal display, mRNA display, biscistronic DNA display, P2A DNA display, CIS display, yeast display, or bacterial display, wherein the combinatorial library comprises polypeptides linked to corresponding nucleic acid molecules encoding the polypeptides;
(ii) contacting the combinatorial library with the HLA proteins or fragments thereof;
(iii) separating HLA proteins or fragments thereof demonstrating specific binding with the combinatorial libraiy; and (iv) sequencing all or a portion of the nucleic acid molecules of the combinatorial library bound to the HLA proteins or fragments thereof to identify the neoantigens.
12. The method of claim 11, wherein the combinatorial library of polypeptides comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
13. The method of claim 12, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
14. The method of any of claims 1-13, further comprising administering to the patient an adjuvant concurrently with the therapeutically effective amount of the one or more peptides.
15. The method of claim of any of claims 1-14, wherein administering the one or more peptides to the patient is intravenously, intraperitoneally, subcutaneously, intramuscularly, or intratumorally.
16. The method of any one of claims 1 to 13, wherein specific binding between neoantigens and HLA proteins or fragments thereof is determined by:
(i) culturing a cell transformed with at least one nucleic molecule comprising a nucleotide sequence encoding:
an MHC class II component comprising at least a portion of an IVIHC class II a. chain and at least a portion of an MHC class II 13 chain, such that the MHC class II a chain and MHC class II 13 chain form a peptide binding groove; and a spaceholder molecule and a first processable linker, wherein the spaceholder molecule is linked to the MHC class II component by the processable linker and the spaceholder molecule binds within the peptide binding groove thereby hindering the binding of any other peptide within the peptide binding groove; the step of culturing being conducted to produce the MHC class II component;
(ii) recovering the MHC class II component;
(iii) processing the processable linker, thereby releasing the spaceholder molecule from the peptide binding groove;
(iv) incubating the MHC class 11 component in the presence of a neoantigen, wherein the incubation facilitates the binding of the neoantigen to the peptide binding groove;
(v) recovering the MHC class II component that has bound the neoantigen.
1 7. The method of claim 1 6, wherein the spaceholder molecule has the consensus sequence AAXAAAAAAAXAA (SEQ ID NO: 30).
1 8. The method of claim 1 7, wherein the spaceholder molecule is selected from the group consisting of PVSKMRMATPLLMQA (SEQ ID NO: 25); AAMAAAAAAAMAA
(SEQ ID NO: 26); AAMAAAAAAAAAA (SEQ ID NO: 27); AAFAAAAAAAAAA (SEQ
ID NO: 28); and ASMSAASAASMAA (SEQ ID NO: 29).
19. The method of any one of claims 1 6 to 1 8, wherein the processable linker is linked to the MHC class II a chain of the MHC class II component.
20. The method of any one of claims 17 to 19, wherein recovering the MHC
class II component with bound neoantigen comprises affinity chromatography with an antibody recognizing the MHC class II component.
21. The method of any one of claims 1 to 13, wherein specific binding between neoantigens and HLA proteins or fragments thereof is determined by phage display, the HLA
proteins or fragments thereof are expressed on the surface of a phage, and the neoantigens are incubated with the phage to assay specific binding.
22. The method of any one of claims 1 to 21, further comprising an in silico analysis to determine specific binding between neoantigens and MHC class I
proteins or fragments thereof, wherein the in silico analysis comprises applying a computational algorithm to predict relative binding to MHC I proteins based on the peptide sequences of the neoantigens.
23. A method of treating a patient having a disease, the method comprising the step of:
obtaining tumor cells from a tumor resected from the patient;
detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient;
identifying a neoantigen resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient;
designing a peptide based on the neoantigen;
generating a nucleic acid sequence that encodes the peptide; and administering to the patient a therapeutically effective amount of an oligonucleotide having the nucleic acid sequence that encodes the peptide.
24. The method of claim 23, wherein detecting the plurality of patient-specific tumor mutations comprises genomic profiling with next generation sequencing of a targeted gene panel.
25. The method of claim 24, wherein the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
26. The method of any one of claims 23 to 25, wherein the genomic analysis comprises identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
27. The method of any one of claims 23 to 26, wherein the plurality of patient-specific tumor mutations comprises a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof; and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which binds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
28. The method of any one of claims 23 to 27, further comprising identifying Major Histocompatibility Complex (MHC) class 1 and 2 genotypes of the patient.
29. The method of claim 28, wherein identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
30. The method of any one of claims 23 to 29, wherein identifying the neoantigen comprises:
(i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA proteins or fragments thereof;
(ii) contacting the HLA proteins or fragments thereof with the library of pepti de constructs;
(iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA proteins or fragments thereof and (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA
proteins or fragments thereof 31. The method of claim 30, wherein the library of peptide constructs comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
32. The method of claim 31, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
33. A method of treating cancer in a patient, the method comprising:
obtaining tumor cells from a tumor resected from the patient;
detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient;
identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient;
generating a messenger ribonucleic acid (rnRNA) polynucleotide comprising an open reading frame encoding one or more peptides based on the neoantigens; and administering to the patient a therapeutically effective amount of the mRNA
polynucleotide.
34. The method of claim 33, wherein the mRNA polynucleotide comprises at least one chemical modification.
35. The method of claim 34, wherein the chemical modification is selected from p s eudouri dine, Nl-methylp s eudouri dine, N1-ethyl ps eudouri dine, 2-thi ouri dine, 4'-thi ouri dine, 5-rnethylcytosine, 5-rnethyluridine, 2-thi o-1 -rnethyl-1 -deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihy drouri dine, 2-thi o-ps eudouri dine, 4-methoxy -2-thio-p s eudouri dine, 4-methoxy -p s eudouri din e, 4-thi o-1 -methyl-ps eudouri dine, 4-thi o-p s eudouri dine, 5- aza-uri dine, dihydropseudouridine, 5-methoxyuridine and 2'-0-methyl uridine.
36. The method of claim 35, wherein the chemical modification is in the carbon 5-position of the uracil.
37. The method of claim 35, wherein the chemical modification is a N1-methylpseudouridine or Nl-ethylpseudouridine.
38. The method of any one of claims 33 to 37, wherein at least 80% of the uracils in the open reading frame have a chemical modification.
39. The method of any one of claims 33 to 38, wherein the mRNA
polynucleotide further encodes a 5' terminal cap.
40. The method of claim 39, wherein the 5' terminal cap is 7mG(5')ppp(5')NlmpNp.
41. The method of any one of claims 33 to 40, wherein detecting the plurality of patient-specific tumor mutations comprises genomic profiling with next generation sequencing of a targeted gene panel.
42. The method of claim 41, wherein the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
43. The method of any one of claims 33 to 42, wherein the genomic analysis comprises identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
44. The method of any one of claims 33 to 43, wherein the plurality of patient-specific tumor mutations comprises a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof, and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which binds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
45. The method of any one of claims 33 to 44, further comprising identifying Major Histocompatibility Complex (MHC) class 1 and 2 genotypes of the patient.
46. The method of claim 45, wherein identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
47. The method of any one of claims 33 to 46, wherein identifying the neoantigens comprises:
(i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA proteins or fragments thereof, (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs;
(iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA proteins or fragments thereof; and (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA proteins or fragments thereof 48. The method of claim 47, wherein the library of peptide constructs comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
49. The method of claim 48, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
50. The method of any one of claims of any one of claims 33 to 46, wherein identifying the neoantigens comprises:
(i) generating a genetically encoded combinatorial library of polypeptides with phage display, ribosomal display, mRNA display, biscistronic DNA display, P2A DNA display, CIS display, yeast display, or bacterial display, wherein the combinatorial library comprises polypeptides linked to corresponding nucleic acid molecules encoding the polypeptides;
(ii) contacting the combinatorial library with the HLA proteins or fragments thereof;
(iii) separating HLA proteins or fragments thereof demonstrating specific binding with the combinatorial library; and (iv) sequencing all or a portion of the nucleic acid molecules of the combinatorial library bound to the HLA proteins or fragments thereof to identify the neoantigens.
51. The method of claim 50, wherein the combinatorial library of polypeptides comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
52. The method of claim 51, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
53. The method of any one of claims 33 to 52, wherein administering the mRNA
polynucleotide to the patient is intravenously, intraperitoneally, subcutaneously, intramuscularly, or intratumorally.
54. The method of any one of claims 1 to 53, further comprising administering an effective amount of a therapeutic population of tumor infiltrating lymphocytes (T1Ls).
55. The method of claim 54, wherein the therapeutic population of TILs is administered simultaneously or sequentially with the peptides or mRNA
polynucleotide.
56. The method of claim 54 or 55, wherein the therapeutic population of TILs has been activated and/or educated by at least one neoantigen presented by the peptides or encoded by the mRNA polynucleotide.
57. The method of any one of claims 54 to 56, wherein administering the peptides or mRNA polynucleotide with the therapeutic population of TILs enhances the immunogenic response and/or anti-tumor activity in the patient.
1. A method of treating cancer in a patient, the method comprising:
obtaining tumor cells from a tumor resected from the patient;
detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient;
identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient;
generating one or more peptides based on the neoantigens; and administering to the patient a therapeutically effective amount of the one or more peptides.
The method of cl aim 1 , wherein detecting the plurality of pati ent-specific tumor mutations comprises genomic profiling with next generation sequencing of a targeted gene panel.
3. The method of claim 2, wherein the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
4. The method of any one of claims 1 to 3, wherein the genomic analysis comprises identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
5. The method of any one of claims 1 to 4, wherein the plurality of patient-specific tumor mutations comprises a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof; and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which binds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
6.
The method of any one of claims 1 to 5, further comprising identifying Major Histocompatibility Complex (MHC) class 1 and 2 genotypes of the patient.
7.
The method of claim 6, wherein identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
8.
The method of any one of claims 1 to 7, wherein identifying the neoantigens comprises:
(i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA proteins or fragments thereof (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs;
(iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA proteins or fragments thereof; and (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA
proteins or fragments thereof 9.
The method of claim 8, wherein the library of peptide constructs comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
1 O.
The method of claim 9, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
11. The method of any one of claims 1 to 7, wherein identifying the neoantigens comprises:
(i) generating a genetically encoded combinatorial libraiy of polypeptides with phage display, ribosomal display, mRNA display, biscistronic DNA display, P2A DNA display, CIS display, yeast display, or bacterial display, wherein the combinatorial library comprises polypeptides linked to corresponding nucleic acid molecules encoding the polypeptides;
(ii) contacting the combinatorial library with the HLA proteins or fragments thereof;
(iii) separating HLA proteins or fragments thereof demonstrating specific binding with the combinatorial libraiy; and (iv) sequencing all or a portion of the nucleic acid molecules of the combinatorial library bound to the HLA proteins or fragments thereof to identify the neoantigens.
12. The method of claim 11, wherein the combinatorial library of polypeptides comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
13. The method of claim 12, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
14. The method of any of claims 1-13, further comprising administering to the patient an adjuvant concurrently with the therapeutically effective amount of the one or more peptides.
15. The method of claim of any of claims 1-14, wherein administering the one or more peptides to the patient is intravenously, intraperitoneally, subcutaneously, intramuscularly, or intratumorally.
16. The method of any one of claims 1 to 13, wherein specific binding between neoantigens and HLA proteins or fragments thereof is determined by:
(i) culturing a cell transformed with at least one nucleic molecule comprising a nucleotide sequence encoding:
an MHC class II component comprising at least a portion of an IVIHC class II a. chain and at least a portion of an MHC class II 13 chain, such that the MHC class II a chain and MHC class II 13 chain form a peptide binding groove; and a spaceholder molecule and a first processable linker, wherein the spaceholder molecule is linked to the MHC class II component by the processable linker and the spaceholder molecule binds within the peptide binding groove thereby hindering the binding of any other peptide within the peptide binding groove; the step of culturing being conducted to produce the MHC class II component;
(ii) recovering the MHC class II component;
(iii) processing the processable linker, thereby releasing the spaceholder molecule from the peptide binding groove;
(iv) incubating the MHC class 11 component in the presence of a neoantigen, wherein the incubation facilitates the binding of the neoantigen to the peptide binding groove;
(v) recovering the MHC class II component that has bound the neoantigen.
1 7. The method of claim 1 6, wherein the spaceholder molecule has the consensus sequence AAXAAAAAAAXAA (SEQ ID NO: 30).
1 8. The method of claim 1 7, wherein the spaceholder molecule is selected from the group consisting of PVSKMRMATPLLMQA (SEQ ID NO: 25); AAMAAAAAAAMAA
(SEQ ID NO: 26); AAMAAAAAAAAAA (SEQ ID NO: 27); AAFAAAAAAAAAA (SEQ
ID NO: 28); and ASMSAASAASMAA (SEQ ID NO: 29).
19. The method of any one of claims 1 6 to 1 8, wherein the processable linker is linked to the MHC class II a chain of the MHC class II component.
20. The method of any one of claims 17 to 19, wherein recovering the MHC
class II component with bound neoantigen comprises affinity chromatography with an antibody recognizing the MHC class II component.
21. The method of any one of claims 1 to 13, wherein specific binding between neoantigens and HLA proteins or fragments thereof is determined by phage display, the HLA
proteins or fragments thereof are expressed on the surface of a phage, and the neoantigens are incubated with the phage to assay specific binding.
22. The method of any one of claims 1 to 21, further comprising an in silico analysis to determine specific binding between neoantigens and MHC class I
proteins or fragments thereof, wherein the in silico analysis comprises applying a computational algorithm to predict relative binding to MHC I proteins based on the peptide sequences of the neoantigens.
23. A method of treating a patient having a disease, the method comprising the step of:
obtaining tumor cells from a tumor resected from the patient;
detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient;
identifying a neoantigen resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient;
designing a peptide based on the neoantigen;
generating a nucleic acid sequence that encodes the peptide; and administering to the patient a therapeutically effective amount of an oligonucleotide having the nucleic acid sequence that encodes the peptide.
24. The method of claim 23, wherein detecting the plurality of patient-specific tumor mutations comprises genomic profiling with next generation sequencing of a targeted gene panel.
25. The method of claim 24, wherein the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
26. The method of any one of claims 23 to 25, wherein the genomic analysis comprises identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
27. The method of any one of claims 23 to 26, wherein the plurality of patient-specific tumor mutations comprises a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof; and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which binds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
28. The method of any one of claims 23 to 27, further comprising identifying Major Histocompatibility Complex (MHC) class 1 and 2 genotypes of the patient.
29. The method of claim 28, wherein identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
30. The method of any one of claims 23 to 29, wherein identifying the neoantigen comprises:
(i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA proteins or fragments thereof;
(ii) contacting the HLA proteins or fragments thereof with the library of pepti de constructs;
(iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA proteins or fragments thereof and (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA
proteins or fragments thereof 31. The method of claim 30, wherein the library of peptide constructs comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
32. The method of claim 31, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
33. A method of treating cancer in a patient, the method comprising:
obtaining tumor cells from a tumor resected from the patient;
detecting a plurality of patient-specific tumor mutations in the tumor cells with a genomic analysis of tumor DNA and/or RNA and normal DNA and/or RNA from the patient;
identifying neoantigens resulting from somatic mutations that demonstrate specific binding with human leukocyte antigen (HLA) proteins or fragments thereof corresponding to a genotype of the patient;
generating a messenger ribonucleic acid (rnRNA) polynucleotide comprising an open reading frame encoding one or more peptides based on the neoantigens; and administering to the patient a therapeutically effective amount of the mRNA
polynucleotide.
34. The method of claim 33, wherein the mRNA polynucleotide comprises at least one chemical modification.
35. The method of claim 34, wherein the chemical modification is selected from p s eudouri dine, Nl-methylp s eudouri dine, N1-ethyl ps eudouri dine, 2-thi ouri dine, 4'-thi ouri dine, 5-rnethylcytosine, 5-rnethyluridine, 2-thi o-1 -rnethyl-1 -deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihy drouri dine, 2-thi o-ps eudouri dine, 4-methoxy -2-thio-p s eudouri dine, 4-methoxy -p s eudouri din e, 4-thi o-1 -methyl-ps eudouri dine, 4-thi o-p s eudouri dine, 5- aza-uri dine, dihydropseudouridine, 5-methoxyuridine and 2'-0-methyl uridine.
36. The method of claim 35, wherein the chemical modification is in the carbon 5-position of the uracil.
37. The method of claim 35, wherein the chemical modification is a N1-methylpseudouridine or Nl-ethylpseudouridine.
38. The method of any one of claims 33 to 37, wherein at least 80% of the uracils in the open reading frame have a chemical modification.
39. The method of any one of claims 33 to 38, wherein the mRNA
polynucleotide further encodes a 5' terminal cap.
40. The method of claim 39, wherein the 5' terminal cap is 7mG(5')ppp(5')NlmpNp.
41. The method of any one of claims 33 to 40, wherein detecting the plurality of patient-specific tumor mutations comprises genomic profiling with next generation sequencing of a targeted gene panel.
42. The method of claim 41, wherein the genomic profiling comprises whole genome profiling, whole exome profiling, and/or transcriptome profiling.
43. The method of any one of claims 33 to 42, wherein the genomic analysis comprises identifying a plurality of patient-specific tumor mutations in expressed genes by nucleic acid sequencing of tumor and normal samples from the patient and the mutations are present in the genome of cancer cells of the patient but not in normal cells from the subject.
44. The method of any one of claims 33 to 43, wherein the plurality of patient-specific tumor mutations comprises a point mutation, splice-site mutation, frameshift mutation, read-through mutation, gene-fusion mutation, insertion, deletion, or a combination thereof, and the plurality of patient-specific tumor mutations encodes at least one mutant polypeptide having a tumor-specific neoepitope which binds to an HLA protein or fragment thereof with a greater affinity than a wild-type polypeptide.
45. The method of any one of claims 33 to 44, further comprising identifying Major Histocompatibility Complex (MHC) class 1 and 2 genotypes of the patient.
46. The method of claim 45, wherein identifying the MHC class 1 and 2 genotypes of the patient comprises analysis of whole exome sequencing (WES) and/or RNA
sequencing from tumor and/or normal tissue.
47. The method of any one of claims 33 to 46, wherein identifying the neoantigens comprises:
(i) providing a library of peptide constructs, wherein each peptide construct of the library comprises a peptide portion and an identifying nucleic acid portion that identifies the peptide portion, and the peptide portion of at least one of the peptide constructs is capable of specific binding to the HLA proteins or fragments thereof, (ii) contacting the HLA proteins or fragments thereof with the library of peptide constructs;
(iii) separating the at least one peptide construct comprising a peptide portion capable of specific binding to the HLA proteins or fragments thereof from peptide constructs comprising a peptide portion not capable of specific binding to the HLA proteins or fragments thereof; and (iv) sequencing all or a portion of the identifying nucleic acid portion of the at least one peptide construct capable of specific binding to the HLA proteins or fragments thereof 48. The method of claim 47, wherein the library of peptide constructs comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
49. The method of claim 48, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
50. The method of any one of claims of any one of claims 33 to 46, wherein identifying the neoantigens comprises:
(i) generating a genetically encoded combinatorial library of polypeptides with phage display, ribosomal display, mRNA display, biscistronic DNA display, P2A DNA display, CIS display, yeast display, or bacterial display, wherein the combinatorial library comprises polypeptides linked to corresponding nucleic acid molecules encoding the polypeptides;
(ii) contacting the combinatorial library with the HLA proteins or fragments thereof;
(iii) separating HLA proteins or fragments thereof demonstrating specific binding with the combinatorial library; and (iv) sequencing all or a portion of the nucleic acid molecules of the combinatorial library bound to the HLA proteins or fragments thereof to identify the neoantigens.
51. The method of claim 50, wherein the combinatorial library of polypeptides comprises variant peptides designed from an analysis of the plurality of patient-specific tumor mutations predicting the impact of each mutation on a corresponding protein and excluding silent mutations and mutations in noncoding regions.
52. The method of claim 51, wherein the variant peptides comprise mutations predicted to impact the structure of the corresponding protein.
53. The method of any one of claims 33 to 52, wherein administering the mRNA
polynucleotide to the patient is intravenously, intraperitoneally, subcutaneously, intramuscularly, or intratumorally.
54. The method of any one of claims 1 to 53, further comprising administering an effective amount of a therapeutic population of tumor infiltrating lymphocytes (T1Ls).
55. The method of claim 54, wherein the therapeutic population of TILs is administered simultaneously or sequentially with the peptides or mRNA
polynucleotide.
56. The method of claim 54 or 55, wherein the therapeutic population of TILs has been activated and/or educated by at least one neoantigen presented by the peptides or encoded by the mRNA polynucleotide.
57. The method of any one of claims 54 to 56, wherein administering the peptides or mRNA polynucleotide with the therapeutic population of TILs enhances the immunogenic response and/or anti-tumor activity in the patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163166697P | 2021-03-26 | 2021-03-26 | |
US63/166,697 | 2021-03-26 | ||
PCT/US2022/022074 WO2022204583A1 (en) | 2021-03-26 | 2022-03-26 | Methods and compounds for neoantigen vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3212877A1 true CA3212877A1 (en) | 2022-09-29 |
Family
ID=83397965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3212877A Pending CA3212877A1 (en) | 2021-03-26 | 2022-03-26 | Methods and compounds for neoantigen vaccines |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240240259A1 (en) |
EP (1) | EP4313129A1 (en) |
JP (1) | JP2024511799A (en) |
KR (1) | KR20230162677A (en) |
CN (1) | CN117479951A (en) |
AU (1) | AU2022245391A1 (en) |
CA (1) | CA3212877A1 (en) |
WO (1) | WO2022204583A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018214556A1 (en) * | 2017-02-01 | 2019-08-15 | Modernatx, Inc. | Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides |
US20220098578A1 (en) * | 2019-01-31 | 2022-03-31 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
-
2022
- 2022-03-26 AU AU2022245391A patent/AU2022245391A1/en active Pending
- 2022-03-26 KR KR1020237036982A patent/KR20230162677A/en unknown
- 2022-03-26 CA CA3212877A patent/CA3212877A1/en active Pending
- 2022-03-26 US US18/551,356 patent/US20240240259A1/en active Pending
- 2022-03-26 WO PCT/US2022/022074 patent/WO2022204583A1/en active Application Filing
- 2022-03-26 JP JP2023559016A patent/JP2024511799A/en active Pending
- 2022-03-26 EP EP22776775.3A patent/EP4313129A1/en active Pending
- 2022-03-26 CN CN202280037941.5A patent/CN117479951A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022245391A9 (en) | 2023-10-26 |
WO2022204583A1 (en) | 2022-09-29 |
US20240240259A1 (en) | 2024-07-18 |
EP4313129A1 (en) | 2024-02-07 |
JP2024511799A (en) | 2024-03-15 |
AU2022245391A1 (en) | 2023-10-12 |
WO2022204583A9 (en) | 2022-10-20 |
KR20230162677A (en) | 2023-11-28 |
CN117479951A (en) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bentzen et al. | Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes | |
JP6752231B2 (en) | Compositions and Methods for Screening T Cells for Specific Populations Using Antigens | |
US9803246B2 (en) | Receptor gene for peptide cancer antigen-specific T cell | |
US20210040558A1 (en) | Method to isolate tcr genes | |
Lu et al. | Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing | |
US20200292526A1 (en) | Methods of identifying cellular attributes related to outcomes associated with cell therapy | |
US11319590B2 (en) | Enhanced immune cell receptor sequencing methods | |
US20230193203A1 (en) | Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy | |
US20240240259A1 (en) | Methods and compounds for neoantigen vaccines | |
CN110741260B (en) | Methods for predicting the availability of disease-specific amino acid modifications for immunotherapy | |
Peng et al. | Sensitive, Non‐Destructive Detection and Analysis of Neoantigen‐Specific T Cell Populations from Tumors and Blood | |
US20220143083A1 (en) | Reverse immunosuppression | |
TW202426040A (en) | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |